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Abstract of thesis entitled: Gene Expression Profiling of Cardinal 
Ligament in Hong Kong Chinese Women with Uterine Prolapse. 
Submitted by LIU Yuet-man 
for the degree of Master of Philosophy at The Chinese University of 
Hong Kong in June 2006 
Uterine prolapse is a common distressing pelvic floor dysfunction affecting 
women of all ages, particularly the elderly. Preliminary data have shown that there 
might be a relationship between uterine prolapse, abnormal cardinal ligament 
collagen metabolism, and differential gene expression. We aim to study the gene 
expression profile of the cardinal ligament in 12 Chinese women with uterine 
prolapse and 5 normal controls. In this study, high-throughput Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 oligonucleotide microarrays comprising 
over 47,000 human transcript probe sets were used to profile 3 first-degree, 5 
second-degree, and 4 third-degree prolapse cardinal ligaments and 5 normal controls. 
Fifty eight genes were significantly differentially expressed in prolapse cardinal 
ligament samples when compared with normal controls. The microarray data were 
> 
• validated using real-time PGR on 20 genes of most interest. They include IGKV, 
F2RL2, IGKC, ITGB2, IL18, CCRl, TYROBP, SNFILK, PHLDAl, ELL2, EGR3, 
MYC, HESl, AFF3, ADAMTS9, ADAMTSl, F0SL2, EGR2, KLFIO and C0L16A1 
i i i 
from the comparison between prolapse and normal controls. Our micro array data was 
shown to be consistent with the real-time PGR results with respect to the direction of 
fold change of genes. The data provided here should facilitate the understanding of 
pathophysiology of uterine prolapse and its progression. In addition, this gene 
expression study would also facilitate the understanding of how the genetic factors 












的基因來做即時聚合鏈反應’這二十個基因包括了 ： IGKV’ F2RL2, IGKC, ITGB2, 
IL18, CCR1, TYROBP, SNF1LK, PHLDA1, ELL2, EGR3, MYC, HES1, AFF3, 







AGE - advanced glycation end-product 
AhR - aryl hydrocarbon receptor 
C - constant region 
cDNA - complementary deoxyribose nucleic acid 
CI — confidence interval 
cRNA — complementary ribonucleic acid 
dChip - DNA-Chip 
DNA - deoxyribose nucleic acid 
E 2 - 1 7 / 9 - e s t r a d i o l 
ECM — extracellular matrix 
ER — estrogen receptor 
FACIT — fibril-associated collagens with interrupted 
FDR - false discovery rate 
FGF - fibroblast growth factor 
FRET - fluorescence resonance energy transfer 
GAPDH — glyseraldehyde-3-phosphate dehydrogenase 
GO - gene ontology 
HRT - hormone replacement therapy 
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ICAM - intercellular cell-adhesion molecule 
Ig - immunoglobulin 
IVT 一 in-vitro transcription 
J - j o i n i n g region 
MAS5 — microarray analysis Suite v5.0 
MBEI — model-based expression index 
MM - mismatch 
MMP - matrix metalloproteinase 
MRI - magnetic resonance imaging 
mRNA — messenger ribonucleic acid 
OCT - optimal condition temperature 
OR - odds ratio 
PGR - polymerase chain reaction 
PM - perfect match 
POP - pelvic organ prolapse 
POP-Q - pelvic organ prolapse quantification 
> 
• PR — progesterone receptor 
RANTES - regulated on activation normal T expressed and secreted 
RNA - ribonucleic acid 
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rRNA - ribosomal ribonucleic acid 
RT-PCR — reverse transcription-polymerase chain reaction 
SBE - Smad binding element 
ssDNA - single-stranded deoxyribose nucleic acid 
TCDD - 2,3,7,8- tetrachlorodibenzo-p-dioxin 
TCR — T cell receptor 
TGFp - transforming growth factor-beta 
TSP - thrombospondin 
V - variable region 
VEGF - vascular endothelial growth factor 
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CHAPTER 1 INTRODUCTION 
Uterine prolapse is one of the common pelvic organ prolapses (POP) 
affecting women of all ages, particularly the elderly and parous women. It is a 
distressing condition affecting the women's quality of life. Although vaginal delivery 
and menopause are considered as the major risk factors for uterine prolapse, they 
alone, fail to fully explain the genesis and progression of this pelvic floor disorder as 
uterine prolapse has been observed in nulliparous women and premenopausal women. 
This implies genetic factor may increase or decrease a woman's likelihood of 
developing uterine prolapse. 
Microarray is a high-throughout transcriptional profiling technique. It allows 
us to study tens of thousands of expressed genes in the cardinal ligament from 
patients with uterine prolapse. Therefore, gene changes crucial to the development 
and progression of uterine prolapse could be discovered. Further characterization 
of these molecular targets also allows them to be exploited in the diagnosis and 
prognosis, as well as treatment of this distressing condition. 
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1.1 Incidences and Prevalence 
Uterine prolapse is a common distressing pelvic floor dysfunction affecting 
women of all ages, particularly the elderly and parous women. About 50% of all 
parous women show some degree of pelvic floor laxity, with 10 to 20% being 
symptomatic (DeLancey, 1993). In a retrospective cohort study by Olsen et al., the 
lifetime risk of undergoing surgical intervention for uterine prolapse by age 80 was 
estimated to be around 11% (Olsen et al., 1997). Recurrence was common; with 
29.2% of cases needed reoperation, and the time intervals between repeat procedures 
decreased with each successive repair (Olsen et al., 1997). The incidence of uterine 
prolapse also increases after menopause (Olsen el al., 1997; Versi et al., 2001). 
In Hong Kong, the cases of POP contributed to over 1% (806 new cases in 
1999) of all gynecological admission every year according to the latest territory-wide 
audit conducted by Hong Kong College of Obstetricians & Gynaecologist. Before 
1996, uterine prolapse was believed to be rare in Hong Kong and it was even 
concluded that low socioeconomic status Chinese women "rarely" developed uterine 
prolapse (Zacharin et al., 1977). However, in 1996, a retrospective study, which 
investigated the change in the incidence of POP and stress urinary incontinence in 
Chinese women in Hong Kong, overturned the traditional belief (Brieger et al., 1996). 
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In 1993, the medical records of 2,312 patients admitted for major gynecological 
surgery for benign conditions in five out of seven major public hospitals in Hong 
Kong were reviewed by an audit of all gynecological operations performed in these 
hospitals. Twenty five percent (578 cases) were identified as having POP and or 
urinary problems, and 14.6% (339 cases) had a diagnosis of POP, including 335 
cases of uterine prolapse, 213 cases of cystocele, rectocele or enterocele. The data 
revealed that uterine prolapse is no longer a rare health disorder in Hong Kong. The 
apparent rarity may be related to a general reluctance of the female patients to 
present to a doctor or many women do not have symptoms (Brieger et al., 1996). 
Uterine prolapse may have always existed but underestimated in the Chinese in Hong 
Kong. 
1.2 Anatomy of Uterus and its Support Mechanism 
Uterus is a muscular organ located between the bladder and rectum. The 
fundus, which is the superior portion of the uterus, is covered anteriorly and 
posteriorly by the peritoneum. The body of the uterus is enclosed between the broad 
ligaments. Each broad ligament extends from the lateral side of the uterus and 
contains a Fallopian tube, the round and ovarian ligaments, and the uterine and 
ovarian vessels. The broad ligaments do not contribute significantly to uterine 
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support (Moore, 1985; Wahle et al., 1996). 
Uterine support is mainly provided by the pelvic floor musculature and two 
sets of ligaments: the cardinal and the uterosacral ligaments (Bartscht and DeLancey, 
1998; DeLancey, 1992). The cardinal and uterosacral ligaments pass from the cervix 
to the arcus tendineus and sacrum respectively. These ligaments are localized 
thickenings of the suberous fascia and fuse at the cervix to provide the major uterine 
and apical support (Adam, 2000; Wahle et al., 1996). The pelvic floor musculature 
that contributes to uterine prolapse includes the levator ani muscle group 
(pubococcygeus, iliococcygeus, puborectalis) and the coccygeal muscles (Moore, 
1985). Other structures, such as the bony pelvis, the urogenital diagram, and the 
perineal body, also contribute partial uterine and vaginal support (Wahle et al., 1996). 
Clinicoanatomic researches have identified the cardinal ligament as the major 
supportive component of the pelvic floor, especially the uterus (Bartscht and 
DeLancey, 1998; DeLancey, 1992). The cardinal ligament is a condensation of 
subserous fascia arising from pelvic side walls (Lang et al., 2003). Collagen forms 
70-80% of the dry weight of the ligament (Hart et al., 1995). Mostly it is type I 
collagen, with small quantities of type III，V, and VI (Benjamin and Ralphs, 1997). 
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Other extracellular matrix (ECM) proteins like elastin, tenascin, fibronectin, fibril, 
and proteoglycans are also present (Falconer et al., 1998). Fibroblast is the majority 
of cells in the ligaments with the function of producing collagen and elastic fibers 
(Hart et al., 1995). 
1.3 Pathophysiology of Uterine Prolapse 
Uterine prolapse is one of the common POP. Pelvic organ prolapse is a 
general term referring to any combination of anterior or posterior vaginal wall 
prolapse with or without maintained cervical or apical support, or vaginal apical 
prolapse (Kobashi and Leach, 2000). Anterior vaginal wall prolapse comprises 
urinary bladder prolapse and is usually termed cystocele. Posterior vaginal wall 
prolapse involves rectal herniation, which is termed rectocele. Vaginal apical 
prolapse, which involves intestinal herniation, consists of uterine prolapse, vault 
prolapse, and enterocele (Kobashi and Leach, 2000). 
Uterine prolapse is the result of a defect in the support of the upper vagina and 
cervix by the cardinal-uterosacral complex (DeLancey, 1992). Trauma due to 
childbirth, chronic elevations in abdominal pressure or possibly atrophy, have been 
suggested to cause weakening of the cardinal-uterosacral ligament complex. This 
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would cause the cervix to descend and move anteriorly. The uterus then begins to 
rotate posteriorly, such that the intra-abdominal pressure is directed on the anterior 
surface of the uterus. The uterus becomes progressively more retrovcrted until the 
axis of the uterus is in an essentially vertical position at which time prolapse occurs 
(Adam, 2000; Chopra et al.，1996). 
1.4 Classification of Uterine Prolapse 
Uterine prolapse is a condition in which the cervix descends and occupies the 
upper third of the vagina. According to the dynamic pelvic magnetic resonance 
imaging (MRI) of patients with uterine prolapse and the Pelvic Organ Prolapse 
Quantification (POP-Q) system, uterine prolapse can be sub-categorized into first, 
second or third degree (Barbaric et al., 2001). First-degree prolapse is the descent 
(0-2 cm) of the uterus and cervix within the vagina, but the cervix does not reach the 
introitus. Second-degree prolapse is the descent (2-4 cm) of the cervix to the level of 
the introitus. Third-degree prolapse is the descent of the cervix and uterus out of the 
vagina. In the most severe case，the cervix, uterus and vaginal wall completely 
prolapse- through the introitus. This is called procidentia. This may lead to ulceration 
of the cervix and thickening of the vaginal mucosa (Barbaric el al., 2001). 
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1.5 Etiology of Uterine Prolapse 
The exact etiology of uterine prolapse is still unknown and is believed to be 
multifactorial. There are five main predisposing factors that have been consistently 
associated with increased risks of the disorder. 
Childbirth 
The greatest causative factor for the development of uterine prolapse is 
childbirth. A case-control study of 108 Southern European women with uterine 
prolapse and 100 controls showed that parous women had a higher risk of uterine 
prolapse (odds ratio (OR): 2.6; 95% confidence interval (CI): 1.6 - 8.8) compared 
with the controls. Compared with women with no vaginal delivery, those with one 
vaginal delivery had higher risk of uterine prolapse (OR: 3.0; CI: 1 - 9.5) and the risk 
increased with the number of vaginal deliveries (OR: 4.5; CI: 1.6 - 13.1) (Chiaffarino 
et al.，1999). 
Vaginal delivery results in trauma to the pelvic floor, particularly the nerves 
and connective tissues, such as muscles, ligaments and fascias that support the pelvic 
floor and prevent pelvic organs from dropping down. Several studies have suggested 
that as the fetal vertex passes through the vaginal canal, this stretch the levator ani 
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muscles and the pudendal nerve, leading to denervation of the pelvic floor and 
muscle weakness, which in turn result in stretching of the cardinal-uterosacral 
complex (Allen et al.，1990; Smith et al., 1989; Weidner et al., 2000). 
Multiparity and heavier babies, that may cause further or greater pudendal 
nerve damage, were also indicated with higher incidence of uterine prolapse. In 
addition, the use of forceps and prolonged second stage of labor were found to cause 
nerve damage and damage to the fascia and neuromuscular tissue of the pelvic floor 
(Smith et a l , 1989; Snooks et al., 1986). 
Menopause 
The incidence of uterine prolapse increases after menopause (Olsen et al., 
1997; Versi et al., 2001). The menopausal state is characterized by deficiency in 
estrogen, which would influence collagen formation in the connective tissues of the 
pelvic floor (Makinen et al., 1986; Versi et al., 1988). The cervix of the uterus is 
dominated by large numbers of collagen fibers and ground substance, with 70% of 
the coHagen is type I，and 30% is type III (Uldbjerg et al., 1983). After menopause, 
the collagen content in the body declines and the pelvic floor tissues become 
weakened and atrophic. The condition may be aggravated by any increase in 
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intra-abdominal pressure, such as chronic cough, constipation or heavy lifting 
(Makinen et al., 1986; Versi et al., 1988). However, the specific events at the cellular 
and molecular level that occur in the pelvic floor with menopause remain undefined. 
Gynecological surgery 
The risk of prolapse of the vaginal vault and enterocele increases following 
hysterectomy. The disruption of the attachments of the uterosacral-cardinal ligament 
complex to the cuff is considered to be responsible for post-hysterectomy 
vaginal-vault prolapse (Symmonds et al., 1981; Waters, 1956). In addition, 
suprapubic surgical procedures for urinary incontinence (e.g. Burch colposuspension) 
would also change the anatomy of the pelvic floor and lead to prolapse in some cases. 
The possible causes include reduced and weakened collagen, or "anteversion" of the 
anterior vaginal wall following colposuspension (Jackson el al., 1996; Norton et al., 
1995). 
Congenital factor 
Abnormal connective tissue is one of the risk factors that lead to pelvic floor 
disorders. This may due to an abnormality in collagen synthesis in the fascia and 
ligaments of the pelvic floor. There is evidence that women with uterine prolapse 
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have less total collagen content and higher collagenolytic activity in their 
pubocervical fascia than their controls, and that the collagen present is of a weaker 
type than in controls (Jackson et al., 1996; Makinen et al., 1986). These findings 
indicate the importance of weak collagen tissue in predisposing to uterine prolapse. 
In addition, women with joint hypermobilily, which is a clinical marker for 
connective tissue abnormalities, have a significantly higher prevalence of uterine 
prolapse compared to women with normal mobility (Norton et al., 1990). This 
suggests underlying connective tissue abnormality is one etiology of pelvic 
relaxation (Norton et al., 1990). Another congenital defect that is thought to have a 
role in uterine prolapse is spina bifida, which is an incomplete closure in the spinal 
column. Although this is often quoted as a cause of uterine prolapse, particularly in 
young nulliparous women, there are only a few case reports describing its 
relationship to uterine prolapse (Torpin, 1942). Furthermore, other studies showed 
that some children were born with uterine prolapse (Ajbor and Okojie, 1976; Rathore 
and Bhatti, 1986). 
Genetic factor 
The genetic background, such as different race, may predict those subjects 
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likely to develop uterine prolapse. A study has shown racial differences in pelvic 
floor integrity between Chinese and Caucasian women. The Chinese women were 
characterized by a belter developed and thicker muscle mass of the levator ani, and a 
higher expression of collagen in the posterior pubourethral ligaments than the 
Caucasian women (Zacharin et al., 1977). Other studies have also showed that 
postmenopausal women with uterine prolapse had a lower amount of collagen in the 
parametrium and vaginal epithelium than their age-matched controls (Jackson et al., 
1996; Takano et al., 2002). The effect of genetic factors on the development of 
uterine prolapse can also be observed from family history, with the women with 
mothers or sisters reporting uterine prolapse records have a higher risk when 
compared with women whose mother or sisters reported no prolapse (Chiaffarino et 
al. 1999). However, the exact role of genetic factor in the pathogenesis of uterine 
prolapse is not elucidated. 
Other factors 
Other factors, such as underlying neurological disease, chronic slates that 
increase intra-abdominal pressure (e.g. chronic obstructive pulmonary disease, 
chronic constipation, or obesity) and cigarette smoking are commonly noted as risk 
factors or associated findings in subjects with uterine prolapse (Olsen et al., 1997). 
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Interestingly, occupation was shown to have an association with uterine prolapse, 
with housewives and assistant nurses, who had heavy physical work, were at a three 
times higher risk than professional managerial women and women with less physical 
demand in their work (Chiaffarino et al. 1999; Jorgensen et al., 1994). 
1.6 Treatment of Uterine Prolapse 
Several considerations, especially the degree of prolapse and the patient's 
symptomatology, must be made when choosing the type of treatment for uterine 
prolapse. Patients with minimal prolapse often require no surgery. Other 
considerations, such as childbearing, current and expected sexual function, the size 
of the uterus, uterine pathology, as well as the overall health status of the patient, 
must also be taken into account. 
1.6.1 Conservative Treatment 
Conservative treatment may be considered if a patient does not want, or is not 
fit enough for surgery. It may also be used for temporary relief before surgery. 
Pessary is the primary nonsurgical treatment for uterine prolapse. A pessary is an 
inert plastic ring, which is placed in the vagina. It supports the uterus and vault of the 
vagina. Once a ring is fitted, it is usually changed every four to six months by 
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physicians. However, the use of pessaries may cause mechanical irritation or 
ulceration of the vaginal mucosa in some patients. Another conservative treatment 
for uterine prolapse is estrogen replacement therapy. It is usually administrated as a 
cream topically to the vagina. This may improve the thickness of the vaginal tissues 
in some patients. Furthermore, although pelvic floor exercises are not an effective 
treatment when uterine prolapse is well established, it is clinically useful as a 
prophylactic treatment, particularly postpartum and postoperatively. 
1.6.2 Surgical Treatment 
Surgery is another treatment for uterine prolapse to restore vaginal support 
and function. Most procedures for the treatment of uterine prolapse are performed 
through the vagina, with only a few requiring an abdominal approach. Vaginal 
hysterectomy and Manchester repair are the common operations for uterine prolapse. 
In vaginal hysterectomy, the uterus is removed through a surgical incision 
made within the vagina. After the removal of uterus, a strong part of the 
uterosacral-cardinal ligament complex is shortened and re-attached to the vagina to 
restore the support of vaginal apex (Hogston et al., 2002). 
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In Manchester repair, the body of the uterus is not removed. The uterosacral 
ligaments are divided and shortened, the cervix is amputated and the shortened 
ligaments are approximated anterior to the cervical stump (Hogston et al., 2002). 
1.7 Molecular Basis of Uterine Prolapse 
Although vaginal delivery and menopause are considered as the major risk 
factors for uterine prolapse, they alone, fail to fully explain the genesis and 
progression of this pelvic floor disorder for the following reasons. Firstly, severe 
uterine prolapse has been observed in nulliparous women and premenopausal women, 
not only in parous women and women in menopause. Secondly, most women who 
undergo vaginal delivery do not have severe uterine prolapse. Thirdly, the occurrence 
of prolapse is usually several decades after the women underwent vaginal delivery 
(Davis, 1996; Harris el al., 1998; Meeks et al., 1994). These imply there is 
considerable individual variability, which could be the genetic factor that increases a 
woman's likelihood of developing uterine prolapse. 
Many studies implicated that genes involved in ECM activity and collagen 
metabolism were differentially affected in prolapse tissues, signifying the importance 
of ECM activity in the etiology of uterine prolapse. Simultaneously, reports about 
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biochemical changes in tissue level including abnormalities of connective tissue 
structure or its repair mechanism could also be a major factor contributing to uterine 
prolapse. 
1.7.1 Collagen Metabolism 
Collagen is a fibrous protein that is the main component of connective tissues 
and it is the most abundant protein in mammals (Jackson et al., 1996). It has great 
tensile strength, and is the main component of ligaments, tendons, skin and bone. It 
is responsible for skin elasticity, and its degradation leads to wrinkles that 
accompany aging. There are 19 types of collagen with type I and III being the main 
structural components of vaginal epithelial tissue and endopelvic fascia (Jackson et 
al., 1996). Collagen undergoes marked remodeling and alterations in response to 
aging, hormones, trauma, and pregnancy; and its metabolism directly affect the 
structural integrity of the pelvic floor connective tissue. Il was showed thai reduction 
in total collagen content is highly associated with uterine prolapse (Jackson et al., 
1996; Makinen el al., 1986; Takano et al., 2002). In addition, collagen turnover, as 
indicated by matrix metalloproteinase activity, is up to four times higher in prolapse 
tissue (Jackson et al., 1996). The increased collagenolytic activity implies there is a 
loss of collagen from prolapse tissue. Furthermore, changes in collagen metabolism 
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in the ligaments of prolapsed uteri are characterized by a higher expression of 
collagen III (Ewies et al., 2003). As collagen III is responsible for the elasticity and 
extensibility of the tissue, therefore, its increased expression may result in laxity of 
the tissue. 
1.7.2 Extracellular Matrix Metabolism 
Elastin 
Elastin is a protein in connective tissue that is elastic and allows skin to return 
to its original position when it is poked or pinched. It is an important component of 
elastic fibers and plays a major functional role in the maintenance of the integrity of 
the ligaments (Mithieux and Weiss, 2005). Elastin expression was found to be three 
to four times lower in women with prolapse when compared with those without 
prolapse (Ewies et al., 2003). This is consistent with the study by Yamamoto, which 
showed a reduced expression of elastin gene transcripts and elastin synthesis in 
cultured fibroblasts derived from cardinal ligaments of elderly Japanese women with 
uterine prolapse when compared with their age-matched controls (Yamamoto et al., 
1997). As elastin is an important component of elastic fibers, and thus, the decrease 
in its expression would imply the loss of maintenance of integrity of the ligaments. 
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Tenascin 
Tenascin, which is a large glycoprotein, is present transiently in the ECM of 
cells. It is involved in morphogenetic movements, tissue patterning, and tissue repair 
(Liu et al., 1995). Generally, it is found in adult tissues undergoing remodelling such 
as healing wounds (Wallner et al., 1999). It was showed that there had been a higher 
expression of tenascin in the ligaments of prolapsed uteri (Ewies et al., 2003). The 
increased expression of tenascin would imply a tissue trauma in the ligament. 
Matrix Metalloproteinases 
The remodeling of connective tissues throughout the body is controlled 
through a balance between the tissue-degrading matrix metalloproteinases (MMPs) 
and their counter regulatory inhibitors. MMPs are a family of structurally related 
enzymes that degrade virtually all components of connective tissue. Matrix 
metalloproteinase-2 (MMP-2) and MMP-9 degrade the primary constituents of 
connective tissues in pelvic floor, such as the denatured fibrillar collagens I and III, 
collagen V, and elastin (Sternlicht et al., 2001; Woessner 1996). Estrogen has been 
shown to regulate MMP expression in uterus, cervix and ovary (Mclntush and Smith, 
1998; Yoshida et al., 1993). A study by Moalli has shown that estrogen suppressed 
the proenzymes of the tissue-degrading MMP-2 and MMP-9 expression in 
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fibroblasts that are derived from the supportive connective tissue of the pelvic floor 
(Moalli et a l , 2002). This study is consistent with that of Jackson et al. (1996), 
suggesting that estrogen deficiency after menopause would increase MMPs 
expression in the connective tissues of the pelvic floor, which in turn causes a loss of 
collagen and ECM proteins. 
1.7.3 Advanced Glycation End-products 
The function of collagenous tissues is primarily mechanical which is 
achieved by the formation of intermolecular cross-links binding the long rod-like 
molecules within the fibers, thereby preventing sliding of the molecules under load 
and increasing the tensile strength of the fiber (Avery and Bailey, 2005). The 
age-related cross-links and hence tissue strength depend on the rate of turnover of the 
collagen. A series of enzymic and non-enzymic intermolecular cross-links are 
involved in the aging of collagen and consequently increase the mechanical strength 
and stiffness of the tissues. The enzymic mechanism involves divalent and trivalent 
intermolecular cross-links, which further stabilize the collagen fibers. On the other 
hand, when the turnover of mature collagen is slow, a second mechanism of 
cross-linking, which involves non-enzymic, adventitious reaction with tissue glucose 
and its metabolites would occur. This process is known as glycation. Products from 
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the adventitious non-enzymic reaction of glucose with the lysines in the triple helix 
would accumulate. These products are subsequently oxidized to a complex series of 
advanced glycation end-products (AGEs), some of which are intermolecular 
cross-links between the triple helices rendering the fiber to stiffen up for optimal 
functioning of the collagen fibers (Avery and Bailey, 2005). Another study also 
showed that the AGEs formation in collagen would inhibit cell matrix interactions, 
most likely via the loss of specific arginine residues involved in integrin-medialed 
cell attachment. This introduces a possible mechanism by which some of the 
deleterious changes in tissues with age and disease are occurring (Paul and Bailey, 
1999). 
A study has shown that there was an increase in AGEs, pentosidine, in the 
vaginal-epithelial tissue from premenopausal women with uterine prolapse when 
compared with controls. Thus, the abnormalities of connective tissues with increased 
AGEs may predispose women to prolapse by affecting the mechanical strength and 
stiffness of the pelvic tissues (Jackson et al., 1996). 
I 
1.7.4 Estrogen and Estrogen Rcccptors 
At the cellular level, mechanical and hormonal signals influence cell 
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morphology, cytoskeletal organization, cell survival, cell differentiation, and gene 
expression. It is well known that sex hormone stimuli and regulate the expression of 
diverse ECM components. Estrogen is critical for the development and maintenance 
of reproductive tissues (Arnold et al., 1997). Nuclear estrogen receptors (ERs) 
mediate most of the actions of estrogens, which results in transcriptional activation 
and suppression, integration of intracellular signaling pathways and control of cell 
cycle progression (Moggs and Orphanides, 2001). Estrogen induces pleiotrophic 
responses in target tissues, acting through classic steroid receptor-mediated pathways 
and through transactivation of fos/jun (API) mechanisms. Estrogen receptor a (ERa) 
and ER|3, which are present in cardinal ligament, are two types of specific receptors 
that bind estrogen (Kuiper el al., 1998). 
Clinically, one of the important roles of estrogen in tissue level is to induce 
differentiation mechanisms endowed with characterization of the protein and 
proteoglycan constituents of the ECM as exemplified by the changes observed by 
Ewies et al. (2003, 2004). It was shown that the number of ER in the uterine 
ligaments'was significantly lower in the premenopausal women with uterine prolapse 
than those without. These findings indicated ER deficiency might play a role in the 
development of uterine prolapse (Lang et al., 2003). Another study found that 
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collagen III expression was directly related to the presence of prolapse and was 
suppressed with the use of hormone replacement therapy (HRT) (Ewies et al., 2003). 
However, the effect of estrogen on the expression of other ECM proteins, in both 
transcriptional and translational level, is not known. 
In animal models, estrogen improves the integrity of pelvic connective tissues 
and ER modulators are associated with uterine prolapse (Silfen et a l , 1999). Yet 
estrogen could be equally important in regulating the proliferation of cells (Yu et al., 
1999). Recently, our preliminary result showed that the overall growth rate of seven 
cell strains of fibroblasts derived from cardinal ligament in seven patients (PI to P7) 
with uterine prolapse was significantly slower than that of seven cell strains of 
fibroblasts derived from seven control patients without prolapse (CI to CI) under 
normal culture conditions. Furthermore, four cell strains each from patients (P2, P3, 
P4 and P6) and controls (CI, C2, C4 and C5) with no significant difference in their 
mean age were selected to investigate the effect of estrogen in cell proliferation. We 
found that addition of \ 1 ^ -estradiol (E2) suppressed cell proliferation of all the 
fourteen cell strains of prolapse and control fibroblasts when compared to the vehicle 
control (0 mol/1 E2), especially in fibroblasts derived from prolapsed cardinal 
ligament. The four cell strains of fibroblasts derived from prolapsed cardinal 
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ligament showed a significantly lower overall proliferative rate than that of the four 
controls at all E2 concentrations (lO'"* mol/1, 10"^  mol/1, 10'^ mol/1 and mol/1). In 
addition, by comparing to the vehicle control (0 mol/1 E2), the overall inhibitory 
effect was the most prominent in the four cell strains of patient fibroblasts (85.56 土 
48.10% decrease in cell number) when compared to the four controls (10.83 土 
34.41% decrease in cell number) at physiological concentration of 10" mol/1 E2 (Liu 
et al., 2005). In conclusion, all these suggest that pelvic floor support structures are 
targets for estrogen action, and structural and ECM protein component changes 
influenced by estrogen may contribute to the development of the disease. 
These data give us some insight into the molecular pathophysiology of 
uterine prolapse, but progress in this area has been slow due to the complex ECM 
interactions that occur simultaneously. 
1.8 Gene Expression Profiling of Uterine Prolapse 
Recently, the technology of microarray is applied in the study of uterine 
prolapse. 'In two recent gene expression studies using microarray analysis on 
pubococcygeus muscle and periurethral vaginal tissue from women with uterine 
prolapse or other pelvic disorder like stress incontinence (Chen et al., 2005; Visco 
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and Yuan, 2003), both research groups identified differential gene expression of 
structural proteins as well as ECM proteins that may contribute to pelvic floor 
integrity. 
In Visco and Yuan's study (2003) on five Caucasian women with uterine 
prolapse using microarray analysis on pubococcygeus muscle biopsy, it was showed 
that the molecular profiling differences in pubococcygeus muscle between five 
patients with prolapse and five controls were related to differential gene expression 
of proteins related to actin and myosin, as well as ECM proteins. In particular, they 
showed twenty genes were more than 5-fold under-expressed, such as 
myosin-binding protein H (24.7-fold), skeletal muscle myosin heavy polypeptide 3 
(17.4-fold), c-fos protein (15.7-fold) and cartilage oligomeric protein precursor 
(6.0-fold). Eighteen genes were more than 5-fold over-expressed in patients with 
prolapse, such as smooth muscle myosin heavy-chain (11.8-fold), myosin light-chain 
kinase (5.8-fold) and tenascin (5.1-fold) (Visco and Yuan, 2003). These genes were 
related to muscle collagen and ECM proteins, suggesting that uterine prolapse may 
be related, to differential gene expression of structural proteins that are responsible 
for pelvic floor integrity. However, the exact role of these genes in uterine prolapse 
remains unknown. 
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The differential gene expression study in vaginal tissues from women with 
stress urinary incontinence is the most recent transcriptomics study on pelvic floor 
dysfunction (Chen et al., 2005). Chen showed that there was differential gene 
expression in the periurethral vaginal wall of four premenopausal women with stress 
urinary incontinence when compared with four age-matched controls by using the 
GeneChip Human Genome U133 oligonucleotide chip set (Affymetrix, Santa Clara, 
California). In particular, they found 58 over-expressed genes and 36 
under-expressed genes in their patient's samples. The over-expressed genes such as 
elafin, keratin 16，collagen XVII and plakophilin 1 were related to ECM metabolism. 
The differential gene expression of elafin, a serine protease inhibitor involved in the 
elastin degradation pathway and wound healing, suggested that elastin remodeling 
may play an important role of pelvic floor tissue maintenance and integrity. 
1.9 Microarray Gene Expression Profiling Analysis 
Microarray analysis is a high-throughput and large-scale technology to study 
gene expression of several thousand of genes simultaneously. Gene expression 
.describes how "active" a particular gene is and it is quantified by the amount of 
mRNA transcribed from that gene. The pattern of gene expression in a cell is a 
characteristic of its current state. In addition, virtually all differences in cell state or 
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cell type are correlated with changes in mRNA levels of many genes. Thus, it is good 
to have information on all the genes that are present in a genome and study the 
complex interplay of all these genes simultaneously. 
With the help of microarray, the whole genome expression profile under the 
influence of a particular factor can be studied in a short period of time. In addition, it 
helps us to understand the networks of bio-molecular interactions at a global scale. 
Gene expression study can be used to understand the phenomena related to aging or 
fetal development. Screening tests for various conditions can also be designed if 
those conditions are characterized by specific gene expression patterns. Drug 
development, diagnosis, functional genomics, structural genomics and many other 
fields may also benefit a lot from this tool which allows accurate collection of gene 
expression information for thousands of genes at a time (Draghici, 2003). 
In this study, GeneChip Human Genome U133 Plus 2.0 arrays, which are 
oligonucleotide arrays, were used (Affymetrix, Santa Clara, California). It comprises 
.47,000 transcripts to initiate a comprehensive analysis of the transcriptional changes 
that occur in cardinal ligament tissues from patients with and without uterine 
prolapse. With this microarray gene analysis, we sought to identify a set of genes that 
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differ between the cardinal ligament in prolapsed patients and that in control patients 
and to focus further work on the candidate genes. Thus, the principle of 
oligonucleotide array will be discussed in detail. 
1.9.1 Types of Microarray 
A DNA microarray is a substrate, usually made of nylon membrane, glass or 
plastic, on which single-stranded DNAs (ssDNA) with various sequences are 
deposited on it. The ssDNA on the substrate is called a probe, with each representing 
a gene that is assigned a specific location on the array, and then microscopically 
spotted (< 1 mm) to that location. When a target, which is generated from a particular 
biological sample, is added, the DNA in the sample that contains sequences 
complementary to the sequences of the DNA deposited on the surface of the array 
will hybridize to those complementary sequences. Since the target is usually labeled 
with fluorescent dye or a radioactive substance, the hybridization spot can be 
detected and quantified easily (Draghici, 2003). 
. A microarray consists of thousands of probes representing the genes of an 
organism. Over 30,000 spots can be placed on one slide through the use of highly 
accurate robotic spotters. This allows the analysis of virtually every gene present in a 
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genome. There are two main types of microarrays, oligonucleotide arrays and 
complementary DNA (cDNA) arrays (Draghici, 2003). 
Oligon ucleotide A rrays 
Oligonucleotide arrays, which are trademarked as a GeneChip by Affymetrix, 
use small 25 base pair gene fragments as the deoxyribose nucleic acid (DNA) to be 
spotted onto an array. 20 copies of this DNA are spotted for each gene to be placed 
on the array. These DNA fragments are called perfect match (PM) probes, which is 
the exact sequence of a chosen fragment of the gene. They are elaborately selected to 
have little cross-reactivity with other genes so that non-specific hybridization will be 
minimized. However, some non-specific hybridization will occur. In order to 
compensate this, a mismatch (MM) probe that is identical to the PM probe except for 
a mismatch nucleotide in the middle of the fragment is placed next to the first. The 
Perfect Match/Mismatch (PM/MM) probe strategy allows hybridization to happen at 
a critical temperature, thai is, the PM probe hybridizes to our messenger RNA 
(mRNA) and even a single mismatch would prevent the MM probe from hybridizing 
.at that specific temperature. If our target mRNA is present, the PM probes, but not 
the MM probes, would bind to the target mRNA and give measurable fluorescence. 
Finally, the MM probe is subtracted from the PM probe signal lo eliminate any false 
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or contaminating fluorescence within that measurement, which results in perfect 
hybridization. The average difference between all the 20 PM and MM probe sets is 
considered proportional to the expression level of a gene (Draghici, 2003). 
The synthesis of oligonucleotide arrays in GeneChip is based on two 
techniques: photolithography and combinatorial chemistry. The photolithographic 
process begins by coating a 5" x 5" quartz wafer with a light-sensitive chemical 
compound. This light-sensitive chemical prevents coupling between the wafer and 
the first nucleotide of the DNA probe being created, but it can be removed by 
exposure to light. Lithographic masks, which are designed with 18-20 micron square 
windows that allow light to pass through areas where a specific nucleotide is needed, 
are used to either block or transmit light onto specific locations of the wafer surface. 
The surface is then flooded with a solution containing adenine, thymine, cytosine or 
guanine. Coupling would occur only in those regions on the glass that have been 
deprotected through illumination with ultraviolet light. The coupled nucleotide also 
bears a light-sensitive protecting group to ensure the probes that do not attach their 
» 
.appropriate nucleotide are not incorrectly synthesized, and thus the cycle can be 
repeated. In this way, the microarray is built as the probes are synthesized through 
repeated cycles of random access combinatorial chemistry (that is combinations of 
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probes are simultaneously synthesized). Commercially available arrays typically 
manufactured probes with 25 nucleotides in length (Draghici, 2003). 
An oligonucleotide array is generally used for two purposes: (1) 
quantification of the amount of mRNA in a single sample, for example, to determine 
the amount of mutated and non-mutated mRNA in a sample or (2) the comparison of 
two different samples hybridized to two individual arrays. • 
Purified total ribonucleic acid (RNA) from each sample is first reverse 
transcribed to double-stranded cDNA. Then, synthesis of biotin-labeled 
complementary ribonucleic acid (cRNA) is carried out by the target labeling assays. 
The biotin-labeled cRNA is cleaned up and quantified by using spectrophotometric 
analysis. Gel electrophoresis is then used to check unfragmented samples before the 
hybridization on the array. The biotin-labeled cRNA is then fragmented and added to 
hybridization buffer. This is in turn hybridized onto the array. After that, the arrays 
are washed and stained to visualize the amount of hybridization. Lastly, they are 
.scanned by the Affymetrix GeneChip scanner. The intensities of the scanned images 
are then converted into numerical format. 
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cDNA arrays 
A cDNA array uses larger pieces of DNA as probes when compared with that 
in oligonucleotide arrays. cDNA probes for making the array can be generated from 
a commercially available cDNA library or by polymerase chain reaction (PGR) to 
amplify specific genes from genomic DNA. A cDNA microarray experiment 
involves the preparation of two samples for hybridization to the array: a control 
sample and an experimental sample. They are mRNA extracted from cells and 
reverse transcribed into cDNA. Unlike oligonucleotide arrays, a fluorescent dye is 
incorporated into the newly formed cDNA. Different dyes are used to label different 
samples. For example, the control sample is labeled with a green-fluorescent dye 
called Cy3 and the experimental sample labeled with a red-fluorescent dye called 
Cy5. Since the samples are labeled differently, they can be combined and hybridized 
to the microarray together. The two samples will competitively bind to the probes on 
the array and the sample containing more gene expression for a particular probe will 
win out. That is, if there is more of an mRNA transcript in the control sample than in 
the experimental sample, then more Cy3 will bind to the probe on the array and the 
. spot will be green fluorescent. If a transcript is more in the experimental sample, the 
spot will be red fluorescent. When the two samples have the equal amount of 
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transcript, the dyes will cancel each other out and the spot will be in yellow 
fluorescence. 
1.9.2 Comparison of Oligonucleotide and cDNA Arrays 
The first difference between oligonucleotide and cDNA arrays is that probes 
in cDNA arrays can be long, with known or unknown sequences, while that in 
oligonucleotide arrays are short sequences of known genes due to the limitation of 
the synthesis technology. As cDNA arrays do not require probe design as 
oligonucleotide arrays need, this allows the entire genome of an organism to be 
represented on the array easily. Thus cDNA arrays are more useful for the analysis of 
gene expression on a global level. On the other hand, oligonucleotide arrays are more 
reliable due to their greater hybridization specificity by the PM/MM probe design. 
This makes oligonucleotide arrays more useful for monitoring expression levels of a 
differentially spliced transcript, which are common in human mRNA. Separate 
probes for each exon can be printed on the array and heterogeneous transcripts that 
would all bind to the same cDNA probe will bind differentially to each 
» 
‘ oligonucleotide probe. However, the PM/MM probe strategy makes analysis of 
oligonucleotide array data more difficult than that of cDNA array, and usually 
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specific software are required for the analysis of oligonucleotide arrays (Draghici, 
2003). 
1.10 Quantitative Real-time PCR 
Quantitative real-time PCR is a method to rapidly and precisely quantify gene 
activity by detecting mRNA levels of our gene of interest. Thus, the exact increase in 
the amount of DNA as it is amplified can be determined. In our study, quantitative 
real-time PCR is used to further confirm the genes with significant changes in 
expression between prolapse and control samples in microarray analysis. 
1.10.1 Principle ofTaqMan Real-time PCR 
There are several different types of real-lime PCR, and the one that we used 
is TaqMan® real-time PCR. Generally, the TaqMan® probe consists of two types of 
fluorophores, one is the quencher which is usually a long-wavelength colored dye, 
such as red, and another one is the reporter, which is usually a short-wavelength 
colored dye, such as green. The reporter dye is found on the 5' end of the probe and 
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• the quencher at the 3’ end. In between is the primer specific to the target DNA. 
Before the probe is met with the Taq polymerase, energy is transferred from the 
reporter to the quencher by the use of Fluorescence Resonance Energy Transfer 
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(FRET). Thus, the fluorescence emission from the reporter is reduced and become 
undetectable. When the TaqMan® probe and primer binds to the target DNA, Taq 
polymerase will create a complementary strand. When the Taq polymerase adds 
nucleotides to the template strand, it releases the reporter, which is now far away 
from the quencher. The reporter can then emit its fluorescence and making it 
detectable. In contrast, the quencher becomes undetectable. The fluorescence signal 
emitted from the reporter is then received and quantified by computer. 
1.10.2 Other Types of Real-time PGR 
There are two other commonly used real-time PGR methods, the molecular 
beacon method and the SYBR® Green method. Same as the TaqMan® method, these 
two methods allow detection of PCR products via the generation of a fluorescent 
signal. The molecular beacon method utilizes a reporter probe that is wrapped around 
into a hairpin. It also has a quencher dye that must be in close contact to the reporter 
to work. An important difference of the molecular beacon method in comparison to 
the TaqMan® method is that the probe remains intact throughout the PCR product, 
> 
• and is rebound to the target at every cycle. The SYBR® Green probe was the first to 
be used in real-time PCR. It is a fluorogenic dye that exhibits little fluorescence 
when in solution, but emits a strong fluorescence signal upon binding to 
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double-stranded DNA. Owing to the binding to any double-stranded DNA, the 
SYBR® Green method would result in inaccurate data, especially compared with the 
specificity found in the other two methods. 
1.11 Project Aims 
Uterine prolapse is one of the common pelvic floor disorders affecting 
women of all ages, particularly the elderly and parous women. Although vaginal 
delivery and menopause are considered as the major risk factors for uterine prolapse, 
they alone, fail to fully explain the genesis and progression of this pelvic floor 
disorder as uterine prolapse have been observed in nulliparous women and 
premenopausal women. This implies genetic factor may increase or decrease a 
woman's likelihood of developing uterine prolapse. 
Early diagnosis and treatment for uterine prolapse is extremely important, not 
only to improve prognosis but also clinical outcome. It also reduces the cost burden 
related to pelvic floor disorders and improves marital relationship and sexual function 
» 
• of women who had pelvic floor dysfunction (Yip et al., 2003a). It was showed that 
there were controversial results in the prevalence of pelvic floor disorder in women 
with and without interval delivery in local population compared to others (Yip et al., 
3 4 
2003b). The high prevalence of uterine prolapse in Hong Kong provided definite 
evidence that Chinese women in Hong Kong frequently require surgery for uterine 
prolapse (Brieger et al., 1996). In Hong Kong, 14% of all cases admitted for 
gynecological surgery for benign diseases have a diagnosis of uterine prolapse 
(Brieger et al., 1996). However, their clinical presentations, responses to treatment, 
and family history were variable (Yip and Chung, 2003). This further supports the 
importance of investigating the molecular changes on pelvic floor tissues among 
Chinese in the etiology of uterine prolapse. 
Therefore, the objective of this project was to investigate the gene expression 
profile of cardinal ligament in Hong Kong Chinese patients with uterine prolapse and 
control patients without prolapse. We hypothesize there is a differential gene 
expression pattern between the cardinal ligaments in patients with uterine prolapse 
and that in controls. In this study, high-density oligonucleotide micro array is used to 
determine an integrated picture of gene expression in the cardinal ligament. 
» 
1.12 Significance of Study 
Identifying genes that are differentially expressed in uterine prolapse has 
important implications in understanding the pathophysiology of uterine prolapse and 
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its progression. In addition, this gene expression study would also facilitate the 
understanding of how the genetic factors afl^ct the development of uterine prolapse 
and allow the development of genetic screening tool for women at risk. Further 
characterization of these molecular targets also allows them to be exploited in the 
diagnosis and prognosis, as well as treatment of this distressing condition. 
> 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Patients 
Patients with uterine prolapse and control patients without prolapse were 
recruited at the Department of Obstetrics and Gynaecology, Prince of Wales Hospital, 
The Chinese University of Hong Kong. This study received the institutional clinical 
ethics committee approval. Those subjects who had concomitant malignant pelvic 
diseases or patients who were receiving hormone replacement therapy were excluded 
from this study. Subjects unwilling to participate were also excluded. The patient and 
control samples were collected and labeled as LI , L2, and L3. . . L43 chronologically, 
in which L4, L5, L6, L7, L8, L12, L14, L16 and L32 were control samples and the 
remaining 34 samples were patient samples. A total of 34 patient samples and 9 
control samples were used for total RNA extraction, but only the total RNA from 12 
patient and 5 control samples were qualified after checking the RNA quantity and 
» 
‘ quality. Thus, cardinal ligament samples from 12 patients with uterine prolapse (LI3, 
L17, L20, L21, L22, L23, L26, L30, L31, L39, L42 and L43) and 5 control patients 
(L8, LI4，LI6, L25 and L34) were used for microarray gene expression profiling 
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analysis. An additional 51 patients with uterine prolapse and 46 control patients were 
further recruited as independent sample groups for real-time PCR validation. 
2.1.2 Cardinal Ligament Specimen 
Cardinal ligament biopsy specimens were obtained during vaginal 
hysterectomy from 34 patients with uterine prolapse or abdominal hysterectomy 
performed for nonprolapse / nonmalignant indications in 9 controls. A standardized 
biopsy was performed. Specifically, during vaginal hysterectomy the cardinal 
ligament was identified after anterior and posterior colpotomy, and the urinary 
bladder was dissected away from the anterior surface of the uterus. A biopsy of the 
cardinal ligament was made one cm distal to its insertion site. The samples were 
freed from surrounding adipose tissue or blood vessels if present. Similarly, a biopsy 
of the cardinal ligament was made in normal subjects. The samples were then divided 
into two parts, one embedded in optimal condition temperature (OCT) compound 
immediately, and the other was snap-frozen in liquid nitrogen and then stored 
at -80°C. RNA was extracted from the frozen tissue samples, and then used to 
» 
• perform microarray analysis. 
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2.2 Methods 
2.2.1 ITomogenization of Cardinal Ligament Tissues 
Total RNA was extracted from the frozen human cardinal ligament tissue 
samples by using Trizol Reagent (Molecular Research Center Inc, Cincinnati, Ohio). 
The tissues (about 50-100 mg) were homogenized in 1 ml of Trizol Reagent with a 
handheld homogenizer for 2 minutes. • 
2.2.2 Total RNA extraction 
The homogenate was stored at room temperature for 5 minutes. Two hundred 
fj.1 of chloroform was added to the homogenate, which was shaken vigorously for 15 
seconds. The mixture was centrifuged at 12,000g for 15 minutes at 4°C. After the 
centrifugation, the aqueous phase (about 0.5 ml) was transferred to a fresh tube and 
mixed with 0.5 ml of isopropanol. This was stored at room temperature for 10 
minutes and centrifuged at 12,000g for 10 minutes at 4°C. The RNA pellet was 
washed with 1 ml of 75% ethanol and subsequently centrifuged at 7,500g for 5 
» 
‘ minutes at 4°C. The RNA pellet was air-dried for 5 minutes and the RNA was 
dissolved in 15 |il ofRNase-fi .ee water by passing the solution 20 times through a 
pipette tip. 
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The RNA was then purified by using the RNeasy kit (Qiagen, Valencia, 
California). The RNA sample was adjusted to a volume of 100 jil with RNase-free 
water, which was then added with 350 jil Buffer RLT. The solution was mixed 
thoroughly. 250 |il 100% ethanol was added to the diluted RNA and mixed 
thoroughly. 700 |il of the sample was applied to an RNeasy mini column placed in a 
2 ml collection tube, which was centrifuged for 15 s at ^8 ,000g . The RNeasy 
column was transferred into a new 2 ml collection tube and 500 |a1 Buffer RPE was 
applied onto the RNeasy column, which was centrifuged for 15 s at ^8 ,000g to 
wash the column. The flow-through was discarded. The column was re-washed with 
another 500 |il Buffer RPE and centrifuged for 2 min at ^ 8 , 0 0 0 g to dry the RNeasy 
silica-gel membrane. The flow-through was discarded. To ensure the complete 
removal of Buffer RPE, the column was centrifuged at full speed for 1 min. The 
RNeasy column was transferred to a new 1.5 ml collection tube and 30 i^l RNase-free 
water was pipetted directly onto the RNeasy silica-gel membrane. The tube was 
centrifuged for 1 min at ^ 8,000g to elute the RNA. 
» 
• The yield and purity of RNA were determined by spectrophotometry. An 
absorbance of 1 unit at 260 nm corresponds to 40 jig of RNA per ml of distilled water. 
The ratio between the absorbance values at 260 and 280 nm gives an estimate of 
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RNA purity. For pure RNA, the A260/A280 ratio should be close to 2.0. For accurate 
measurement, the quantity and purity of the total RNA extracted from 34 patient and 
9 control samples were further checked by Agilent 2100 Bioanalyzer using the RNA 
6000 Nano Assay (Agilent Technologies, Palo Alto, California). Total RNA from 12 
patient and 5 control samples were qualified after checking the RNA quantity and 
quality. Thus, cardinal ligament samples from 12 patients with uterine prolapse (LI3， 
L17, L20, L21, L22, L23, L26, L30, L31, L39, L42 and L43) and 5 control patients 
(L8, LI4 , L I6 , L25 and L34) were used for microarray gene expression profiling 
analysis. 
2.2.3 Oligonucleotide Microarray 
Microarray analysis on individual cardinal ligament biopsy specimens from 
12 patients with uterine prolapse and 5 control subjects without prolapse were 
performed. Seventeen GeneChip Human Genome U133 Plus 2.0 Arrays were used 
(Affymetrix, Santa Clara, California). 
» 
2.2.3.1 Two-cycle cDNA Synthesis 
As the RNA yield ranged from 3 f.ig to 5 two-cycle cDNA synthesis was 
used to synthesize complementary DNA (cDNA) from 10 to 100 ng starting total 
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RNA according to the manufacturer's protocol. 
Step 1: First-cycle, first strand cDNA synthesis 
100 ng of total RNA sample was mixed with 2 |il of T7-01igo (dT) 
Primer/Poly-A Controls Mix in a 0.2 ml PGR tube. RNase-free water was added to a 
final volume of 5 The tube was gently flicked a few times to mix, and then 
centrifuged briefly to collect the solution at the bottom of the tube. The tube was 
incubated for 6 minutes at 70°C • The sample was cooled at 4°C for 2 minutes and 
centrifuged briefly to collect the sample at the bottom of the tube. Five |al of 
First-Cycle, First-Strand Master Mix prepared from 2 5X Strand Reaction Mix, 
1 i^ il DTT (O.IM), 0.5 |il RNase inhibitor, 0.5 |il of dNTP (lOmM) and 1 i^l of 
superscript II was added to each sample. The tube was gently flicked a few times to 
mix, and then centrifuged briefly to collect the solution at the bottom of the tube. The 
solution was incubated for 1 hour at 42°C and then heated at 70°C for 10 minutes. 
The sample was cooled for at least 2 minutes at 4°C. 
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• Step 2: First-cycle, second-strand cDNA synthesis 
10 |il of First-Cycle, Second-Strand Master Mix prepared from 4.8 f.il 
RNase-free water, 4 …freshly diluted MgCb (17.5mM), 0.4 …dNTP (10 mM), 0.6 
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1^1 E. coli DNA Polymerase I and 0.2 i^l RNase II was added to each sample from 
step 1. The tube was incubated for 2 hours at 16°C, then 10 minutes at 75°C and 
cooled for 2 minutes at 4°C. 
Step 3: First-cycle, In-vitro Transcription amplification of cRNA 
30 fil of First-cycle, in-vitro transcription (IVT) Master Mix prepared from 5 
fil lOX Reaction Buffer, 5 i^l ATP solution, 5 \i\ CTP solution, 5 \i\ UTP solution, 5 
[i\ GTP solution and 5 fil Enzyme Mix was transferred to each cDNA sample. The 
sample was incubated for 16 hours at 37°C. 
Step 4: First-cycle, cleanup of cRNA 
50 |il of RNase-free water and 350 |il of IVT cRNA Binding Buffer were 
added to the IVT reaction in the previous step. 250 of ethanol (96-100%) was 
added to the lysate. The sample was applied to the IVT cRNA Cleanup Spin Column 
and centrifuged for 15 seconds al ^8 ,000g. 500 i^l of IVT cRNA Wash Buffer was 
added to the column and centrifuged for 15 seconds at ^8 ,000g for RNA washing. 
> 
• After that, 500 \.i\ of 80% ethanol was added to the column and centrifuged for 15 
seconds at ^8 ,000g . 13 \i\ of RNase-free water was applied directly onto the spin 
column membrane. The cRNA yield was determined by measuring the absorbance at 
4 3 
260nm. 
Step 5: Second-cycle, first-strand cDNA synthesis 
2 |Lil of freshly prepared random primers (0.2fig/|il) was mixed with the 
purified cRNA in the previous step. The mixture was incubated for 10 minutes at 
70°C. The sample was cooled at 4�C for 2 minutes. 9 |li1 of Second-Cycle, 
First-Strand Master Mix prepared from 4 |il 5X First Strand Reaction Mix, DTT 
(O.IM), 1 |al RNase inhibitor, l|il dNTP (lOmM) and 1 |il Superscript II was added 
to each cRNA /random primer sample. The sample was incubated for 1 hour at 42°C 
and cooled for 2 minutes at 4°C. 1 of RNase H was added to each sample, which 
was heated at 95°C for 5 minutes and cooled for 2 minutes at 4°C. 
Step 6: Second-cycle, second-strand cDNA synthesis 
4 [x\ of freshly diluted T7-01igo (dT) Primer (SfiM) was added to each 
sample in step 5 for a final volume of 25 ^il. The sample was incubated for 6 minutes 
at 70�C and cooled at 4°C for 2 minutes. 125 of Second-Cycle, Second-Strand 
» 
• Master Mix prepared from 88 RNase-free water, 30 5X Second Strand Reaction 
Mix, 3 |il dNTP (10 mM) and 4 E. call DNA Polymerase I was added to each 
sample. The sample was incubated for 2 hours at 16°C. 2 of T4 DNA Polymerase 
4 4 • 
was added to the samples for a final volume of 152 The sample was incubated for 
10 minutes at 16°C and the cooled at 4°C for 2 minutes. 
2.2.3.2 Cleanup of Double-stranded cDNA 
500 [i\ of the cDNA sample obtained from the previous step was applied to 
the cDNA Cleanup Spin Column. 600 of cDNA Binding Buffer was added to the 
column and centrifuged for 1 minute at ^ 8,000g. The flow-through was discarded. 
750 1^1 of cDNA Wash Buffer was applied onto the column and centrifuged for 1 
minute at ^ 8,000g. Fourteen of cDNA Elution Buffer was added to the column, 
incubated for 1 minute, and centrifuged at 25,000g to elute the cDNA. 
2.2.3.3 Synthesis of Biotin-labcled cRNA 
12 \x\ of cDNA obtained from the previous step was mixed together with 4 \i\ 
lOX IVT Labeling Buffer, 12 |il IVT Labeling NTP Mix, 4 IVT Labeling Enzyme 
Mix to a final reaction volume of 40 i^l with RNase-free water. The mixture was 
incubated at 37°C for 16 hours. 
> 
4 5 
2.2.3.4 Cleanup and Quantification of Biotin-labcled cRNA 
Step 1: Cleanup of hiotin-laheled cRNA 
60 of RNase-free water was added to the IVT buffer and mixed. 
Three-hundred fifty i^l IVT cRNA Binding Buffer were added to the sample. 
Two-hundred fifty |_il ethanol (96-100%) were added to the lysate and mixed well by 
pipetting. Seven hundred )il sample were applied to the IVT cRNA Cleanup Spin 
Column and the column was centrifuged for 15 seconds at ^8,000g. The 
flow-through was discarded. Five hundred |li1 IVT cRNA Wash Buffer were added 
onto the column and centrifuged for 15 seconds at ^8 ,000g to wash. Five hundred 
\x\ of 80% ethanol were added onto the spin column and centrifuged for 15 seconds 
at ^ 8,000g. Ten |.il of RNase-free water were added directly onto the spin column 
membrane and the column was centrifuged for I minute at 25,000g to elute the 
cRNA. 
Step 2: Quantification of the cRNA 
> 
‘ The yield and purity of the eluted cRNA were determined by 
spectrophotometric analysis. The convention of 1 absorbance unit at 260 nm equals 
40 |ig/ml RNA was applied. The ratio between the absorbance values at 260 and 280 
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nm was also measured. For pure RNA, the A260/A280 ratio should be close to 2.0. 
2.2.3.5 Fragmenting the cRNA for target preparation 
Eight |il 5X Fragmentation Buffer were added to 20 |.ig purified cRNA, 
together with RNase-free water to a final volume of 40 |il. The reaction mixture was 
incubated at 94°C for 35 minutes and put on ice. The distribution of RNA fragment 
sizes was checked by Bioanalyzer analysis. The standard RNA fragment sizes were 
approximately 35 to 200 bases. 
2.2.3.6 Target hybridization 
Hybridization cocktail for a single probe array was prepared from 15 |ig 
fragmented cRNA, 5 \i\ Control Oligonucleotide B2 (3nM), 15 |il 20X Eukaryotic 
Hybridization Controls (bioB, bioC, bioD, ere), 3 Herring Sperm DNA (lOmg/ml), 
and 3 |il BSA (50mg/ml). One hundred fifty i^l 2x Hybridization Buffer, 30 fil 
DMSO, and water were diluted to a final volume of 300 fil. The hybridization 
cocktail was heated to 99°C for 5 minutes and 45°C for 5 minutes. The probe array 
» 
‘ was equilibrated to room temperature immediately before use. Meanwhile, the array 
was wetted by filling it through one of the septa with appropriate volume of IX 
Hybridization Buffer. The probe array was then filled with IX Hybridization Buffer 
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at 45°C for 10 minutes with rotation. The probe array cartridge was filled with 200 |al 
of the hybridization cocktail. The probe array was placed into the Hybridization 
Oven and hybridized for 16 hours at 45°C with rotation at 60rpm. 
2.2.3.7 Array Washing, Staining and Scanning 
Streptavidin Phycoerythrin (SAFE) Solution Mix was prepared from 600 pi 
2X Stain Buffer, 48 |liI BSA (50mg/ml), 12 )il Streptavidin- Phycoerythrin (SAFE) 
(Img/ml), and 540 |li1 de-ionized water. Antibody Solution Mix was prepared from 
300 III 2X Stain Buffer, 24 BSA (50mg/ml), 6 |il Goat IgG Stock (lOmg/ml), 3.6 
0.5 mg/ml anti-streptavidin biotinylated antibody, and 266.4 |il de-ionized water. 
The probe array was first washed with non-stringent wash buffer (6X SSPE, 
0.01% Tween-20) at 25°C for 10 cycles, followed by washing with stringent wash 
buffer (100 mM MES, 0.1 M [Na+], 0.01% Tween 20) at 50°C for 4 cycles. The array 
was stained in SAFE solution at 25°C for 10 minutes, and washed with non-stringent 
wash buffer at 25°C for 10 cycles. The array was second stained in antibody solution 
» 
• at 25°C for 10 minute. The anti-streptavidin biotinylated antibody would bind to the 
biotin-streptavidin-phycoerythrin-tagged cRNA molecule, so that more 
streptavidin-phycoerythrin would bind to it for signal amplification, and the Goat 
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IgG would bind to the unhybridized streptavidin-phycoerythrin for background 
suppression. Then it was followed by staining in SAFE solution at 25°C for 10 
minute. The array was washed with non-stringent wash buffer at 30°C for 15 cycles. 
After washing the probe array, the array was scanned and the intensities of 
the scanned images were converted into numerical values in the latest binary-format 
(Version 4) CEL file. The scanner was controlled by Affymetrix® Microarray Suite 
(MAS) or GCOS. 
2.2.3.8 Statistical Analysis of Microarray Data 
Step 1: Data preparation 
DNA-Chip Analyzer (dChip) (version 1.3) software (www.dCHIP.org) (Li 
and Wong, 2001a, b) was used as the data analysis tool. In order to read the data in 
dChip software, the binary-format (Version 4) CEL file was first converted to the 
text-format (Version 3) CEL file by using Affy CEL file converting tool downloaded 
» 
" from the website: 
(http://www.affymetrix.com/support/devdoper/tools/affvtools.affx). 
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Step 2: Files preparation 
A U133 plus2 Library File, which contained information of transcripts/genes 
on the chip that we had used, was input into the dChip program. A Gene Information 
File, containing information about the genes such as gene ontology (GO), was also 
input into the dChip analysis program. 
Step 3: Viewing CEL image 
The intensity range is from 1% quartile to 95% quartile of all the perfect 
match and mismatch probe intensities. When the intensity is below the 1 % quartile, 
the color seen is black. When the intensity is beyond the 95% quartile, the color is 
yellow. 
Step 4: Normalization of arrays 
Since different array images usually have different overall brightness during 
scanning, especially when they are generated at different times and places, thus, 
normalization is required to adjust the brightness of the arrays to a comparable level 
» 
‘ before comparing the expression levels of genes between different arrays. By using 
the default values in the software, an array with median overall intensity is chosen as 
the baseline array. Subsequently other arrays are normalized against this baseline. 
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Step 5: Calculation of Model-based expression indexes 
By using the default values in the software, the model-based expression 
index (MBEI), which represents the expression level of each probe set, from multiple 
arrays were calculated. 
Step 6: Filtering genes 
Filtering genes was to exclude genes that show little variation across the 
samples or are absent in the majority of the samples from the clustering analysis. 
There were two criterions to filter genes: (1) ratio between the standard deviation and 
the mean of a gene's expression values (standard deviation / mean) across all samples 
is between 1 and 10; (2) a gene to be called "Present" in more than 20% percentage 
of arrays. After filtering genes, genes with large variation were selected 
Step 7: Unsupervised data analysis 
An unsupervised data analysis method, hierarchical clustering, was then used 
to cluster genes and samples with similar behaviors. It is essentially a grouping 
» 
• technique that aims to find genes with similar behaviors (expression profiles). It is 
called unsupervised analysis because it does not require any prior knowledge in the 
process. 
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Step 8: Supervised data analysis 
Comparative analysis is also used to identify genes that show significant 
differential gene expression between the two groups of samples. There are three 
filtering criterions when comparing prolapse and normal samples: (1) Fold change 
between the two group means should be greater than 2; (2) 90% lower bound fold 
change larger than 1.5; (3) /rvalue for un-paired t-test of significant difference 
between two compared groups less than 0.05. False discovery rate (FDR) was 
assessed by 100 permutations. 
Step 9: Annotation classification 
A web tool, FatiGo (http://fatigo.bioinfo.cnio.es), was used to find significant 
associations of GO terms with groups of genes. 
2.2.4 Quantitative Real-time Polymerase Chain Reaction 
2.2.4.1 Primers and Probes 
Primers and TaqMan probes for the 20 selected genes were purchased from 
» 
‘ Applied Biosystems (Foster City, California). 
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2.2.4.2 Reverse Transcription 
RNA extracted from 51 patient and 46 control cardinal ligament samples and 
the Human Universal Reference Total RNA (BD Biosciences Clontech, Palo Alto, 
California) was reverse-transcribed to cDNA by SuperScript™ First-Strand 
Synthesis Kit (Invitrogen Life Technology, Carlsbad, California). For each sample, 2 
jig total RNA, 600 ng random primers, and 10 nmol/1 dNTP in 12 reaction mixture 
were first heated at 65°C for 5 minutes. Four 5XFirst-Strand Buffer, 0.2 |amol/l 
DTT, and 40 lU RNaseOUT were added to the reaction mixture, which was then 
heated to 42°C for 2 minutes. A total of 200 lU SuperScript II reverse transcriptase 
were added to each reaction mixture. The reaction mixture was heated to 25°C for 10 
minutes, 42°C for 50 minutes, and 70°C for 15 minutes. 
2.2.4.3 Plate Setup 
Serial dilutions (50,000 pg, 10,000 pg, 2,000 pg, 400 pg, 80 pg, and 16 pg) 
of cDNA samples prepared from the Human Universal Reference Total RNA were 
used to construct standard curves for the calculation of the candidate genes and 
» 
‘ endogenous reference control, glyseraldehyde-3-phosphate dehydrogenase (GAPDH), 
amplifications. All the samples were done in duplicate in a 384-well optical reaction 
plate covered with ABI PRISM® optical adhesive cover designed for ABI PRISM® 
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7900HT Sequence Detection System. 
2.2.4.4 Real-time PGR Reaction Mixture Setup 
To check the transcript expression of the candidate genes and GAPDH, 
real-time PGR was performed thereafter in a 5 |il volume of the final reaction 
solution containing 1 |il of the RT reaction product (diluted atl:20X), 2.5 |il of 2X 
TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, California), 
0.25 [l\ of TaqMan Probes, and 1.25 |il distilled water. The amplification conditions 
were: 50°C for 2 minutes, 95°C for 10 minutes, 45 cycles of 95°C for 15 seconds, 
60°C for 1 minute. The fluorescence signal emitted was collected by ABI PRISM® 
7900HT Sequence Detection System and the signal was converted into numerical 
values by SDS 2.1 software (Applied Biosystems, Foster City, California). 
2.2.4.5 Statistical analysis of Real-time PCR Data 
The expression level of a gene was first calculated from the Relative 
Standard Curve Method. The quantities of amplification copies of both target and 
> 
‘ endogenous reference, GAPDH, were determined from the corresponding standard 
curves. The relative expression of each target gene was determined by dividing the 
target amount by GAPDH amount to obtain a normalized target value. The 
5 4 
normalized values of the target gene of the patient group samples were compared to 
that of controls to obtain the expression fold change. Extreme outliers were 
eliminated by plotting the Box-plots by SPSS. 
Statistical analysis of significant difference among patient samples and 
control samples was tested by Mann-Whitney Test. The Pearson product-moment 
correlation was used to evaluate the correlation of the expression level of candidate 
genes of microarray and real-time PCR expression at 95% confidence interval. 
» 
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CHAPTER 3 RESULTS 
The gene expression profiles of twelve patient samples with uterine prolapse and 
five control samples were studied by microarray analysis. Hierarchical clustering was 
performed to cluster genes and samples with similar behaviors. Comparative analysis 
was also performed to identify genes that show significant differential gene expression 
between the patient samples with uterine prolapse and control samples. The significant 
associations of GO terms with groups of genes were found by FatiGo. Differentially 
expressed genes were also identified from the comparisons between patient samples 
with different degrees of prolapse and control samples. In addition, patient samples with 
third-degree prolapse were also compared with those with first-degree prolapse to 
identify differentially expressed genes. 
Based on the supervised comparative analysis and annotation classification of 
the differentially expressed genes in prolapse samples, 20 genes with most interest were 
further studied and confirmed by using quantitative real-time PCR, both in 17 samples 
» 
“ studied by microarray analysis and in independent sample groups of 51 patient and 46 
control samples. Eight pairs of age-matched and parity-matched patient and control 
samples were also randomly selected for further analysis. The Pearson product-moment 
5 6 • 
correlation was used to evaluate the correlation of the expression level of candidate 
genes of microarray and real-time PGR expression at 95% confidence interval. 
3.1 Microarray Gene Expression Data Analysis 
3.1.1 Unsupervised Gene Selection 
470 of 54675 probe sets satisfied the filtering criteria: (1) Variation across 
samples (standard deviation / mean): 1 � S t a n d a r d eviation / Mean < 10; (2) Present call 
percentage in the array > 20%. Figure 3.1 showed the unsupervised hierarchical 
clustering dendrogram (p-value for gene clustering < 0.001, p-value for sample 
clustering <0.05). The control and patient samples were not separate well under the 
unsupervised hierarchical clustering analysis. Only the control samples LI4, L25 and 
L34 clustered together and were not clearly separated from the patient samples L13, L17, 
L20, L21, L22, L23, L26, L30, L31, L39, L42 and L43. In addition, the patient samples 
with different degrees of prolapse did not separately cluster together clearly. 
» 
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Figure 3.1 Hierarchical clustering dendrogram of 470 genes from unsupervised gene 
selection analysis with criteria: (1) Variation across samples (standard deviation/mean): 
1 <Standard deviation / Mean < 10; (2) Present call percentage in the array > 20%. The 
p-value for gene clustering < 0.001 while the p-value for sample clustering <0.05. Red 
represents the up-regulated probe sets while blue represent the down-regulated probe 
sets. Control samples are indicated as (C) and patient samples are indicated as (P). 
Samples with different degrees of prolapse are indicted by: (N) N o prolapse; (F) 
First-degree prolapse; (S) Second-degree prolapse; (T) Third-degree prolapse. 
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3.1.2 Supervised Gene Selection 
3.1.2.1 Gene Expression Profiles Distinguish Cardinal Ligament with Uterine 
Prolapse from Control and Identify Differentially Expressed Genes 
Using (1) lower bound fold change larger than 1.5; (2) p-value for t-test less than 
0.05 to compare between the patient and control samples, 76 probe sets representing 58 
genes satisfied the comparison filtering criteria were obtained with 25% median FDR by 
100 permutations. Twenty nine genes were differentially up-regulated, and 29 genes 
were differentially down-regulated in the patient samples. The output gene list was 
shown in Table 3.1. Figure 3.2 showed the hierarchical clustering dendrogram (p-value 
< 0.05) of the 58 differentially expressed genes. The control and patient samples 
separated well. 
Annotation classification (p-value < 0.001) accessed by GO of the differentially 
expressed gene was shown in Figure 3.3. In the category of molecular function, the 
number of genes with significant associations of GO terms was 19 and it showed that 
the genes were mainly involved in DNA binding (42.11%), metal ion binding (42.11%), 
» 
‘ cation binding (36.84%), and transmembrane receptor activity (15.79%). In the category 
of biological process, the number of genes with significant associations of GO terms 
was 22; and the genes were mainly involved in primary metabolism (59.09%), cellular 
5 9 • 
metabolism (59.09%), regulation of cellular physiological process (50%), regulation of 
metabolism (40.91%), immune response (31.82%), and defence response (31.82%). In 
the category of cellular component, the number of genes with significant associations of 
GO terms was 19; and it showed that the majority of genes were in nucleus (47.37%), 
integral to membrane (42.11%), intrinsic to plasma membrane (26.32%); while others 
were in mitochondrion, immunological synapse, cytoskeleton, and anchoring collagen 
(5.26%). The genes involved in each molecular function, biological process, and cellular 
component were listed in Table 3.2a, b, and c respectively. 
> 
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Table 3.1 List of differentially expressed genes (lower bound fold change > 1.5; p < 
0.05) in cardinal ligaments in patients with uterine prolapse compared to controls. 
Accession Gene Name Symbol Map Lower Bound 
Fold Change 
(Fold Change) 
29 up-regulated genes in prolapse samples compared with controls 
AF103529 Immunoglobulin kappa light chain IGKV 2p l2 3.92 
variable region (IGKV gene), (42.57) 
clone 25 
BG548679 Immunoglobulin kappa light chain 2.57 
VKJ region mRNA, partial cds (21.06) 
AI378647 Coagulation factor II (thrombin) F2RL2 5q l3 2.5 
receptor-like 2 (10.47) 
BG485135 Immunoglobulin kappa constant IGKC 2p l2 2.37 
(4.85) 
NM_000095 Cartilage oligomeric matrix protein COMP 19pl3.1 2.17 
(6.54) 
AA588092 Solute carrier family 40 SLC40A1 2q32 2.13 
(iron-regulated transporter), (3.39) 
member 1 
AL040763 ATP-binding cassette, sub-family ABCB5 7p21.1 2.06 
B (MDR/TAP), member 5 (9.45) 
M28825 CDIA antigen, a polypeptide CDIA Iq22-q23 1.97 
(14.44) 
BF338860 Membrane-spanning 4-domains, MS4A6A n q l 2 . 1 1.87 
subfamily A, member 6A (2.71) 
S55735 limmunoglobulin heavy constant IGHAl 14q32.33 丨.85 
alpha I (4.27) 
AFl 10329 Mitochondrial glutaminase GLS2 12ql3 1.84 
pseudogene (6.48) 
AI633559 ‘ CDNAFLJ37310 fis, clone 1.79 
. ‘ BRAMY2016706 (2.80) 
AU145431 Decorin DCN 12q21.33 1.75 
(3.05) 
AW088232 Paired box gene 6 (aniridia PAX6 11 p i3 1.74 
keratitis) (11.44) 
NM_152677 Zinc finger and SCAN domain ZSCAN4 19ql3.43 1.73 
containing 4 (3.97) 
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(Continued) 
NM_000211 Integrin, beta 2 (antigen CD 18 ITGB2 21q22.3 1.73 
(p95), lymphocyte (2.47) 
function-associated antigen 1; 
macrophage antigen 1 (mac-1) beta 
subunit) 
AA573523 Erythrocyte membrane protein EPB41L1 2 0 q l l . 2 - q l 2 1.72 
band 4.1-like 1 (5.84) 
AF285167 ATP-binding cassette, sub-family ABCAl 9q31.3 1.70 
A ( A B C l ) , member 1 (2.80) 
NM_001562 Interleukin 18 丨 L18 丨 Iq22.2-q22.3 1.68 
(3.86) 
NM—001295 Chemokine (C-C motif) receptor 1 CCRl 3p21 1.61 
(2.79) 
AI017540 ST3 beta-galacloside ST3GAL5 2 p l l . 2 1.61 
alpha-2,3-sialyltransferase 5 (2.75) 
AI184968 Complement component 1, q CIQG lp36.11 1.61 
subcomponent, gamma (2.63) 
polypeptide 
NM_001228 Caspase 8, apoptosis-related CASP8 2q33-q34 1.60 
cysteine protease (2.01) 
NM_003332 TYRO protein tyrosine kinase TYROBP 19ql3.1 1.58 
binding protein (2.17) 
AF272036 Ras-related GTP binding D RRAGD 6q l5 -q l6 1.58 
(2.01) 
NM_006344 C-type (calcium dependent, CLEClOA 17pl3.1 1.57 
carbohydrate-recognition domain) (2.19) 
lectin, superfamily member 14 
(macrophage-derived) 
NM_014210 Ecotropic viral integration site 2A EVI2A 17ql l .2 1.54 
(2.06) 
AI671186 - Regeneration associated muscle RAMP l l p l 3 1.50 
. ‘ protease (2.28) 






























































































































































































































































































































































































































































































































































































































































NM—005655 Kruppel-like factor 10 / T G F B KLFIO 8q22.2 -1.69 
inducible early growth response (-2.20) 
NM—022908 Hypothetical protein FLJ12442 FLJ12442 3p21.1 -1.66 
(-2.28) 
AF153330 Solute carrier family 19 (thiamine SLC19A2 lq23.3 -1.62 
transproter), member 2 (-2.62) 
NM—005195 CCAAT/enhancer binding protein C E B P D 8 p l l . 2 - p l l . l -1.60 
(C/EBP), delta (-2.60) 
AL391688 Synaptotagmin-like 4 SYTL4 Xq21.33 -1.60 
(granuphilin-a) (-2.05) 
AI052103 Chromosome 6 open reading f rame C 6 o r f l 7 0 6q22.3 -1.60 
170 . (-1.98) 
AV704962 Sterol-C4-iTiethyl oxidase-like S C 4 M 0 L 4q32-q34 -1.58 
(-2.46) 
BC006440 Hypothetical protein M G C l 3 1 6 8 MGC13168 12q l5 -1.58 
/// hypothetical protein M G C l 3168 (-2.34) 
H43976 Mortality factor 4 like 2 MORF4L2 Xq22 -1.57 
(-2.34) 
NM—001856 Collagen, type XVI, alpha 1 C 0 L 1 6 A 1 Ip35-p34 -1.57 
(-2.00) 
NM—015062 Peroxisome proliferative activated PPRCl 10q24.32 -1.57 
receptor, gamma, (-1.90) 
coactivator-related 1 
AL833001 ELOVL family member 5, elongation E L 0 V L 5 6p21.1-p l2 .1 -1.56 
of long chain fatty acids (FEN l/Elo2, (-2.45) 
SUR4/Elo3-like, yeast) 
NM—003334 Ubiquitin-activating enzyme El U B E l Xp 11.23 -1.54 
(A 1S9T and BN75 temperature (-1.95) 
sensitivity complement ing) 
BC037941 - Coatomer protein complex, subunit CO PA Iq23-q25 -1.51 
. ‘ ^ (-2.29) 
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m ' ^ ^ E S I pleckstrin homology-l ikc domain, fam i t yA , member 1 1 :'厂 ^ ^ ^ pieckstrin homoiogy-Uke domain, family A, member 1 
齡 m m hairy and enhancer of split 1, (Drosophl la) 恐•^ W r^i-J' '•‘麵 im hairy and enhancer of spitt 1, (Drosophila) ^JBT MftWi BUB H synaptotagmin-liko 4 (granuphilin-a) ML^^^H ：. hypothetical protein FU 12442 ^ m ^ ^ ^ ^ j^lH • ' - V B Hi ubiqurtiivactivating enzyme E1 (A1S9T and BN75 temperature oensitivit.. 
B B HHI jIIP ^^ collagen, type XVI, alpha 1 - J I ^ B r^"',. • • • … _ • gb:AK025148.1 /DB„XREF-gi: 10437607 /FEA«mRNA /CNT« 1 /TID-Hs... L M • PP ^JBI • • lH MRNA; cDNA DKFZp686E2444 (from Clone DKFZp686e2444) � jmr^ ”Immunoglobulin kappa tight chain VKJ reflion mRNA, partial cds 
m • ，广r hypothetical protein MOC2716S • • gb:AJ408433 /De_XREF-fli: 12655549 /FEA"DNA/CNT-1 /TID-Hs,307.. 
simi lar to immunoglobul in kappa light chain VC region • • gb:AF103529,1 /D日一XREF-gi:4378387 /FEA-mRNA/CNT-1 /TID-Hs 2 jJ;^： immunoglobulin kappa constant /// Clone P2-32 anti-oxidized LDL imm... 
：发h : • • H saptena mRNA for rearranged Ig kappa light chain variable region (II . . 
^ H ^ B immunoglobul in kappa constant /// Isolate M5 immunoglobul in kappa lig.. 
^ ^ Immunoglobul in koppa conotant K^ Immunoglobulin kappa constant 
__ H HL— mm immunoglobulin Kappa constant 厂 mLJBI嫩 | | l J j jHB^ gb:AW088232 /DBJXREF-fll:6044037 /DB_XREF-xc99c09.x1 /CLONE.. 
^ • B f B i ^ J M B ^ r ^ 1 CD1A entigon, a polypeptide H -^iS^ iijBr HHS^ ^^  erythrocyte membrane protein band 4.1-like 1 r r r� . iil^ fe ^HMEL — 一 gb:AI334015 /DB_XREF-gl:4070574 /DB_XREF-qq18b05>1 /CLONE-, n- 飽� 纖 ATP-binding cassette, sub-family B (MDR/TAP). member 5 HL^ “‘访 mPmiPHI Wl ^B^ caopase 8, apoptosis-related cysteine protease ^Bjjjli ^ ^ ^ J g ^ HkB mitogen-activsteci protein kinase kinase kinase 4 1 ^BI^^JPI^^，: • 0b:AV661099 /DB.XREF-gi:9882113 /DB_XREF-AV661099 /CLONE-— ^^^mpH^^llll^:!^ 二L H^lll^^ zinc fingor protein"494 r Hm^^^^UIP^ mH HH H TYRO protein tyrosine kinase binding protein 
H P H H H P • chemoWno (C-C motif) receptor 1 
一 .説 carti lage oligomeric matrix protein 
1 H P ^ l H H I ^ ^ H complement component 1 • q subcomponent , gamma polypeptide 
. 减 m ^ ^ ^ J B coagulat ion factor II ( thrombin) receptor- l ike 2 ^^ mitochondrial glutominase pseudogene r ^T^H^^H CDNA FLJ10198 fis, Clone HEM 8A1004806 iir^^yHlllH 醒 ^^ IHK'V ' i ^p l gb;AA588092 ADB_XREF-gi;2402267 /DB_XREF-nm98g07.s1 /CLONE., 
r ftSs ^^"^^^^BBi tudor domain containing 6 ^J j lR^T Qb;AI017540/DBJ<REF«gi:323ie76/DB.XREF»ou35c02x1 /CLONE»l.. 厂 湖 ^^P^，.SB Jjl^B^^^^?® -^^： regeneration fts»oci«ted muscle protease r ocotropic viral Integration site 2A ‘ ^f^Hpijl^H membrone-sponning 4-clomeins, subfamily A, member 6A B^^^ElldH HI ^^^TB C-type (calcium dependent, carbohydrate-recognition domain) lectin,« . ！® 麵 ATP-binding cassette, siib-famity A (A日C1). member 1 M^H^BHI ra “ 嫌“丨 Ras-related GTP binding D - ^ J B •載 ATP-binding cassette. «ub-famity A (ABC1). member 1 
| | H | | | f ^ | | | | t ' ： ' ' - | | B interleuWn 18 (tnterfcrorvgommei-inducing factor) r . ''^jUfcB^B H tntegrin. beta 2 (antigen CD18 (p95). tymphocyte function-associated a... 
I Hi H H H H membrane-ftpanning 4-c(onnain«, subfamily A, member 6A 
mmmmm mmmmm 
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) 
Figure 3.2 Hierarchical clustering dendrogram of 76 probe sets from supervised gene 
selection analysis with criteria: (1) Lower bound fold change larger than 1.5; (2) p-value 
for t-test less than 0.05, Red represents the up-regulated probe sets while blue represent 
the down-regulated probe sets. Control samples are indicated as (C) and patient samples 
are indicated as (P). Samples with different degree of prolapse are indicted by: (N) N o 
prolapse; (F): First-degree prolapse; (S): Second-degree prolapse; (T): Third-degree 
prolapse. 
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Molecular- function. Level : 4 b ' 20 ' 40 ' 60 ' 80 • lOO 
DNA b i n d i n g • • • • • • • 42. i lX 
n e t a l i o n b i n d i n g H H B H H H H 42.11X 
cation binding H H H 36-842 
transnenbrane receptor activity H B H 15 -792 
purine nucleotide binding H i 10.53% 
cytokine binding • 5.26% 
folic acid transporter activity • 5-26X 
protein self binding • 5-26X 
transcription corepressor activity • 5.26X 
ubiquitin—like activating enzyne activity • 5.262 
peptidase activity • 5.26X 
transcript-ion coactivator activity • 5.26X 
sterol transporter activity • 5.26X 
electrochenical potential—driven transporter»•• • 5.26% 
receptor binding • 5-262 
ion channel activity • 5-26% 
peptide receptor activity • 5.26% 
g rowth f a c t o r a c t i v i t y • 5-26^ 
folic acid binding • 5.262 
hydrolase activity, acting on acid anhydrides • 5.26X 
enzyne b i n d i n g • 5-26% 
ubiquitin activating enzyne activity • 26% 
anion transporter activity • 5.26% 
cytokine activity • 5.26% 
thianin transporter activity • 5.26X 
transcription factor binding • 5.262 
alpha-type channel activity • 5.262 
0 20 40 60 80 100 
1 I I I I I I I I I I 
Figure 3.3a Annotation classification (p-value < 0.001) of the differentially expressed 
genes in cardinal ligament tissues in patients with uterine prolapse compared to controls. 
Distributions of the GO terms under molecular function were shown. 
» / 
6 6 • 
Biological process. Level: 4 b ' ' 40 ' 60 ' 80 ' '100 
prinary netabolisn H H I H B H H H H B I 59.09% 
cellular netabolisn I H H H H H H H H H 59-09% 
regulation of cellular physiological process H H H H H H ^OZ 
regulation of netabolisn H H H H H H I 40.91J； 
Innune response H H H H H I 31.82艺 
defense response H H H H H 31.62Z 
establishnent of localization • • • • • 27,272 
transport H H H H 22.732 
signal transduction H H H 22,73% 
response to other organisn I H H H 18-18% 
cell-cell sigfnalini； • H 18,18% 
response to Mounding H H H 18.18Z 
nacronolecule netabolisn H H H 18.18% 
cell proliferation m 18.18% 
response to pest, pathogen or parasite H H H 1Q.18Z 
negative regulation of cellular process H H 13.642； 
cell death • • 13.64% 
negative regulation of physiological process H H I 13.64% 
taxis • • 9.09：^  
positive regulation of cellular process H 9,09Z 
ion lioneostasls H I 9,09Z 
response to chenlcal stxnulus H 9.09% 
nervous systen developnent H I 9.09% 
loconotory behavior H 9.09；^  
cell honeostasls • • 9.09% 
skeletal dcvclopncnt H i 9,09Z 
regulation of signal transduction • 4.55J； 
cell-cell adhesion • 4,55Z 
regfulation of organisnal physiological proce^ ^  ^  • 4.55% 
reproductive organxsnal physiological process • 4,55% 
pregnancy • 4.55% 
vasculature dcvelopnent • 4 
response to nechanical stinulus • 4.55% 
biosynthesis • 4.55^ 
cell-substrate adhesion • 4 -55^； 
nechanosensory behavior • 4.55% 
cell organization and biogenesis • 4.55% 
cellular norphogcnesis • 4.552 
cell cycle • 4-5521 
nusclc dcvelopncnt • 4,55Z 
localization of cell • 4.55% 
circadlan rhythn • 4.55^ 
cell motility • 4.55% 
organ Morphogenesis • 4.55Z 
nitrogen conpouncl netabolisn • 4-55% 
regulation of cell adhesion • 4.55% 
positive regulation of physiological process • 4-55% 
cell activation • 4.552 
br;aln developnent • 4.55% 
• neurophyslolo£;lcal process • 4.55Z 
sleep • 4,55Z 
0 20 40 60 80 100 
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Figure 3.3b Annotation classification (p-value < 0.001) of the differentially expressed 
genes in cardinal ligament tissues in patients with uterine prolapse compared to controls. 
Distributions of the GO terms under biological process were shown. 
I 
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C e l l u l a r component. Level: 5 • • • • • • " > • • • ^ ‘ 0 20 40 60 80 100 
nucleus • • • • • • • 47.372； 
integral to nenbrane H H B 42.11^ 
in t r ins ic to plasna nenbrane H H H I 26.32之 
nitochondrion • 5.26^ 
inmjnological synapse • 5.26^ 
cytoskeleton • 5.26^ 
anchoring collagen • 5.26X 
0 20 40 60 80 iOO 
1 I I I I I I I I I I 
Figure 3.3c Annotation classification (p-value < 0.001) of the differentially expressed 
genes in cardinal ligament tissues in patients with uterine prolapse compared to controls. 
Distributions of the GO terms under cellular component were shown. 
> 
6 8 • 
Tabic 3.2 showing the genes involved in each GO term under (a) Molecular function (b) 
Biological process and (c) Cellular component by annotation classification (p-value < 
0.001) of the differentially expressed genes cardinal ligament tissues in patients with 
uterine prolapse compared to controls. 
Molecular function Genes 
DNA binding EGR2, SNFILK, MYC, KLFIO, ZSCAN4, 
H E S 1 ’ E G R 3 ’ C E B P D 
Metal ion binding EGR2, COMP, SNFILK, U B E l , KLFIO, 
ZSCAN4, EGR3, MGC13168 
Cation ion binding EGR2, COMP, SNFILK, KLFIO, ZSCAN4, 
EGR3, MGC13.168 
Transmembrane receptor activity CCR1, CD 1 A, EVI2A 
Purine nucleotide binding U B E l , ABCAl 
Cytokine binding CCRl 
Folic acid transporter activity SLC19A2 
Protein self binding CASP8 
Transcription corepressor activity SNFl LK 
Ubiquitin-like activating enzyme activity UBEl 
Peptidase activity CASP8 
Transcription coactivator activity SNFl LK 
Sterol transporter activity ABCAl 
Electrochemical potential-driven transporter activity SLC19A2 
Receptor binding IL18 
Ion channel activity MGC13168 
Peptide receptor activity CCRl 
Growth factor activity . 丨LI 8 
Folic acid binding SLC19A2 
Hydrolase activity, acting on acid anhydrides ABCAl 
Enzyme binding ITGB2 
Ubiqujtin activating enzyme activity UBEl 
. Anion transporter activity ABCAl 
Cytokine activity ILl 8 
Thiamine transporter activity SLC 19A2 
Transcription factor binding SNFILK 
Alpha-type channel activity MGL13168 


































































































































































































































































































































































































































































































































































































































































































































































































Reproductive organismal physiological C 0 L 1 6 A 1 
process 
Pregnancy C 0 L 1 6 A 1 
Vasculature development IL18 
Response to mechanical stimulus EGR2 
Biosynthesis IL18 
Cell-substrate adhesion ITGB8 
Mechanosensory behaviour EGR2 
Cell organization and biogenesis 1TGB8 
Cellular morphogenesis ITGB8 
Cell cycle M Y C 
Muscle development EGR3 
Localization of cell ITGB8 
Circadian rhythm EGR3 
Cell motility ITGB8 
Organ morphogenesis IL18 
Nitrogen compound metabolism 1TGB8 
Regulation of cell adhesion IL18 
Positive regulation of physiological IL18 
process 
Cell activation IL18 
Brain development EGR2 
Neurophysiological process SLC19A2 
Sleep 丨 LI 8 
• 
Cellular component Genes 
Nucleus EGR2, S N F I L K , MYC, KLFIO, ZSCAN4, H E S l ’ EGR3’ 
CEBPD, R R A G D 
Integral to membrane SLC19A2, C C R l ’ TYROBP’ C D I A , EVI2A, M G C l 3168， 
. ‘ 丨 TGB2，ABCA1 
Intrinsic to plasma membrane C C R l , TYROBP, C D I A , 1TGB2, A B C A l 
Mitochondrion CASP8 
Immunological synapse C D I A 
Cytoskeleton CASP8 
Anchor ing collagen C 0 L 1 6 A 1 
7 1 • 
3.1.2.2 Gene Expression Profiles Distinguish Cardinal Ligament with Different 
Degrees of Uterine Prolapse from Control and Identify Differentially 
Expressed Genes 
We have used (1) lower bound fold change larger than 1.5; (2) p-value for t-test 
less than 0.05 to compare patient samples with different degrees of prolapse and control 
samples. In the comparison of three first-degree prolapse samples and five control samples, 
133 probe sets representing 115 genes satisfied the comparison filtering criteria were 
obtained with 30.8% median FDR by 100 permutations. Twenty two genes were 
up-regulated and 93 genes were down-regulated in the first-degree prolapse samples 
compared with that in the controls. In the comparison of five second-degree prolapse 
samples and five control samples, 52 probe sets representing 45 genes satisfied the 
comparison filtering criteria were obtained with 48.1% median FDR by 100 permutations. 
Sixteen genes were up-regulated and 29 genes were down-regulated in the second-degree 
prolapse samples compared with that in the controls. In the comparison of four 
third-degree prolapse samples and five control samples, 67 probe sets representing 57 
genes satisfied the comparison filtering criteria were obtained with 46.1% median FDR by 
» 
‘ 100 permutations. Ten genes were up-regulated and 47 genes were down-regulated in the 
third-degree prolapse samples compared with that in the controls. The output gene lists 
were shown in Table 3.3a, b, and c. 
7 2 • 
Table 3.3 (a) List of differentially expressed (lower bound fold change > 1.5; p < 0.05) 
genes in cardinal ligaments in patients with first-degree uterine prolapse compared with 
controls. 
Accession Gene Name Symbol Map Lower Bound 
Fold Change 
(Fold Change) 
22 up-regulated genes in first-degree prolapse samples compared with controls 
BF590528 gb:BF590528 2.41 
/DB_XREF=gi: 11682852 (22.16) 
/DB_XREF=7h36hl0.xl 
/CLONE=IMAGE:3318115 





M28825 CD 1A antigen, a CDIA Iq22-q23 2.34 
polypeptide (18.44) 
AW026963 Serine/threonine kinase 35 STK35 20pl3 2.20 
(4.77) 
AV698647 Immunoglobulin lambda 1GLC2 22ql 1.1-ql 1.2 2.10 
constant 2 (Kern-Oz- marker) (3.07) 
BC034605 CDNA clone IMAGE: 1.96 
4838146 (5.20) 
X76775 Major histocompatibility HLA-DMA 6p21.3 1.89 
complex, class II, DM alpha (2.77) 
BF338860 Membrane-spanning MS4A6A llcil2.1 1.79 
4-domains, subfamily A, (2.70) 
member 6A 
L03419 Fc fragment of IgG, high FCGRIA Iq21.2-q21.3 1.72 
" affinity la, receptor for (2.54) 
. ’ (CD64) 
AF085899 Glycophorin E GYPE 4q31.3 1.71 
(2.31) 
AI972498 Glycoprotein, GGTA 丨 9q34.11 1.70 
alpha-galactosyltransferase 1 (2.37) 
NM_001228 Caspase 8, apoptosis-related CASP8 2q33-q34 1.70 
cysteine protease (2.16) 
7 3 • 
( C o n t i n u e d ) 









BF109557 F-box protein 10 FBXOlO 9ql3 .2 1.66 
(3.58) 
NIVI_002747 Mitogen-acitvated protein MAPK4 18ql2rq21 1.63 
kinase 4 (2.03) 
NM—001803 CDW52 antigen CD52 lp36 1.62 
(CAM PATH-1 antigen) (2.00) 
BF511741 Latrophilin 3 LPHN3 4ql3 .1 1.60 
(2.55) 
AL022324 Similar to omega protein LOC91353 22q 11.23 1.60 
(2.09) 
BF002474 CTD (carboxy-terminal CTDSPL 3p21.3 1.58 
domain, RNA polymerase II, (2.79) 
polypeptide A) small 
phosphatase-like 
S81973 Polyhomeotic like 3 PHC3 3q26.2 1.58 
(Drosophila) (2.51) 
AL359651 Glulamate receptor, GRIN3A 9q31.1 1.57 
ionotropic, (3.01) 
N-methyl-D-aspartate 3A 
BC017833 Primase, polypeptide 2A, PRIM2A 6 p l 2 - p l l . l 1.54 
58kDa (11.63) 
U52696 ‘ cAMP responsive element C R E B L l / 6p21.3 1.53 
. ‘ binding protein-like 1 III TNXB (2.38) 
tenascin XB III cAMP 
responsive element binding 
protein-like 1 III tenascin XB 
7 4 “ 
( C o n t i n u e d ) 
93 down-regulated genes in first-degree prolapse samples compared with controls 
AI818409 Wingless-type MMTV WNT16 7q31 -11.29 
integration site family, (-125.31) 
member 16 
NM_002467 Pleckstrin homology-like PHLDAl 12ql5 -4.29 
domain, family A, member 1 (-7.99) 
NM_17335 KIAA0774 K1AA0774 13ql2.3 -3.37 
(-7.99) 
AI743452 v-myc myelocytomatosis MYC 8q24.12-q24.13 -3.32 
viral oncogene homolog (-6.03) 
NM_012081 SNFl-like kinase SNFILK 21q22.3 -2.98 
(-6.71) 
NM_003234 Transferrin receptor (p90, TFRC 3q29 -2.97 
CD71) (-32.13) 
NM_000399 Elongation factor, RNA ELL2 5q l5 -2.86 
polymerase 11, 2 (-5.43) 
NM_004430 Transferrin receptor (p90, TFRC 3q29 -2.79 
CD71) (-7.06) 
NM_020249 Early growth response 2 EGR2 10q21.1 -2.73 
(Krox-20 homology, (-5.05) 
Drosophila) 
AI860150 Early growth response 3 EGR3 8p23-p21 -2.67 
(-5.85) 
AL832657 Adisintegrin-likeand ADAMTS9 3pl4.3-pl4.2 -2.59 
metalloprotease (reprolysin (-3.91) 
type) with thrombospondin 
type 1 motif, 9 
N50864 FOS-like antigen 2 F0SL2 2p23.3 -2.35 
(-3.27) 
M60278 Ring finger protein 24 RNF24 RNF24 -2.32 
„ ‘ (-9.26) 
, NM_005627 Serum/ glucocorticoid SGK 6q23 -2.24 
regulated kinase (-5.53) 
Al l27432 Diphtheria toxin receptor HBEGF 5q23 -2.24 
(heparin-binding epidermal (-4.40) 
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NM_014366 DnaJ (Hsp40) homolog, DNAJB9 19pl3.2 -1.84 
subfamily B, member 9 (-3.36) 
AW003297 RNA, U47 small nuclear RNU47 lq25.1 -1.83 
(-3.02) 
AK024318 Guanine nucleotide binding GNL3 3p21.1 -1.82 
protein-like 3 (nucleor) (-2.99) 
NM_022767 Ral GEF with PH domain RALGPS2 lq25.2 -1.82 
and SH3 binding motif 2 (-2.82) 
W95007 Ubiquitin specific protease USP46 4q l2 -1.79 
46 (-3.41) 
AW467048 Interferon stimulated ISG20L1 15q26.1 -1.79 
exonuclease gene lOkDa-like .. (-2.44) 
1 
AFl 53330 Acyl-CoA synthetase ACSL4 Xq22.3-q23 -1.78 
long-chain family member 4 (-4.00) 
AA778938 Splicing factor YT521-B YT521 4ql3.2 -1.78 
(-2.40) 
AFl53330 Solute carrier family 39 (zinc SLC39A8 4q22-q24 -1.74 
transporter), member 8 (-3.28) 
AF293026 Sec61 beta subunit SEC61B 9q22.32-q31.3 -1.73 
(-2.40) 
AV700621 Solute carrier family 19 SLC39A8 4q22-q24 -1.72 
(thiamine transporter), (-3.24) 
member 2 
AW627671 Steroid receptor RNA SRAl 5q31.3 -1.72 
activator 1 (-2.70) 
NM—015062 Transforming growth factor, TGFBRl 9q22 -1.72 
beta receptor I (-2.23) 
AW627671 Cytoplasmic polyadenylation CPEB2 4pl5.33 -1.72 
element binding protein 2 (-2.23) 
NM_015062 Peroxisome proliferative PPRCl 10q24.32 -1.72 
» 
. activated receptor, gamma, (-2.05) 
coactivator-related 1 
X89894 Nuclear receptor subfamily 4, NR4A3 9q22 -1.69 
group A, member 3 (-3.92) 
NM_001856 Collagen, type XVI, alpha 1 C0L16A1 Ip35-p34 -1.68 
(-2.08) 
7 7 • 
(Continued) 
A1928037 Rap2-binding protein 9 RPIB9 7q21.12 -1.67 
(-2.53) 
NM_005195 CCAAT/enhancer binding CEBPD 6p25 -1.66 
protein (C/EBP), delta (-2.81) 
AV700891 gb:AV70089I -1.65 








AF216292 Heat shock 70kDa protein 5 MS PA 5 9q33-q34.1 -1.64 
(glucose-regulated protein, (-3.00) 
78kDa) 
BC001258 Phosphoglucomutase 3 PGM3 6q l4 .1 -q l5 -1.64 
(-2.94) 
AF070569 Hypothetical protein MGC14376 17pl3.3 -1.64 
MGC14376 (-2.56) 
AI572079 Snail homolog2 (Drosophila) SNAI2 8 q l l -1.63 
(-2.85) 




NM_000786 Cytochrome P450, family 51, CYP51A1 7q21.2-q21.3 -1.63 
subfamily A, polypeptide 1 (-2.54) 
BE138647 Eukaryotic translation EIF5B 2 p l l . l - q l l . l -1.63 
initiation factor 5B (-2.50) 
BC001140 ^ Dual specificity phosphatase DUSP23 lq23.2 -1.63 
. ’ 23 (-2.03) 
S73498 UDP-N-acteylglucosamine UAPl lq23.2 -1.62 
pyrophosphorylase 1 (-3.02) 
7 8 • 
(Continued) 









NM—015516 Leucine rich repeat LRRC54 l l q l 3 . 5 -1.61 
containing 54 (-2.72) 
BC005838 Beta 5- tubul in/ / /beta TUBB 6p21.33 -1.61 
5-tubulin (-2.53) 







sequence from clone 774G10 
on chromosome 
Xpl l .23-11.3 Contains a 
pseudogene similar to cyclin 
protein, ESTs, STS and GSSs 
/DEF=Human DNA sequence 
from clone 774G10 on 
chromosome Xpl 1.23-11.3 
Contains a pseudogene 
similar to cyclin protein, 
.. ‘ ESTs, STS and GSSs 
. AA721230 Ral GEF with PH domain RALGPS2 lq25.2 -1.58 
and SH3 binding motif 2 (-3.78) 
NM_006569 Cell growth regulator with CGREFl 2p23.2 -1.58 
EF hand domain 1 (-2.73) 
AV706522 Protein phosphatase iK PPM IK 4q22.1 -1.58 
(PP2C domain containing) (-2.50) 
7 9 • 
(Continued) 
AA902652 Phosphoribosylaminoimidazo PA ICS 4pter-q21 -1.58 




AI569804 Hypothetical gene supported LOC375295 2q31.1 -1.57 
by BC013438 (-3.14) 
AF074331 3'-phosphoadenosine PAPSS2 10q23-q24 -1.57 
5'-phosphosulfate synthase 2 (-2.51) 
NM_020150 S A R l a g e n e h o m o l o g 1 (S. S A R I A 10q22.1 -1.57 
cerevisiae) (-2.40) 
AW205632 Ribosomal protein S6 RPS6 9p21 . -1.57 
(-2.07) 
AL391688 Synaptotagmin-like 4 SYTL4 Xq21.33 -1.56 
(granuphilin-a) (-2.74) 
AC004010 Adhesion molecule with A M I G 0 2 12ql3.11 -1.55 
Ig-like domain 2 (-2.77) 
NM_018048 Mago-nashi homolog FLJ10292 12pl3.2 -1.55 
(-2.58) 
AL567295 Adaptor-related protein AP2B1 1 7 q l l . 2 - q l 2 -1.55 
complex 2, beta 1 subunit (-2.28) 
NM—004508 Isopentenyl-diphosphate IDIl 10pl5.3 -1.55 
delta isomerase (-2.13) 
NM_005384 Nuclear factor, interleukin 3 NFIL3 9q22 -1.54 
regulated (-2.70) 
AW150923 Signal sequence receptor, SSR3 3q25.31 -1.54 
gamma . (-2.39) 
(translocon-associaled 
protein gamma) 
NM_005371 Methyltransferase-like 1 METTLl 12ql3 -1.54 
. . ‘ (-2.21) 
. AP601745 Zinc finger protein 295 ZNF295 21q22.3 -1.53 
(-2.56) 
A1911518 G patch domain containing 4 GPATC4 lq22 -1.53 
(-2.20) 
8 0 
( C o n t i n u e d ) 








DKFZp566A193 (from clone 
DKFZp566A193) 




AV718487 gb:AV718487 -1.52 








AF161528 Comparative gene CGI-37 16q22.1 -1.52 
identification transcript 37 (-2.47) 
BC005299 Cytochrome c, somatic CYCS 7pl5 .3 -1.52 
. (-2.13) 
NM—005750 Chromosome 4 open reading C4orf6 4p l6 .2 -1.52 
frame 6 (-1.88) 
AL537042 ADP-ribosylation factor 4 ARF4 3p21.2-p21.1 -1.51 
. . ‘ (-2.91) 
. U51,478 ATPase, Na+/K+ ATP1B3 3q23 -1.51 
transporting, beta 3 (-2.20) 
polypeptide 




NM_001855 Collagen, type XV, alpha 1 C0L15A1 9q21-q22 -1.50 
(-2.55) 
AL565749 Tubulin, beta, 3 TUBB3 16q24.3 -1.50 
(-2.42) 
AL565074 Tubulin, alpha 1 TUBAl 2q35 -1.50 
» 
8 2 • 
Table 3.3 (b) List of differentially expressed (lower bound fold change > 1.5; p < 0.05) 
genes in cardinal ligaments in patients with second-degree uterine prolapse compared 
with controls. 
Accession Gene Name Symbol Map Lower Bound 
Fold Change 
(Fold Change) 
16 up-regulated genes in second-degree prolapse samples compared with controls 
NM_000095 Cartilage oligomeric matrix COMP 19pl3.1 3.09 
protein (5.36) 
M28825 CDIA antigen, a polypeptide CDIA Iq22-q23 2.21 
(17.27) 
AW088232 Paired box gene 6 (aniridia, PAX6 11 p i3 2.00 
keratitis) (14.15) 
AF285167 ATP-binding cassette, ABCAl 9q31.3 1.95 
sub-family A (ABC 1), (3.22) 
member 1 
S69189 acyl-Coenzyme A oxidase 1, ACOXl 17q24-q25 1.88 
palmitoyl (15.65) 
AW468201 UDP-GlcNAc:betaGal B3GNTL1 17q25.3 1.86 
beta-1,3-N-acelylglucosamin (5.19) 
yltransferase-like 1 III 
hypothetical protein 
LOG 146712 
NM_000211 Integrin, beta 2 (antigen ITGB2 21q22.3 1.75 
CD 18 (p95), lymphocyte (2.80) 
function-associated antigen 1; 
macrophage antigen 1 
(mac-1) beta subunit) 
AA573523 Erythrocyte membrane EPB41L1 2 0 q l l . 2 - q l 2 1.74 
protein band 4.1-like 1 (5.84) 
NM_012069' ATPase, (Na+)/K+ ATP1B4 Xq24 1.71 
. transporting, beta 4 (3.06) 
polypeptide 
AI671186 Regeneration associated RAMP 11 p i3 1.68 
muscle protease (2.65) 
AI912770 Calcium channel, CACNAIE Iq25-q31 1.60 
voltage-dependent, alpha IE (2.22) 
subunit 
8 3 • 
(Continued) 
AF272036 Ras-related GTP binding D RRAGD 6q l5 -q l6 1.60 
(2.06) 
NM_000177 Gelsolin (amyloidosis, GSN 9q33 1.59 
Finnish type) (2.52) 
NM_002705 Periplakin PPL 16pl3.3 1.58 
(2.81) 
BF002474 CTD (carboxy-terminal CTDSPL 3p21.3 1.57 
domain, RNA polymerase (2.58) 
II, polypeptide A) small 
phosphase-like 
NM—004079 Cathepsin S CTSS lq21 1.56 
29 down-reguhUed genes in second-degree prolapse samples compared with controls 
NM_004143 Cbp/p300-interacting CITED 1 Xql3.1 -4.07 
transactivator, with (-19.64) 
Glu/Asp-rich 
carboxy-terminal domain, 1 
AI795908 Pleckstrin homology-like PHLDAl 12ql5 -2.45 
domain, family A, member 1 (-4.56) 
AL833557 MRNA; cDNA -2.19 
DKFZp686E2444 (from (-14.24) 
clone DKFZp686E2444) 
BF063657 Elongation factor, RNA ELL2 5q l5 -2.07 
polymerase II’ 2 (-3.53) 
NM—005524 Hairy and enhancer of split 1, HESl 3q28-q29 -2.04 
(Drosophila) (-2.86) 
NM_030751 SNFl-like kinase/// SNFILK 21q22.3 -1.97 
SNFl-like kinase (-3.88) 
BF111990 K1AA0999 l lq23.3 -1.89 
. . � (-3.60) 
. AW’085505 AF/FMR2 family, member 3 AFF3 2ql l .2 -12 -1.81 
(-2.62) 
A1378893 Progesterone receptor PGR Ilq22-q23 -1.75 
(-2.59) 
H24547 Hypothetical protein l l p l 5 . 5 -1.73 
LOC338651 (-123.37) 
8 4 • 
(Continued) 
NM_024714 Ras homolog gene family, RHOF 12q24.31 -1.73 
member F (in filopodia) (-2.60) 
AI860I50 FOS-like antigen 2 F 0 S L 2 2p23.3 -1.73 
(-2.27) 
NM—022908 丨lypotlietical protein FLJ12442 3p21.1 -1.69 
FLJ12442 (-2.32) 
AL391688 Synaptotagmin-like 4 SYTL4 Xq21.33 -1.69 
(granuphilin-a) (-2.24) 
AA732944 Angiopoietin-like 1 ANGPTLl lq25.2 -1.68 
(-2.22) 
BC033328 CDNA clone IMAGE: -1.67 
4827119 . (-5.06) 
NM_001856 Collagen, type XVI, alpha 1 C0L16A1 Ip35-p34 -1.67 
(-2.25) 
AW003297 Ral GEF with PH domain RALGPS2 lq25.2 -1.66 
and SH3 binding motif 2 (-2.50) 
AK02I957 Collagen, type XXVII, alpha COL27A1 9q32 -1.64 
1 (-2.82) 
AK000106 Epidermal growth factor EGFR 7 p l 2 -1.63 
receptor (erythroblastic (-2.51) 
leukaemia viral (v-erb-b) 
oncogene homolog, avian 
AV704962 Sterol-C4-methyl S C 4 M 0 L 4q32-q34 -1.61 
oxidase-Iike (-2.61) 
AA639705 Squalene epoxidase SQLE 8q24.1 -1.59 
(-3.46) 
H43976 Mortality factor 4 like 2 MORF4L2 Xq22 -1.59 
(-2.47) 
NM_020249 A disintegrin-like and ADAMTS9 3p l4 .3 -p l4 .2 -1.58 
metalloprotease (reprolysin (-2.31) 
.. type) with thrombospondin 
» 
• type 1 motif, 9 
BC001207 Melanoma antigen, family D, 1V1AGED4 -1.58 
4 (-2.29) 
NM—003334 Ubiquitin-activating enzyme UBEl X p l l . 2 3 -1.58 





A1278445 Transcribed locus, weakly -1.54 
similar to NP_055301.1 (-2.73) 
neuronal thread protein 
AD7C-NTP 
H09620 Hypothetical protein LOC339400 lq21.3 -1.54 
LOC339400 (-2.25) 
A1885290 Spondin 1, extracellular SPONl l l p l 5 . 2 -1.50 
matrix protein (-2.70) 
» 
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Table 3.3 (c) List of differentially expressed (lower bound fold change > 1.5; p < 0.05) 
genes in cardinal ligaments in patients with third-degree uterine prolapse compared with 
controls. 
Accession Gene Name Symbol Map Lower Bound 
Fold Change 
(Fold Change) 
10 up-regulated genes in third-degree prolapse samples compared with controls 
NM—002575 Serine peptidase inhibitor, SERPINB2 18q21.3 2.21 
dade B，（ovalbumin), (11.45) 
member 2 
AA045175 Membrane-spanning MS4A6A l l q l 2 . 1 1.91 
4-domains, subfamily A, (2.76) 
member 6A 
NM—000139 Membrane-spanning MS4A2 l l q l 3 1.63 
4-domains, subfamily A, (2.23) 
member 2 (Fc fragment of 
IgE, high affinity I，receptor 
for; beta polypeptide) 
AI017540 ST3 beta-galactoside ST3GAL5 2 p l l . 2 1.60 
alpha-2,3-sialytransferase (2.78) 
NM_014210 Ecotropic viral integration EVI2A 17ql l .2 1.58 
site 2A (2.34) 
BC020552 Programmed cell death 6 PDCD6 5pter-pl5.2 1.55 
(1.99) 
AI681260 Leukocyte LILRBl 19ql3.4 1.54 
immunoglobulin-like (2.74) 
receptor, subfamily B, 
member 1 
AI200804 Hypothetical protein LOC255313 Xq24 1.52 
LOC255313 (2.22) 
A1702465 ‘ gb:AI702465 1.52 
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AF333388 Similar to 60S ribosomal LOC440737 lq43 -1.95 
protein L35 (-3.04) 
BF063657 Elongation factor, RNA ELL2 5q l5 -1.91 
polymerase II, 2 (-3.56) 
AL833001 ELOVL family member 5, EL0VL5 6p21.1-pl2.1 -1.88 
elongation of long chain fatty (-3.37) 
acids 
NM_020249 A disintegrin-like and ADAMTS9 3pl4.3-14.2 -1.88 
metalloprotease (reprolysin (-2.75) 
type) with thrombospondin 
type 1 motif, 9 
X55503 Metallothionein IV M T I V 16ql3 -1.86 
(-2.69) 
AF262032 Mab-21-like 2 (C. elegans) MAB21L2 4q31 -1.84 
(-4.90) 
AI091372 AXINl up-regulated 1 AXUDl 3p22 -1.81 
(-4.28) 
BE973687 Hairy and enhancer of split 1, HESl 3q28-ci29 -1.81 
(Drosophila) (-2.61) 
NM_013957 Neuregulin 1 NRGl 8p21-pl2 -1.79 
(-165.33) 
AA576961 Pleckstrin homology-like PHLDAl 12ql5 -1.78 
domain, family A, member 1 (-3.39) 
AV733950 Early growth response 1 EGRl 5q31.3 -1.76 
(-3.83) 
BF217861 Metallothionein IE M T I E 16ql3 -1.76 
(functional) (-2.39) 
NM_015062 Peroxisome proliferative PPRCl 10q24.32 -1.75 
activated receptor, gamma, (-2.13) 
coactivator-related 1 
AI675298 ‘ Cyclin LI CCNLl 3q25.31 -1.72 
. ‘ (-3.38) 
N36408 FOS-like antigen 2 F 0 S L 2 2p23.2 -1.69 
(-2.44) 
BC006440 Hypothetical protein MGC13168 12Q15 -1.67 
MGCl 3168 (-2.40) 
8 9 
( C o n t i n u e d ) 
AK023795 Adisintegrin- l ike and A D A M T S l 21q21.2 -1.66 
metalloprotease (reprolysin (-3.02) 
type) with thrombospondin 
type 1 motif, I 




N M _ 0 0 4 7 0 4 RNA, U3 small nucleolar RNU3IP2 3p21.2 -1.66 
interacting protein 2 (-2.31) 
NM—006290 Tumor necrosis factor, TNFA1P3 6p23 -1.63 
alpha-induced protein 3 (-2.33) 
AK026484 Spectrin, alpha, SPTANl 9q33-q34 -1.61 
non-erythrocytic 1 (-2.66) 
(alpha-fodrin) 
BC005163 Solute carrier family 25 SLC25A25 9q34.11 -1.58 
(mitochondrial carrier; (-2.25) 
phosphate carrier), member 
25 
NM—015675 Growth arrest and G A D D 4 5 B 19pl3 .3 -1.57 
DNA-damage-inducible , beta (-3.17) 
AI669495 C A M P responsive element C R E M 1 0 p l l . 2 1 -1.57 
modulator (-3.09) 
AF085950 Full length insert cDNA -1.55 
clone YR76A11 (-2.91) 
A1492873 Protein phosphatase 1, PPPIRIO 6p21.3 -1.55 
regulatory subunit 10 (-2.57) 
BC011527 gb:BC011527.1 -1.54 
/DB_XREF=gi : 15341675 (-4.35) 
/T lD=Hs2.406192.2 /CNT=2 
- ‘ / F E A = m R N A 
• /TIER=ConsEnd /STK=0 
/UG=Hs .406192 
/ U G _ T I T L E = H o m o sapiens, 
clone IMAGE:3872963 , 
mRNA/DEF=HoiTio sapiens, 
clone 1MAGE:3872963, 
m R N A . 
9 0 
(Continued) 
AF289615 gb:AF289615.1 -1.53 





/DEF=Homo sapiens clone 
pp9953 unknown mRNA. 
/PROD=unknown 
BC000069 Retinoic acid receptor RARRES2 7q36.1 -1.53 
responder (tazarotene (-1.87) 
induced)2 
NM_005655 Kruppel-like factor 10/TGFB KLFIO 8q22.2 -1.52 
inducible early growth (-2.09) 
response 
AF153330 Solute carrier family 19 SLC19A2 lq23.3 -1.51 
(thiamine transporter), (-2.52) 
member 2 
AB033053 Zinc finger protein 295 ZNF295 21q22.3 -1.51 
» 
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3.1.2.3 Gene Expression Profiles to Distinguish Cardinal Ligaments between 
Third-degree Prolapses from First-degree Prolapses and to Identify 
Differentially Expressed Genes 
We have used (1) lower bound fold change larger than 1.5; (2) p-value for t-test 
less than 0.05 to compare third-degree prolapse cardinal ligament and first-degree prolapse 
ligament samples. In the comparison of four third-degree prolapse and three first-degree 
prolapse samples, 44 probe sets representing 40 genes satisfied the comparison filtering 
criteria were obtained with 44% median FDR by 100 permutations. Thirty two genes were 
up-regulated and 8 genes were down-regulated in the third-degree prolapse samples 
compared with that of first-degree prolapse. The output gene list is shown in Table 3.4. 
» 
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Table 3.4 List of differentially up-regulated (lower bound fold change > 1.5; p < 0.05) 
genes in the cardinal ligaments of third-degree prolapse compared with that of first-degree 
prolapse. 
Accession Gene Name Symbol Map Lower Bound 
Fold Change 
(Fold Change) 
32 genes up-regulated in third-degree prolapse compared with first-degree prolapse 
BF939365 Calumenin CALU 7q32 2.87 
(5.03) 
NM—015577 Retinoic acid induced 14 RAI14 5pl3.3-pl3.2 2.45 
(24.05) 
NM_002524 Neuroblastoma RAS viral NRAS 1 pi3.2 2.15 
(v-ras) oncogene homolog (2.94) 
NM_004199 Procollagen-proline, P4HA2 5q31 2.05 
2-oxoglutarate 4-ciioxygenase (8.44) 
(proline 4-hydroxylase), alpha 
polypeptide II 
AF074331 3'-pliosplioadenosiiie PAPSS2 10q23-q24 1.97 
5'-phosphosulfate synthase 2 (4.73) 
NM—014737 Ras association (RalGDS/AF-6) RASSF2 20pter-pl2.1 1.86 
domain family 2 (15.19) 
NM_004353 Serine (or cysteine) proteinase SERPINHI l l q l 3 . 5 1.81 
inhibitor, clade H (heat shock (5.00) 
protein 47), member 1, 
(collagen binding protein 1) 
AK024318 Ubiquitin specific protease 46 USP46 4 q l 2 1.81 
‘ (3.46) 
AI972496 Insulin-like growth factor 1 丨GFl 12q22-q23 1.79 
(somatomedin C) (3.33) 
U37283 Microfibrillar associated MFAP5 12pl3.1-pl2.3 1.78 
,, "‘ protein 5 (3.20) 
• AL137654 BUBl budding uninhibited by BUBl 2q l4 1.76 
benzimidazoles 1 homolog (2.61) 
(yeast) 
K03460 Human alpha-tubulin isotype H2-ALPHA 2q21.1 1.74 
H2-aIpha gene, last exon (7.24) 
9 3 
( C o n t i n u e d ) 
BE789881 RAB31’ member RAS RAB31 18pl l .3 1.71 
oncogene family (2.53) 
AF154054 Gremlin 1 homolog, cysteine GREMl 15ql3-ql5 1.64 
knot superfamily (Xenopus (2.71) 
laevis) 
NM—022900 Putative protein product of NBLA04196 7q21.3 1.61 
Nbla04196 (2.70) 
NM_024616 TPA-induced transmembrane TTMP 3ql3.2 1.61 
protein (2.43) 
AI129310 Chromosome 13 open reading C13orfl8 13ql4.13 1.58 
frame 18 (2.61) 
NM_025061 Leucine rich repeat containing LRRC8E 19pl3.2 1.58 
8 family, member E (2.28) 
BF526855 Sarcolemma associated protein SLMAP 3p21.2-pl4.3 1.57 
(2.42) 
AF090884 Unc-13 homolog B (C. elegans) UNC13B 9p l2 -p l l 1.57 
(2.26) 
AA527296 Transportin 1 TNPOl 5cil3.2 1.55 
(2.05) 
AI924426 Elongation factor, RNA ELL2 5q l5 1.54 
polymerase II, 2 (2.97) 
A1432488 Hypothetical protein FLJ11155 1.54 
(2.71) 
AW516665 CDNAFLJ35556 fis, clone 1.54 
SPLEN2004844 (2.31) 
AI431730 Adisintegrin-like and ADAMTS9 3pl4.3-pl4 .2 1.54 
metalloprotease (reprolysin (2.06) 
type) with thrombospondin type 
1 motif, 9 
N48613 Chromosome 6 open reading C6orf65 6pl2.1 1.53 
•• frame 65 (2.56) 
. ALl62032 G protein-coupled receptor 133 GPR133 12q24.33 1.53 
(2.47) 
AK023769 Zinc finger protein 552 1.52 
(2.62) 
AL359651 Glutamate receptor, ionotropic, GRIN3A 3q31.1 1.52 
N-methyl-D-aspartate 3A (2.02) 
9 4 
( C o n t i n u e d ) 
AL122063 Glioma tumor suppressor GLTSCR2 19ql3.3 1.51 
candidate region gene 2 (3.11) 
BC033316 Hypothetical gene supported by LOC440572 lp36.13 1.51 
BC033316 (2.11) 
AV700621 Transforming growth factor, TGFBRl 9q22 1.50 
beta receptor 1 (2.24) 
8 genes down-regulated in third-degree prolapse when compared with first-degree prolapse 
BC035848 Hypothetical protein -1.98 
LOC55580 (-3.70) 
AL832657 Ring finger protein 24 RNF24 20-13-pl2.1 -1.96 
(-143.93) 
H50121 Astrotactin ASTN lq25.2 -1.80 
(-2.87) 
BC041995 GABA(A) GABARAP 17pl3.1 -1.73 
receptor-associated protein (-2.91) 
AL832009 Filamin A interacting protein FILIPl 6ql4.1 -1.70 
1 (-4.33) 
AF400602 C-type (calcium dependent, CLEC7A 12pl3.2-pl2.3 -1.59 
carbohydrate-recognition (-4.22) 
domain) lectin, superfamily 
member 12 
BF109557 F-box protein 10 FBXOlO 9pl3.2 -1.58 
(-2.72) 
AI743452 Similar to LINE-1 reverse LOC401623 Xq28 -1.55 
transcriptase homolog (-2.74) 
> 
9 5 
3.2 Validation of Microarray Data by Quantitative Real-time PCR 
Quantitative real-time PCR was performed to validate the microarray results. 
Based on the supervised comparative analysis and annotation classification results of the 
differentially expressed genes in the cardinal ligaments with prolapse, 7 up-regulated genes 
{IGKV, F2RL2, IGKC, ITGB2, IL18, CCRl and TYROBP) and 13 down-regulated genes 
(SNFILK, PHLDAl, ELL2, EGR3, MYC, HESl, AFF3, ADAMTS9, ADAMTSl, F0SL2, 
EGR2, KLFIO, and C0L16AI) were chosen as candidate genes for further validation by 
quantitative real-time PCR. The expression levels of these 20 candidate genes were further 
studied by real-lime PCR in the 12 patient and 5 control samples that were previously 
analysed in microarray. In addition, the patient and control RNA samples that were not 
used in the microarray analysis were used as independent sample groups for the real-time 
PCR validation. The patient sample size was expanded to 51 while that of the control was 
expanded to 46. In the 51 cases of uterine prolapse, 13 cases were first-degree prolapse, 32 
were second-degree prolapse and 6 cases were third-degree prolapse. The mean age of the 
patient group was 66.8 ±11 .2 years while that of controls was 48.5 土 8.5 years (p-value< 
0.00). In addition, the mean parity of the patient group was 4 ± 2 while that of control was 
» 
2.4 土 1.3 (p-value< 0.001). 
9 6 
3.2.1 Fold Change of Candidate Genes 
Table 3.5 showed the list of fold change of the candidate genes from the real-time 
PCR validation of microarray results with 12 patient and 5 control samples that were 
studied by microarray analysis. Table 3.6 showed the list of fold change of the candidate 
genes from the real-time PCR validation of microarray results with the independent sample 
groups of 51 patient and 46 control samples. The differences between the patient and 
control groups were determined by Mann-Whitney U Test. Figure 3.4 showed the trend of 
fold change of the candidate genes from the microarray and real-time PCR. 
As the mean age and mean parity of the patient group is significantly greater than 
that of controls, 8 pairs of age-matched and parity-matched patients (age: 65.3 土 6.8; parity: 
4 士 2.7) and controls (age: 66 土 7.1; parity: 3 土 1.5) with no significant difference 
(p-value>0.05) in mean age and parity were randomly selected for further analysis. As 
shown in Table 3.7, 14 out of the 20 candidate genes showed consistent significant 
differential expression in these eight patient samples when compared with the eight 
age-matched and parity-matched controls. 
» 
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Table 3.5 List of fold change of the candidate genes from the real-time PCR validation 
results with the 17 samples studied by microarray analysis. 
Gene Lower Bound Fold Change for real-lime PCR 
Symbol Fold Change 
for Microarray 
AH Degree First-degree Second-degree Third-degree 
IGKV 3.92 (p = 0.04) 4.34 (p = 0.04) 1,54 (p = 0.17) 7.40 (p = 0.11) 2.61 (p = 0.08) 
F2RL2 2.50 (p = 0.02) 4.71 (p = 0,06) 3.38 (p = 0.36) 1.89 (p 二 0.14) 13.07 (p = 0.06) 
IGKC 2.37 (p = 0.02) 3.84 (p = 0.03) 2.80 (p = 0.13) 5.83 (p = 0.08) 2.15 (p = 0.09) 
1TGB2 1.73 (p = 0.00) 1,14 (p = 0,92) 0.94 (p = 0.88) 1.40 (p = 0.60) 0.95 (p = 0.81) 
IL18 1.68 (p = 0.01) 1.62 {p = 0.53) 0.80 (p = 0.65) 1.41 (p = 0.75) 2.48 (p = 0.14) 
C C R l 1.61 (p = 0.01) 1.73 (p = 0.23) 1.74 (p = 0.12) ' 1.67 (p = 0.60) 1.79 (p = 0.33) 
T Y R O B P 1,58 (p = 0.00) 1.17 (p = 0.87) 0 .87 (p = 0.76) 1.04 (p = 0.92) 1.56 (p = 0.62) 
S N F I L K -2.63 (p = 0.03) -18.87 (p = 0.01) -41.23 (p = 0.03) -13.46 (p = 0.18) -8.87 (p = 0.01) 
P H L D A l -2 .45 (p = 0,04) -2.29 (p = 0,00) -2.19 (p = 0.03) -2.13 (p = 0.02) -2.63 (p = 0.05) 
ELL2 -2.34 (p = 0.02) -1.73 (p = 0,00) -2.25 (p = 0.05) -1.69 (p = 0.05) -1.40 (p = 0.02) 
EGR3 -2 .27 (p = 0,04) -4.16 (p = 0.04) -2.58 (p = 0.10) -3.38 (p = 0.08) -6.31 (p = 0.22) 
M Y C -2.15 (p = 0.02) -1.87 (p = 0.02) -1.40 (p = 0.05) -1.64 (p = 0.05) -2.50 (p = 0.14) 
H E S l -2.14 (p = 0.00) -2,23 (p = 0.00) -1.95 (p = 0.05) -2.11 (p = 0.02) -2.51 (p = 0,05) 
AFF3 -2 .10 (p = 0.03) -5.26 (p = 0.02) -6.26 (p = 0.30) -4.86 (p = 0.04) -5.01 (p = 0.01) 
A D A M T S 9 -1 .90 (p = 0.02) -1.31 (p = 0.05) -1.73 (p = 0.10) -1.24 (p = 0.05) -1.07 (p = 0.39) 
A D A M T S l -1 .88 (p = 0.01) -3.31 (p = 0.00) -2.77 (p = 0 .03) -3 .00 (p = 0.01) -4.37 (p = 0.05) 
F 0 S L 2 -1 .76 (p = 0.00) -1.16 (p = 0.01) -1.05 (p = 0.10) -1 .18 (p = 0.07) -1.22 (p = 0.03) 
EGR2 -1 .72 (p = 0.02) -2.87 (p = 0,03) -2.61 (p = 0.10) -2.29 (p = 0.11) -4.09 (p = 0.05) 
KLFIO -1 .69 (p = 0.01) -2.34 (p 二 0 .01) -2.33 (p = 0.03) -2,48 (p = 0.02) -2.16 (p = 0.03) 
C 0 L 1 6 A I -1 .57 (p = 0.04) -1.41 (p = 0.00) -1.25 (p = 0.03) -1 .47 (p = 0.01) -1.40 (p = 0.02) 
> 
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Tabic 3.6 List of fold change of the candidate genes from the real-time PCR validation 
results with the independent sample groups of 51 patient and 46 control samples. 
Gene Lower Bound Fold Change for real-time PCR 
Symbol Fold Change 
for Microarray 
AH Degrees First-Degree Second-Degree Third-Degree 
IGKV 3.92 (p = 0.04) 1.58 (p = 0.00) 1.26 (p = 0.18) 1.77 (p = 0.00) 1.40 (p = 0.99) 
F2RL2 2.50 (p = 0.02) 2.21 (p = 0.01) 1.71 (p = 0.14) 2.24 (p = 0.01) 3.50 (p = 0.24) 
IGKC 2.37 (p = 0.02) 2.43 (p = 0,00) 2.11 (p = 0.00) 2.82 (p = 0.00) 1.84 (p = 0.76) 
ITGB2 1.73 (p = 0.00) 1.25 (p = 0.21) 1.06 (p = 0.78) 1.44 (p = 0.01) 0.59 (p = 0.30) 
1L18 1.68 (p = 0.01) 1.58 (p = 0.02) 1.62 (p = 0.05) 1.6! (p = 0.04) 1.22 (p 二 0.43) 
C C R l 1.61 (p = 0.01) 1.62 (p = 0.01) 1.27 (p = 0.47) 1.88 (p = 0.00) 0.94 (p = 0.89) 
T Y R O B P 1.58 (p = 0.00) 1.22 (p = 0.21) 1.04 (p = 0.78) 1.41 (p = O.OI) 0.58 (p 二 0.30) 
S N F I L K -2.63 (p = 0.03) -19.36 (p = 0.00) -18,93 (p = 0,00) -21.45 (p = 0.00) -9.07 (p = 0.04) 
P H L D A l -2.45 (p = 0.04) -2.10 (p = 0.00) -1.97 (p = 0.03) -2.01 (p = 0,01) -3.6 (p = 0.00) 
ELL2 -2.34 (p = 0.02) -1.38 (p = 0.04) -1.47 (p = 0.06) -1.31 (p = 0.30) -1.48 (p = 0.09) 
EGR3 -2 .27 (p = 0.04) -6.66 (p = 0.00) -6,05 (p = 0.00) -5,69 (p = 0.00) -19.07 (p = 0.00) 
M Y C -2.15 (p = 0.02) -2.01 (p = 0.00) -1.87 (p = 0.01) -1 .93 (p = 0.01) -3.63 (p = 0.00) 
HESl -2.14 (p = 0.00) -1.85 (p = 0.00) -1.72 (p = 0.03) -1.79 (p = 0.00) -2.68 (p = 0.11) 
AFF3 -2.10 (p = 0.03) -2.62 (p = 0.00) -2.98 (p 二 0 .01) -2 .36 (p = 0.01) -2.83 (p = 0.10) 
A D A M T S 9 -1 .90 (p = 0.02) -1.27 (p = 0.40) -1.26 (p = 0.98) -1.31 (p = 0.18) -1.13 (p = 0.97) 
A D A M T S l -1 .88 (p = 0.01) -4.19 (p = 0.00) -4.81 (p = 0.00) -3.93 (p = 0.00) -4.20 (p = 0.02) 
F 0 S L 2 -1.76 (p = 0.00) -2.21 (p = 0.00) -2,02 (p = 0.06) -2.14 (p = 0.01) -3.41 (p = 0,12) 
EGR2 -1 .72 (p = 0.02) -2.76 (p = 0.00) -3.06 (p = 0.00) -2 .68 (p = 0.00) -2.60 (p = 0.00) 
KLFIO -1.69 {p = 0.01) -1.97 (p = 0.00) -1.84 (p 二 0 .04) -1.89 (p = 0.00) -2.91 (p = 0.09) 


































































































































































Table 3.7 List of fold change of the 20 candidate genes from the real-time PCR validation 
results with eight pairs age-matched and parity-matched patient and control samples. 
Gene Symbol Lower Bound Fold Change for real-time PCR 
Fold Change 
for Microarray 
IGKV 3.92 (p = 0.04) 1.37 (p = 0.30) 
F2RL2 2.50 (p = 0.02) 2.04 (p = 0.23) 
IGKC 2.37 (p = 0.02) 2.28 (p = 0.01) 
ITGB2 1.73 (p = 0.00) 1.20 (p = 0.60) 
IL18 1.68 (p = 0.01) 1.98 (p = 0.65) 
CCRl 1.61 (p = 0.01) 1.24 (p = 0.27) 
TYROBP 1.58 (p = 0.00) 1.20 (p = 0.60) 
SNFILK -2.63 (p = 0.03) -27.18 (p 二 0.00) 
PHLDAl -2.45 (p = 0.04) -2.49 (p = 0.00) 
ELL2 -2.34 (p 二 0.02) -1.73 (p = 0.02) 
EGR3 -2.27 (p = 0.04) -10.70 (p = 0.00) 
MYC -2.15 (p - 0.02) -2.37 (p = 0.01) 
HESl -2.14 (p = 0.00) -1.97 (p = 0.01) 
AFF3 -2.10 (p = 0.03) -2.28 (p = 0.01) 
ADAMTS9 -1.90 (p = 0.02) -1.70 (p = 0.01) 
AD A M I S 1 -1.88 (p = 0.01) -3.77 (p = 0.00) 
F0SL2 -1.76 (p = 0.00) -2.50 (p = 0.04) 
EGR2 -1.72 (p = 0.02) -2.84 (p = 0.01) 
KLFIO -1.69 (p = 0.01) -1.88 (p = 0.01) 
C0L16A1 -1.57 (p 二 0.04) -1.84 (p = 0.01) 
> 
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3.2.2 Correlation between Microarray and Quantitative Real-time PCR Results 
Table 3.10 shows the Pearson product-moment correlation of microarray and 
real-time PCR expression results. Eighteen out of the 20 candidate genes showed a 
positive Pearson correlation value with p-value < 0.05. These indicate that there was 
significant positive relationship between microarray and real-time PCR results, and all 
the candidate genes showed the same trend of direction of fold change from the two 
experiments. 
Tabic 3.10 Table showing the Pearson product-moment correlation of the expression of 
candidate genes of microarray and real-lime PCR. 
Gene Symbol Pearson Correlation p-value 
IGKV 0.693 0.002 
F2RL2 0.899 0.000 
IGKC 0.627 0.007 
ITGB2 0.620 0.008 
IL18 0.283 0.270 
CCRl 0.633 0.008 
TYROBP 0.232 0.370 
SNFILK 0.757 0.001 
PHLDAl • 0.523 0.031 
ELL2 0.678 0.003 
EGR3 0.824 0.001 
MYC 0.716 0.001 
^ HESl 0.545 0.024 
• ‘ AFF3 0.499 0.041 
ADAMTS9 0.542 0.038 
ADAMTSl 0.764 0.001 
F 0 S L 2 0.594 0.012 
EGR2 0.625 0.007 
KLFIO 0.547 0.023 
C0L16A1 0.588 0.013 
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CHAPTER 4 DISCUSSIONS 
4.1 Global Gene Expression Profiling using Oligonucleotide Microarray 
(R) 
4.1.1 Advantages of using Affymetrix GeneChip Microarray for Gene 
Expression Profiling 
The rapid development in microarray technology enables researchers to 
simultaneously monitor nearly every mRNA transcript in a cell, and to identify 
distinctive expression patterns characteristic of physiological and pathological states 
(Golub et al., 1999). There are varieties of microarray technologies available, in 
which Affymetrix GeneChip® Microarray provides optimal sensitivity, specificity, 
and reproducibility for microarray expression analysis. 
The high sensitivity of Affymetrix GeneChip® Microarray allows the 
identification of rarely expressed transcripts in a complex background. The use of 
unique 25-mer PM-MM probe strategy offers significantly higher sensitivity at low 
target concentrations (1:100,000-1:300,000) than using PM probes alone. In addition, 
> 
the MM probes are effective internal controls since they will hybridize to nonspecific 
sequences as effectively as their counterpart PM probes. Thus, unpredictable 
background signal variations associated with samples from different sources as well 
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as from cross-hybridization can be efficiently quantified and subtracted with the 
utilization of MM probes. Sensitivity/discrimination experiments also showed that 
probes of approximately 25 nucleotides long with a single base MM provide a very 
effective balance between signal intensity and related sequence discrimination 
(Lockhart et al., 1996). 
Furthermore, the global assay optimization strategy, which involves the 
investigation of the hybridization results of all probes on an array as a single data set, 
allows the derivation of assay conditions that maximize the number of genes detected 
on an array. In addition, redundant sampling of each sequence with multiple probe 
pairs in a probe set also provides robustness and reliability in the data obtained. In 
our microarray data, some of the significant differentially expressed genes were 
detected with more than one probe pairs in a probe set with the same expression 
trend. This indicates the considerable reliability of the data. 
Affymetrix GeneChip® Microarray platform also showed high reproducibility 
> 
in an evaluation study which measured reproducibility within a platform by 
measuring the correlation coefficient between fold changes of all the genes in 
replicate chips (Park et al., 2004). In addition, the manufacturer stated that 
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GeneChip® expression arrays generally have less than 2% false change, which is 
determined by hybridizing a single sample to two arrays of the same type, and 
determining the percentage of probe sets that show a significant change. It was 
shown that the false change rate from the arrays is significantly lower than the 
potential variability derived from different biological samples. 
4.1.2 Microarray Analysis Software 
4.1.2.1 DNA-Chip Analyzer Software 
DNA-Chip Analyzer (dChip) is a software package using model-based 
expression analysis of oligonucleotide arrays and several high-level analysis 
procedures such as comparative analysis and hierarchical clustering. The software 
can be freely assessed at www.dchip.org. 
The model-based approach allows probe-level analysis on multiple arrays. By 
pooling information across multiple arrays, the standard errors for the expression 
indices can be assessed. This approach also allows probe selection automatically in 
» 
the analysis stages to reduce errors due to cross-hybridization and image 
contamination (Li and Wong, 2001a). In the model-based expression analysis of 
oligonucleotide arrays, a statistical model for one probe set in multiple arrays is used 
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to account for the probe variability in computing expression levels (Li and Wong, 
2001a). 
Pij = PMij-MM丨广 (fij + £ij Zcfif 二 J’eirN(0’(72) 
It states that the product of model-based expression index (MBEI) in array i 
( 6 i ) and the probe-sensitivity index of probe j ( (p�)，plus random error is the 
difference PM — MM in array /，probe j of this probe set. J is the number of probe 
pairs in the probe set. Fitting the model, arrays with image contamination at this 
probe set (釣 ‘s with large standard error), cross-hybridizing probes (么 ‘s with large 
standard error, which are excluded during iterative fitting) as well as single outliers 
(image spikes) can be identified. Thus, errors due to image contamination, 
cross-hybridization, and single outliers can be reduced. 
Comparative analysis is a high-level analysis performed by dChip. It is used 
to identify genes that are reliably differentially expressed between two samples or 
two groups of samples. "E" and "B" in the analysis procedure stand for "Experiment 
group mean" and "Baseline group mean", which are the mean expression levels of 
» 
arrays in the group computed by considering measurement accuracy. Thus, E/B > 1.5 
or B/E > 1.5 for fold change threshold is set as a filtering criteria. The FDR of a set 
of predictions is the expected percent of false predictions in the set of predictions. 
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Another high-level analysis is hierarchical clustering, which is an 
unsupervised data analysis method used to cluster genes and samples with similar 
behaviors or expression profiles. In the dChip analysis, the expression for a gene 
across all samples are first standardized to have mean 0 and standard deviation 1 
before clustering, and these standardized values are used to calculate correlations 
between genes and samples. The clustering algorithm of genes is that the distance 
between two genes is defined as 1-r, where r is the correlation coefficient between 
the standardized values of the two genes across samples. Two genes with the closest 
distance are grouped into a supergene and connected by branches with length 
representing their distance. The expression level of the newly formed supergene is 
the average of the standardized expression levels of the two genes across samples. 
Next pair of supergene with the smallest distance is then chosen to merge and the 
process is repeated n-1 times to merge all the n genes. A similar procedure is used to 
cluster sample. Thus, in the clustering picture, genes or samples close to each other 
have a high similarity in their standardized expression values across all the samples 
or all the genes respectively. 
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4.1.2.2 Comparison of Statistical Methods for Analysis of Affymetrix GeneChip® 
Microarray Data 
A wide variety of statistical methods have been employed to analyze the 
Affymetrix GeneChip® Microarray Data. There are three commonly used analysis 
approaches: (1) Non-parametric algorithms implemented by Affymetrix in 
Microarray Analysis Suite v5.0 (MASS) (Hubbell et al., 2002; Liu et al., 2002) (2) 
Algorithms built around an error-modeling approach implemented in Rosetta 
Resolver® v3.1 (Roberts et al., 2000), and (3) Algorithms built around an 
intensity-modeling approach implemented in dChip (Li and Wong, 2001 a,b). All 
three methods are based on the difference between PM and MM intensities. 
The MASS analysis is based on non-parametric statistical analysis (Hubbell 
et al., 2002; Liu et a l , 2002). In the absolute analysis, the signal or expression level 
of the target molecule associated with each probe set is defined as the average value 
of PMi - CTi over all pairs in the probe set based on Tukey's biweight algorithm. CT] 
is the contrast value, which estimates a common mean non-specific hybridization 
» 
‘ background for an entire chip from PM by using a convolution model. It is set equal 
to a value that is slightly smaller than the corresponding 尸M, value only when MM, 
value is smaller than PMi. In the case of MMi is larger than PMi, an imputed value of 
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CTi is used for such probe pairs to avoid computing negative values for signal. In the 
comparison analysis, Wilcoxon signed rank test is used to compare the matched 
probe pair intensities from baseline to treatment arrays and determine whether the 
target concentration is changed. Three analyses are performed to compensate for the 
limitations of the simple global normalization procedures. One is based on the 
normalization intensities derived from the scaling procedure while the other two are 
based on perturbing the intensities on one of the two arrays up and down by a default 
perturbation factor of 1.1 (Hiibbell et al., 2002; Liu et al., 2002). 
Rosetta Resolver® v3.1 is an empirical intensity-based error model which is 
used to obtain a conservative estimate of signal variability (Roberts et al” 2000). 
This model depends on the array type and is appropriate when using data from arrays 
hybridized to the same RNA sample. In the absolute analysis, the signal for each 
probe set is defined as the average of PMi - MM, values for the probe pairs after 
eliminating values that lie outside three standard deviations from the mean. No 
attempt i s�made to adjust MM values that are larger than their corresponding PM 
values; therefore, a negative signal may be estimated for many probe pairs. In the 
comparison analysis, a single global normalization is performed between two arrays, 
followed by smaller adjustments for the regional effects within the array and 
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non-linear effects. The fold change is computed as the log of ratio of probe set level 
signals in the two arrays being compared. The error of this log ratio is computed by 
combining the modeled error of the individual signals and the variability of the signal 
with replicates (Roberts et al., 2000). 
A study by Rajagopalan (2003) compared these three statistical methods, in 
terms of their accuracy in detecting and quantifying relative gene expression 
(absolute analysis) and changes in gene expression (comparison analysis), for 
analysis of the data generated in microarray experiments using Affymetrix 
GeneChips®. It showed that all three methods had performed well in quantifying 
gene expression in absolute analysis. In addition, presence calls made by MAS5 and 
Resolver perform well at high concentrations, but they cannot be relied upon at low 
concentrations. The version of dChip based on the PM intensity alone performs 
poorly at low concentrations with a pronounced loss of sensitivity. The PM only 
model of dChip is used only when the MM signal is higher than the MM signal to 
avoid a negative expression value. However, the PM-MM version of dChip showed 
» 
‘ very few negative signals at low concentrations with high sensitivity. 
The performance of Resolver and MASS in detecting 2-fold changes in 
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mRNA transcript concentration is better than that of dChip. Furthermore, at a 
comparable false positive rate, Resolver and MAS5 are able to detect many more 
true changes in transcript concentration than dChip (Rajagopalan, 2003). 
We have chosen the dChip Analyzer (version 1.3) as the analysis tool because 
this PM-MM version of dChip showed very few negative signals at low 
concentrations with high sensitivity, and it performs absolute analysis as good as the 
other two statistical analyses. In addition, dChip is the only software that is freely 
and easily accessible from the web, and our laboratory has rich experience in using 
this software to analyze the microarray data in cancer research. The problem of 
relatively high false positive rates of dChip could be minimized by the validation of 
microarray result by qualitative real-time PGR with a larger sample size. 
4.2 Validation of Microarray Data 
4.2.1 Advantages of using Quantitative Real-time PCR for mRNA 
Quantification 
» 
‘ Microarrays are rapidly becoming a fundamental tool in discovery-based 
genomic and biomedical research. However, the reliability of the microarray results 
is being challenged due to the existence of different technologies and methods of 
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data analysis and interpretation. In the absence of a "gold standard" or reference for 
measurement of gene expression, the microarray results might yield subjective and 
conflicting conclusions (Tan et al., 2003; Yauk et al., 2004). 
Four independent mRNA quantification techniques are commonly used for 
the validation of microarray results, including northern blotting, nuclease protection 
assays, in situ hybridization and reverse transcription-polymerase chain reaction 
(RT-PCR). Northern analysis provides a direct relative comparison of mRNA 
abundance between samples on a single membrane (Parker and Barnes, 1999). It is 
the preferred method for determining transcript size and for detecting alternatively 
spliced transcripts. However, it can distinguish between members of multi-gene 
families only if they are in different sizes. In addition, if RNA samples are slightly 
degraded, the quality of the data and the ability to quantify expression will be 
severely compromised. Nuclease protection assays, including both ribonuclease 
protection assays and SI nuclease assays, are sensitive methods (detection limit is 
4,000 - 5,000 copies of mRNA) for the detection, quantification and mapping of 
> 
‘ specific RNAs in a complex mixture of total cellular RNA (Hod, 1992; Saccomanno 
et al., 1992). It can also resolve comigrating mRNAs and tolerates partially degraded 
RNA, However, there is a lack of probe flexibility and information about the 
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transcript sizes. In situ hybridization is the only method that could localize the 
mRNA expression within tissues or cells among the four. However, its sensitivity is 
low and it requires tissue sections (Parker and Barnes, 1999). 
Reverse transcription-polymerase chain reaction is the most sensitive and 
flexible technique for mRNA detection and quantification among the four methods 
(Wang and Brown, 1999). It is an in vitro enzymatic method to amplifying defined 
sequences of RNA (Rappolee et al., 1988). It has the highest sensitivity with 
theoretical detection limit of one copy of mRNA. It can also detect multiple 
transcripts, distinguish characterized members of multi-gene families and tolerate 
partially degraded RNA. There are two RT-PCR methods for measuring mRNA level: 
the conventional end-point PCR and real-time PCR. For the conventional PCR, the 
amount of final amplified DNA product is measured at end-point and 
electrophoretical separation of the amplified product is required (Rappolee et al., 
1988). 
> 
" In contrast, real-time PCR is often considered as the "gold standard" for gene 
expression measurements and changes (Mackay et al., 2002; Shi et al., 2005), and as 
an independent validation for microarray results in the majority of published 
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microarray studies. It has the advantages in detection sensitivity, sequence specificity, 
large dynamic range as well as its high precision and reproducible quantification 
compared to other techniques. TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, California) utilize the 5' nuclease activity of AmpliTaq 
Gold® DNA polymerase to hydrolyze a TaqMan® probe which is a target-specific 
probe. The TaqMan® probe will bound to its target sequence during PCR. There are 
two sequence-specific primers defining the endpoints of the target sequence and a 
TaqMan® probe with a fluorescent reporter dye (FAMTM) (Applied Biosystems, 
Foster City, California) and a nonfluorescent quencher moiety attached to the 5' and 
3' ends respectively. The primer set and the TaqMan® probe together provide two 
levels of sequence specificity. DNA contamination is minimized by designing 
primers that span at least one intron of the genomic sequence whenever possible. 
During each PCR extension cycle, the Taq DNA polymerase cleaves the reporter dye 
from the probe. Once the reporter is separated from the quencher, it emits its 
fluorescence to allow measurement of PCR amplification as it occurs, cycle by cycle, 
during the highly reproducible exponential phase of PCR. This enables a highly 
> 
‘ accurate and precise quantification of gene expression over a large dynamic range 
(107-fold). 
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4.3 Microarray Gene Expression Data Analysis 
4.3.1 Unsupervised Gene Sclcction 
In the unsupervised hierarchical clustering analysis, we found that the patient 
and control samples, as well as patient samples with different degrees of prolapse, 
did not show an unambiguous separation. One possible reason is that the sample size 
is not large enough. In addition, the clustering dendrogram shows individual samples, 
particularly the control sample L8 and two patient samples L20, L21, showed a set of 
highly up-regulated probes, which is different from other samples in the same group. 
This implied there might be other individual variability factors, such as body weight 
and living style, among the same group and the influence of these individual 
variability factors would affect the gene expression profiling among groups. 
4.3.2 Supervised Gene Sclcction 
4.3.2.1 Gene Expression Profiles Distinguish Cardinal Ligament with Uterine 
Prolapse from Control and Identify Differentially Expressed Genes 
In ^the supervised comparison analysis of the microarray data, only 14 genes 
were obtained by using 2-fold lower bound fold change as cut-off value. Therefore, 
we loosen the cut-off value criteria to 1.5 in order to see more genes that were 
differentially regulated in the cardinal ligament with uterine prolapse although they 
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might only have subtle change expression in the prolapse—patient ligament when 
compared with that of normal controls. We found 58 genes were differentially 
expressed between the patient samples and controls, and the average change in 
expression level between the two groups was at least 1.5-fold and was significant 
with t-test. Twenty nine genes were up-regulated and 29 genes were down-regulated 
in the patient samples. 
GO is one of the widely used ontologies, which organizes information for 
molecular function, biological processes and cellular components for a number of 
different organisms (Ashburner et al., 2000). Molecular function describes 
biochemical activities of a gene product, such as catalytic or binding activities, at the 
molecular level. The term molecular function describes only what is done, without 
specifying where or when the actual activity takes place. Molecular functions 
generally correspond to activities thai can be performed by individual gene products, 
but some activities are performed by assembled complexes of gene products. A 
biological process is a biological objective to which the gene or gene product 
“ contributes. A biological process is not equivalent to a pathway, but it is the result of 
one or more ordered assemblies or molecular functions. The difference between 
molecular function and biological process is that biological process must have more 
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than one distinct step. A cellular component refers to the place in the cells where the 
gene product is active (Ashburner et al., 2000). A web tool, FatiGo 
(http://fatigo.bioinfo.cnio.es), was used to find significant associations of GO terms 
with groups of genes (Mateoes et al., 2002). 
In the annotation classification of 58 differentially expressed genes in 
prolapse cardinal ligament, it was found that some differentially down-regulated 
genes, like EGR2, EGR3, SNFILK and KLFIO, were involved in molecular functions 
of DNA binding, metal ion binding and cation ion binding. This implied the 
down-regulation of these genes in uterine prolapse might affect the DNA or ion 
binding activity, which in turn the transcription factor activity that is important in the 
regulation of expression of other genes involved in uterine prolapse. In addition, 
other up-regulated genes, like IL18, CCRl, IGKC, TYROBP and ITGB2 and one 
down-regulated gene, SNFILK, were found to be involved in the biological processes 
of immune response, defence response, and wound healing. This implied uterine 
prolapse might involve increased inflammation and immune response. Genes like 
> 
‘ IL18, SNFILK, MYC and KLFIO were also found to be involved in cell proliferation 
and cell cycle. In addition, ITGB2 was involved in cell adhesion while C0L16A1 was 
involved in transport. Therefore, the pathogenesis of uterine prolapse might involve 
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DNA and ion binding regulation, immune response and cell proliferation, and the 
differential expression of these genes might be the risk factors or markers for the 
pathogenesis of uterine prolapse. The annotation classification results also enabled us 
to choose a set of candidate genes for further validation by quantitative real-time 
PCR. 
4.3.2.2 Gene Expression Profiles Distinguish Cardinal Ligament with Different 
Degrees of Uterine Prolapse from Control and Identify Differentially 
Expressed Genes 
In the comparison of first-degree prolapse samples and control samples, we 
found that 115 genes, including 22 up-regulated and 93 down-regulated genes were 
differentially expressed in the first-degree prolapse samples when compared with 
controls. These differentially expressed genes might be involved in the initiation 
process of the uterine prolapse. In the comparison of second-degree prolapse samples 
and control samples, we found that 45 genes, including 16 up-regulated and 29 
down-regulated genes, were differentially expressed in the second-degree prolapse 
’ samples when compared with controls. These differentially expressed genes might be 
involved in the progression process from first-degree to second-degree prolapse stage. 
In the comparison of third-degree prolapse samples and control samples, we found 
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that 57 genes, including 10 up-regulated and 47 down-regulated genes, were 
differentially expressed in the third-degree prolapse samples when compared with 
controls. These differentially expressed genes might be involved in the progression 
process from second-degree to third-degree prolapse stage. 
In the three comparisons, genes like PHLDAl, ELL2, HESl and AFF3, 
showed a consistent significant under-expression in all the three prolapse stages 
when compared with controls. In addition, other down-regulated genes, like SNFILK, 
EGR3, MYC, ADAMTS9 and F0SL2 also showed consistent differential expression 
in two prolapse stages when compared with controls. These implied the importance 
of these genes in the initiation and progression of uterine prolapse and thus, they 
were also good candidate genes for further validation by quantitative real-time PCR. 
In addition, although childbirth and menopause have long been considered 
the major risk factors for uterine prolapse, we have showed that 14 out of 20 
candidate genes showed a significant consistent trend of direction of fold change in 
> 
eight pairs of age-matched and parity-matched patient and control samples. These 
results suggested that the differential expression of these 14 candidate genes were 
independent of age and parity, and might depend on other factors such as the genetic 
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factors. 
4.3.2.3 Gene Expression Profiles Distinguish Third-degree Prolapse Cardinal 
Ligament from First-degree Prolapse Cardinal Ligament and Identify 
Differentially Expressed Genes 
In the microarray analysis, we found that 40 genes, including 32 up-regulated 
and 8 down-regulated genes were differentially expressed in the third-degree prolapse 
samples when compared with the first-degree prolapse samples. These genes might be 
involved in the progression of uterine prolapse and thus, further validation and 
characterization of these genes might help us to understand more about the progression 
of prolapse from the first-degree stage lo the third-degree stage. 
4.4 Potential Genes for Further Studies in Uterine Prolapse 
Based on the supervised comparative analysis and annotation classification 
results of the differentially expressed genes in prolapse cardinal ligaments, 7 
up-regulated genes {IGKV, F2RL2, IGKC, ITGB2, ILI8, CCRl and TYROBP) and 13 
I 
‘ down-regulated genes {SNFILK, PHLDAl, ELL2, EGR3, MYC, HESl, AFF3, 
ADAMTS9, ADAMTSl, F0SL2, EGR2, KLFIO and C0L16A1) were chosen as 
candidate genes for further validation by quantitative real-time PGR. Most of the 20 
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candidate genes showed a positive Pearson correlation value with p-value < 0.05. These 
indicated that there is significant positive relationship between microarray and real-time 
PCR results and all the candidate genes showed the same trend of direction of fold 
change from the two experiments. This revealed that our data were highly reproducible. 
The following was a brief introduction of these 20 candidate genes. 
Immunoglobulin Kappa Light Chain Variable Region (IGKV) and 
Immunoglobulin Kappa Constant (IGKC) 
Immunoglobulins are glycoprotein molecules produced by plasma cells in 
response to antigens and function as antibodies in the immune system. 
Immunoglobulins bind specifically to one or a few closely related antigens and each 
immunoglobulin actually binds to a specific antigenic determinant. All 
immunoglobulins have a four-polypeptide chain structure as their basic unit. They 
are composed of two identical light chains (23kD) and two identical heavy chains 
(50-70kD). Both the light and heavy chains can be divided into two regions based on 
the variability in the amino acid sequences: variable region (V) and constant region 
> 
(C). The specificity of the antibody is determined by the amino acid sequence of the 
variable regions in the light and heavy chains while the constant regions give the 
antibody its effector properties needed for inactivating the antigen. In between the 
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variable and constant region is the joining region (J). 
Immunoglobulins can be divided into five different classes based on the 
differences in the amino acid sequences in the constant region of the heavy chains. 
They are Gamma heavy chains (IgG), Mu heavy chains (IgM), Alpha heavy chains 
(IgA), Delta heavy chains (IgD) and Epsilon heavy chains (IgE). In addition, based 
on the small differences in amino acid sequences in the constant regions of the heavy 
chains, immunoglobulins in classes IgG and IgA can be divided into subclasses. For 
the IgG subclasses, there are Gamma 1 heavy chains (IgGl), Gamma 2 heavy chains 
(IgG2), Gamma 3 heavy chains (IgG3), and Gamma 4 heavy chains (IgG4). For the 
IgA subclasses, there are Alpha 1 heavy chains (IgAl) and Alpha 2 heavy chains 
(IgA2). Likewise, immunoglobulins can also be classified into two different types 
based on the differences in amino acid sequences in the constant region of the light 
chains. They are Kappa light chains and Lambda light chains. The Lambda light 
chains can also be divided into subtypes based on the differences in amino acid 
sequences in the constant region of the light chain. They are Lambda 1, Lambda 2, 
> 
“ Lambda 3 and Lambda 4. 
In the microarray analysis, immunoglobulin kappa light chain variable region 
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(IGKV), immunoglobulin kappa light chain VKJ region, immunoglobulin kappa 
constant (IGKC) and immunoglobulin heavy constant alpha 1 (IGHAJ) showed a 
3.92-fold, 2.57-fold, 2.37-fold and 1.85-fold over-expression respectively in the 
prolapse ligament. IGKV, immunoglobulin kappa light chain VKJ region and IGKC 
constitute the light chains of the immunoglobulins, and IGHAl encodes the heavy 
chain of IgA. The over-expression of these immunoglobulin components might be 
related to tissue trauma and in turn induced inflammation response in the cardinal 
ligament in patients with uterine prolapse. Further characterization of these 
immunoglobulin component genes might give us more understanding of the 
involvement of immune response in the pathogenesis of uterine prolapse and identify 
molecular markers for it. 
Coagulation Factor II Receptor-like 2 (F2RL2) 
F2RL2, also called PARS, encodes a member of the protease-activated 
receptor family and is activated by thrombin (Coughlin, 2000; Dery et al., 1998; Hou 
et al., 1998). It is also a member of the large family of seven-transmembrane-region 
‘ receptors that couple to guanosine-nucleotide-binding proteins. Protease-activated 
receptors play a role in coagulation and inflammation by regulating the function of 
monocytes and monocyte-derived antigen-presenting cells (Colognato et al., 2003). 
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Thrombin, besides its major role in hemostasis, is also involved in signaling 
pathways that modulate inflammatory reactions. During inflammation, thrombin is 
induced to stimulate a variety of blood and vascular cells including platelets, 
monocytes, and endothelial and smooth muscle cells (Coughlin, 2000; Dery et al., 
1998; Hou et al., 1998). F2RL2 is activated by proteolytic cleavage of its 
extracellular amino terminus, unmasking a new amino terminus, which functions as a 
tethered ligand and activates the receptor (Coughlin, 2000; Dery et al., 1998; Hou et 
al., 1998). 
F2RL2 is a cofactor for F2RL3 activation by thrombin. It mediates 
thrombin-triggered phosphoinositide hydrolysis and is expressed in a variety of 
tissues. In addition, they might play a role in the thrombin-mediated monocyte 
stimulation (Colognato et al., 2003). On the other hand, another study showed that 
expression of F2RL2 was up-regulated by induction of megakaryocyte phenotype in 
human erythroleukemia cells and thus it suggested that F2RL2 might play a 
developmental role, megakaryocytopoiesis, through the protein kinase C system 
> 
“ (Cupit et al., 2004). The over-expression of F2RL2 (2.5-fold) in the prolapse cardinal 
ligament also implied an inflammation process and tissue trauma in the pathogenesis 
of uterine prolapse. 
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Integrin, beta 2 (ITGB2) 
ITGB2 encodes the beta 2 chain of integrin protein. Integrins are integral 
membrane receptors composed of alpha and beta chains, which are known to 
participate in cell adhesion and cell-surface mediated signaling. For example, 
integrin beta 2 chain would combine with the alpha L chain to form the integrin 
LFA-1，and combines with the alpha M chain to form the integrin Mac-1. The 
various integrins are classified into subfamilies according to the beta subunit they 
have (Resales and Juliano, 1995; Ruoslahti and Reed, 1994). The integrin beta 1 
subfamily is comprised mainly of the receptors for ECM proteins, such as collagen, 
fibronectin, laminin and vitronectin (Ruoslahti, 1991). The integrin beta 2 subfamily 
expression is mainly found in white blood cells, and there are four beta 2 integrins 
within this subfamily: LFA-1, Mac-1, gp 150/95 and a d / / 5 2 (Arnaout, 1990a; Noti 
et al., 2000; Spinger, 1990). These integrins are mainly receptors for adhesion 
molecules on the surfaces of other cells, such as intercellular cell-adhesion molecules 
(ICAM-1) and ICAM-2. The ITGB2 is also shown to play an important role in 
regulating many leukocyte functions. For instance, patients with congenital 
» 
‘ leukocyte-adhesion deficiency syndrome have white blood cells that do not express 
normal levels of integrin beta 2, and these patients present recurring infections and 
die very young (Arnaout, 1990b). 
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During inflammation, different types of leukocyte leave the bloodstream in an 
orderly fashion and adhesion molecules act sequentially to allow leukocytes to leave 
the circulation (Springer, 1994). Selectins first interact with endothelial cells, while 
integrins of the beta 2 subfamily mediate subsequent strong cell attachment and 
migration. Once the leukocytes leave the blood vessels, they would interact with 
ECM proteins through the beta 1 integrins. Thus, both beta 1 and beta 2 integrins 
regulate different cell processes during inflammation (Reyes-Reyes et a l , 2002). 
Studies have also shown that beta 2 integrins are essential for cell migration and 
phagocytosis (Brown, 1995; Brown and Lindberg, 1996) while beta 1 integrins 
regulate the activation of immediate early genes that are important in inflammation 
(Aplin et al., 1998; J u l i a n � a n d Haskill, 1993). 
Furthermore, adhesion of human blood monocytes or monocytic cells to 
ECM proteins (Lin et al., 1994; Lin et al., 1995) and the ligation of beta 1 integrins 
with antibodies induce the activation of the nuclear transcription factor NF- n B, 
which is required for the transcription of inflammatory genes (Cogs well et al., 1994; 
> 
‘ Biscotti et al., 1993). A study has shown that beta 2 integrins can also activate NF- n 
B, but in a different signaling pathway (Reyes-Reyes et al., 2002). In addition, 
another report also showed that beta 2 integrins on neutrophils are also capable of 
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inducing gene activation and cytokine production (Walzog et al., 1999). In our 
microarray study, ITGB2 showed a 1.73-fold over-expression in the prolapse cardinal 
ligament when compared with controls. This result also implied uterine prolapse 
might involve inflammation processes like cell migration and adhesion, phagocytosis, 
as well as regulation of transcription of inflammatory genes. Further characterization 
of this gene might also enable us to identify molecular markers for uterine prolapse. 
Interleukm 18 (IL18) 
IL18 encodes cytokine protein with prominently wide spectrum biological 
actions, such as many proinflammatory functions. IL18 was initially called IFN- 7 
-inducing factor as it stimulates Thl cytokines by T cells and NK cells and promotes 
Thl cell differentiation and immune responses (Danielle, 1999; Okamura et al., 
1995). In addition, IL18, together with IL12, can regulate IFN- 7 (Kohno and 
Kurimoto, 1998). A study has shown that IL18 was an angiogenic mediator and 
played a role in the pathogenesis of rheumatoid arthritis (Park et al., 2001). 
Angiogenesis is integral to many physiological processes, such as wound healing, 
‘ and also to diseases states such as inflammatory conditions (Winkler and Seed, 1997) 
and rheumatoid arthritis (Szekanecz et al., 1998). Cytokines, chemokines, adhesion 
molecules, growth factors, and extracellular matrix receptors are the proflammatory 
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mediators involved in angiogenesis (Folkman, 2006). 
ILl8 is ascribed many inflammatory functions that are consistent with its role 
in angiogenesis. For instance, ILl 8 stimulates the production of other proangiogenic 
cytokines, such as TNF- a , IL-1 j3, and IL8 in non-CD 14+ PBMCs, resting T cells, 
and NK cells (Puren et al., 1998). Stimulation of the chemokine IL8 and other CXC 
chemokines by ILl8 has also been shown in the macrophage cell lines (Ohtsuki, et 
al., 1997; Shapiro et al., 1998). In addition, ILl8 promotes inflammation not only via 
other cytokine actions, but also through the promotion of other inflammatory 
mediators involved in angiogenesis. For instance, ILl8 would up-regulate the 
expression of a potently angiogenic VCAM-1 on RA synovial fibroblasts and hence 
amplifying the angiogenic response (Moreland et al., 1999). In our microarray study, 
IL18 showed a 1.68-fold over-expression in the prolapse cardinal ligament when 
compared with controls. This result suggested that uterine prolapse might involve 
proinflammatory response and angiogenesis. 
> 
Chemokine Receptor 1 (CCRl) 
CCRl encodes a member of the CC chemokine receptor family, which plays a 
major role in the mobilization and activation of the cells of the immune system. It is 
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a seven transmembrane protein similar to G protein-coupled receptors and is 
differentially expressed in leukocyte subpopulations (Horuk, 1994; Rossi and Zoltnik, 
2000). The CCRl receptor has high affinity for Regulated on Activation Normal T 
Expressed and Secreted (RANTES) protein, which is associated with increased 
chemotaxis of leukocytes to inflammatory sites (Horuk, 1994). Chemokines are a 
large family of chemotactic cytokines that are involved in a variety of biological 
processes, such as immunity, regulation of leukocyte trafficking and hematopoiesis 
(Wang et al., 1998; Zlotnik and Yoshie, 2000). Cytokines are subdivided into four 
distinct groups: CXC, CC, C, and CX3C. CC chemokines exert their effects on a 
broad range of cells such as monocyte, basophils, T lymphocytes, NK cells, dendritic 
cells, and eosinophils (Murphy, 1996; Murphy et al., 2000). Chemokines and their 
receptors are crucial during inflammatory responses for a timely recruitment of 
specific leukocyte subpopulations to sites of tissue damage (Rossi and Zoltnik, 
2000). 
Human CCRl expressing monocytes and macrophages have been implicated 
» 
‘ in arthritis, inflammatory renal diseases, and multiple sclerosis (Furuichi et al., 2000; 
Gladue et al., 2003; Katschke et al., 2001). A study also showed that the 
up-regulation of CCRl in peritoneal macrophages of women with endometriosis play 
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an inflammatory role in the pathogenesis of endometriosis (Wieser et al., 2005). 
Another study showed that CCRl, together with its ligand CCL23, induced 
endothelial cell migration and promoted neovascularization and angiogenesis 
(Hwang et al., 2005). In our microarray study, CCRl showed a 1.61-fold 
over-expression in the prolapse cardinal ligament when compared with controls. This 
result is consistent with others that uterine prolapse involve inflammation processes 
and angiogenesis. 
TYRO Protein Tyrosine Kinase Binding Protein (TYROBP) 
TYROBP, also called DAP 12, encodes a transmembrane signaling 
polypeptide, which contains an immunoreceptor tyrosine-based activation motif that 
is coupled to numerous activating receptors expressed on immune cells (Lanier and 
Bakker, 2000). For instance, TYROBP associates with the activated major 
histocompatibility class I-specific receptors, such as killer-cell Ig-like receptor and 
may act as an activating signal transduction element on NK and T cell subsets 
(Tomasello et al., 2000). In addition, TYROBP also associates with Natural 
» 
‘ Cytotoxicity Receptor in NK cells and MDL-1 on monocytes and macrophages 
(Bakker et al., 1999). This protein also plays a role in signal transduction, 
inflammation, bone modeling and brain myelination (McVicar et al., 1998). 
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A study showed that over-expression of DAP 12 in hematopoietic cells in 
/)^P72-transgenic mice caused severe lymphopenia and a massive inflammatory 
syndrome. This indicated that DAP12-dn\Qr\ signals in D^P/i- transgenic mice with 
myeloid abnormalities were involved in inflammation and constituted an essential 
target to control resolution of inflammatory disorders based on 
monocytes/macrophages and neutrophils (Lucas et al., 2002). On the other hand, 
mutations within this gene have been associated with Polycystic Lipomembranous 
Osteodysplasia with Sclerosing Leukoencephalopalhy, also known as Nasu-Hakola 
disease (Paloneva et al., 2000). The over-expression of this gene (1.58-fold) in 
prolapse cardinal ligament also implied an increased inflammation response in 
uterine prolapse. 
SNFl-like Kinase (SNFILK) 
SNFILK encodes a protein kinase in the AMP-activated protein kinase 
superfamily (Stephenson et a l , 2004). SNFILK consists of three domains: a protein 
kinase domain, a domain referred to as ubiquitin-associated domain that is conserved 
in SNFl-related kinases, and a C-terminal domain that contains no functional motifs 
(Drewes et al., 1998). The ubiquitin-associated domains have been implicated in 
processes like inhibition of ubiquitin-mediated protein degradation and cell cycle 
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regulation (Berttolaet et al., 2001; Hartmann-Petersen et a l , 2003). 
SNFILK was first identified in myocardial cells, which might function in the 
earliest stages of myocardial cell differentiation or primitive ventricle chamber 
formation (Sedmera et al., 2003). In addition, SNFILK was expressed in skeletal 
progenitor cells of the somite with a general role in the earliest stages of muscle 
growth and/or differentiation (Stephenson et al., 2004). Furthermore, SNFILK, 
resides within an approximately 5-Mb region of chromosome 21q22.3, has been 
implicated in congenital heart defects often observed in patients with Down 
syndrome (Barlow et al., 2001). 
Stephenson's study suggested that SNFILK did not share functional 
homology with other SNFl-related kinase, but represented a new subclass kinase 
with different molecular activities (Stephenson et al., 2004). It was shown that 
Chinese hamster ovary cells with a truncated SNFILK protein containing the kinase 
and ubiquitin-associated domain expression showed a dramatic decrease in the 
» 
‘ growth rate in the presence of dox with no evidence of apoptosis. In addition, 38% of 
these cells underwent multiple rounds of DNA replication to yield SN and \6N cells 
without cell division (i.e. endoreduplication). These implied that the kinase and 
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ubiquitin-associated domain of the SNFILK might play a role in cell cycle regulation 
by inhibiting cell division and inducing a polyploid state in the cells. However, 
cells with full-length SNFILK expression showed no changes in the cell cycle profile. 
In addition, it was observed that the SNFILK proteins exhibited differing subcellular 
localization profiles, with the protein predominantly localized to the cytoplasm. 
However, during myocyte differentiation, SNFILK was induced to translocate from 
cytoplasm to nucleus. It was hypothesized that at the initial stages of myocyte 
differentiation, inactive SNFILK protein was located predominantly in the 
cytoplasm. When a differentiation-associated signal induced SNFILK to translocate 
to the nucleus, the SNFILK would regulate the early stages of cell growth and 
differentiation by G2/M regulation (Stephenson et al., 2004). In our study, SNFILK 
showed a 2.63-fold under-expression in prolapse cardinal ligament and the 
under-expression of this gene would imply a differential changes in the cell growth, 
cell cycle and differentiation of the cells in the ligament, which in turn lead to the 
pathogenesis of uterine prolapse. 
I 
Pleckstrin Homology-Uke Domain, Family A, Member 1 (PHLDAl) 
PHLDA1 gene belongs to the PHLDA gene family as it contains a pleckstrin 
homology region that may mediate interaction with cellular membranes (Frank et al., 
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1999). It encodes proteins with size of 259 amino acids. The protein contains a series 
of motifs indicative of protein-protein interactions, which include 16 
proline-glutamine and 15 proline-hislidine repeats in the C-terminal region and a 
stretch of 14 glutamine residues in the middle of the protein (Park et al., 1996). It has 
been shown that proteins containing proline-glutamine-rich domains might function 
as transcriptional factors as well as apoptosis-associated proteins in 
neurodegenerative diseases, such as Huntington's disease (Li et a l , 2003). In 
addition, PHLDAl also play an essential role in the activation-induced apoptosis of T 
cells (Park et al., 1996). 
In human, PHLDAl was shown to be constitutively expressed in melanocytic 
nevi and was progressively down-regulated in primary and metastatic melanomas 
(Neef et al., 2002). It was shown that PHLDAl expression was associated with 
reduced cell growth, decreased cloning efficiency, and increased apoptosis sensitivity, 
but not with alternations in cell cycle parameters. Thus, it was suggested that loss of 
PHLDAl expression in melanomas might play a role in deregulated cell growth and 
> 
apoptosis resistance in these tumors (Neef et al., 2002). However, the molecular 
mechanism by which PHLDAl mediated apoptosis remained uncertain. A recent 
study has shown that PHLDAl was induced in response to homocystein, which 
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caused stress in endoplasmic reticulum and programmed cell death, and that 
PHLDAl over-expression decreased cell adhesion and promoted 
detachment-mediated apoptosis in human vascular endothelial cells (Hossain et al., 
2003). 
PHLDAl gene has also been identified independently in other systems. The 
murine PHLDAl, called T cell death-associated gene -51 {TDAG51), was first 
identified in murine T lymphocytes where it was required for activation-induced cell 
death (Park et al., 1996). It was shown to regulate the expression of Fas and T-cell 
receptor activation-induced apoptosis in a T-cell hybridoma by enhancing apoptosis 
(Gomes et al., 1999; Park et al., 1996). The rat homologue was also identified as an 
immediate early gene induced by fibroblast growth factor in a hippocampal neuronal 
cell line and was shown to promote apoptosis (Gomes et a l , 1999). In our study, 
PHLDAl showed a 2.45-fold under-expression in prolapse cardinal ligament. As 
PHLDAl is an apoptotic gene, and thus the under-expression of it may imply a 
decreased apoptosis and increased cell growth in the cells of cardinal ligament 
» 
• according to previous studies. Further characterization of this gene could help us to 
understand more how apoptosis affect the pathogenesis of uterine prolapse. 
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Elongation Factor，RNA Polymerase II，2 (ELL2) 
ELL2 was first identified and characterized by Shilatifard et al., as a novel 
RNA polymerase II elongation factor that were capable of regulating the activity of 
RNA polymerase II elongation complex (Shilatifard et al. 1997). The elongation 
stage of eukaryotic messenger RNA synthesis is a major step for the regulation of 
gene expression (Reines et al., 1996). Misregiilation of transcriptional elongation 
may be one of the important factors in a variety of human diseases (Aso et al., 1996). 
One virally encoded protein (Tat) and five cellular proteins (SII, TFIIF, P-TEFb, 
elongin (SIII), and ELL) have been identified to be involved in the control of the 
RNA polymerase II elongation complex activity (Reines et al., 1996). 
The open reading frame sequence of ELL2 was 66% similar to that of ELL 
(Shilatifard et al., 1997)，which was found to be a frequent target for translocations in 
acute myeloid leukaemia (Mitani et al., 1995; Thirman et al., 1994). In addition, 
structure-function studies showed that the ELL2 transcriptional activity resided in the 
conserved elongation activation domain in the N-terminal region, which was highly 
» 
‘ homologous to ELL (Shilatifard et al., 1997). Mechanistic studies indicated that 
ELL2 and ELL possessed similar transcriptional activities, specifically; they had 
similar effects on the rate of elongation of promoter-specific transcripts by RNA 
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polymerase II (Shilatifard et al., 1997). Past studies demonstrated that ELL could 
increase the overall rate of RNA chain elongation by RNA polymerase II by 
decreasing the frequency or duration of transient pausing by the enzyme at many 
sites along DNA templates (Shilatifard et al., 1996). It was showed that ELL2 could 
also increase the overall rate of elongation by RNA polymerase II during both 
promoter-dependent and -independent transcription (Shilatifard et al., 1997). In 
addition, transcripts synthesized in the presence of ELL2 or ELL were longer and 
appeared to be plasmid length when compared with the transcripts synthesized 
without them (Shilatifard et al., 1997). ELL2 and ELL genes were showed to 
transcribe in many of the same tissues, but the ratio of their transcripts exhibited 
tissue-to-tissue variation (Shilatifard et al., 1997). For instance, the ratio of ELL2 to 
ELL was greater in liver than in kidney, skeletal muscles, lung, and placenta. This 
indicated that ELL2 and ELL might not perform completely general functions, but 
gene- or tissue-specific functions instead (Shilatifard et al., 1997). In our study, the 
under-expression of ELL2 (2.34-fold) would imply a down-regulation of 
transcriptional elongation and in turn a down-regulation of other gene expression in 
» 
. prolapse cardinal ligament. Further studies on the elongation factor ELL2 are 
important for more understanding of their roles in gene regulation, especially in 
pelvic floor tissues and uterine prolapse. 
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Early Growth Response 3 gene (EGR3) 
EGR3 gene encodes proteins of nuclear transcription factors that belongs to 
the Early Growth Response family and shares a common sequence called the EGR 
response element with other members involved in DNA-binding and transactivation 
(O'Donovan et al., 1999). The activities of the EGR members (except EGR4) are 
regulated by specific cofactors, NABl and NAB2 (Russo et a l , 1995; Svaren et al., 
1996). EGR3 was shown to be essential for the development of muscle spindle 
(Tourtellotte et al., 2001). In addition, FasL was the only target gene for EGR3 so far 
and it was induced under the control of EGR3 in T cells activated in a TCR-mediated 
manner or by phorbol ester plus a Ca^^ ionophore (Mittelstadt and Ashwell, 1998). 
EGR3 was reported to be involved in the estrogen-signaling pathway in breast 
cancer cells (Inoue et al., 2004). EGR3 encodes a zinc-finger transcription factor in 
breast cancer cells. There are at least three estrogen-responsive elements upstream of 
EGR3 protein to which ERs would bind, which leading to transactivation. It was 
shown that EGR3 gene expression was greatly induced by E2 in breast caner cell line 
> 
• MCF-7 through ERa regulation (Svaren et al., 1996). In addition, this report also 
showed that FasL was another target gene for EGR3 in breast cancer cell. In our 
microarray data, the EGR3 gene showed a 2.27-fold under-expression in the prolapse 
1 3 8 • 
cardinal ligament and the EGR3 under-expression might correlate with a low level of 
estrogen state in uterine prolapse. These data suggested that EGR3 might also play an 
important role in the estrogen-signaling pathway in the pelvic floor tissues and 
uterine prolapse. 
V-myc Myelocytomatosis Viral Oncogene Homolog (MYC) 
MYC, also called c-MYC, gene encodes a transcription factor protein of the 
basic helix-loop-helix-leucin zipper family. c-MYC was originally identified as 
cellular homologue to the viral oncogene {v-MYC), which causes myeloid leukaemia, 
sarcomas, kidney, liver and other types of tumors in chickens (Gonda et al., 1982). 
Mutations, over-expression, rearrangement and translocation of this gene have been 
associated with a variety of hematopoietic tumors, leukemias and lymphomas, 
including Burkitt lymphoma in human (Spencer et al., 1990; Spencer et al., 1992). 
The MYC oncogene family members include c-MYC, N-MYC, and L-MYC. They 
encode nuclear proteins that promote cell proliferation, growth, and apoptosis and 
inhibit terminal differentiation (Grandori et al., 2000). Several studies have shown 
» 
• that c-MYC is involved in embryonic growth and development (Dang et al., 1999; 
Levens, 2002). In quiescent GO cells, c-MYC is expressed at very low level, but 
under mitogenic signals or stimuli induction, its expression would rapidly increased, 
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and expressed continually in cycling cells (Oster et al., 2002). 
MYC contains a transactivation domain in the N-terminus, a basic 
region/helix-loop-helix/leucine zipper motif in the C-terminus and a 
nuclear-localization signal in the central region (Depinho et a l , 1987). The basic 
region/helix-loop-helix/leucine zipper motif provides the DNA binding function of 
MYC, with the E-box (CACGTG) was identified as a six base pair core of DNA 
binding motif of MYC (Blackwell et al., 1990). A basic 
region/helix-loop-helix/leucine zipper protein, designated MAX, specifically 
associates with c-MYC protein. The MYC-MAX complex binds to DNA in a 
sequence-specific manner and functions as transcriptional regulators (Blackwood and 
Eisenman, 1991). 
MYC is a multifunctional protein. In response to different extracellular 
signals, c-MYC can regulate the transcription of several hundreds of target genes, 
which play an important role in a variety cellular processes, such as cell cycle, 
> 
• growth, differentiation, genomic instability, apoptosis, angiogenesis and 
transformation (Fernandez et al., 2003; James and Eisenman 2002). c-MYC was 
shown to promote cell growth by facilitating the transition from GO/Gl phase to the 
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Gl/S phase of the cell cycle (Mateyak et al., 1999). Other studies showed that MYC 
would inhibit cell differentiation (Foley and Eisenman, 1999; Grandori et al., 2000). 
Besides cell growth and differentiation regulation, MYC expression has also 
shown to induce apoptosis through directly activation of p53 (Zindy et al., 1998) or 
repression of the anti-apoptotic genes such as Bcl2 and Bcl-x (Martinou and Green, 
2001). On the other hand, MYC acts as a positive and negative regulator of genes 
involved in angiogenesis. It has been shown that MYC positively regulated 
angiogenesis through the induction of vascular endothelial growth factor. On the 
other hand, MYC can negatively regulate angiogenesis by repressing the expression 
of the angiogenesis inhibitor thrombospondin-1 (Janz et al., 2000). MYC is an 
oncogene as the over-expression of it can promote cell immortalization by activation 
of the telomerase (Eischen et al., 1999). In addition, abnormal MYC expression has 
been suggested to promote genomic instability, which referred to chromosomal 
aberration like gene amplifications and translocations, in cancer cells. Thus, cells are 
allowed to proliferate continuously despite DNA damage or mutations (Felsher and 
» 
• Bishop, 1999; Vafa et al., 2002). In our study, the under-expression of MYC would 
imply a change in the cell proliferation, apoptosis and angiogenesis in the cells of 
prolapse cardinal ligament. Further functional studies are needed to understand more 
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about how MYC plays a role in the pathogenesis of uterine prolapse. 
Hairy and Enhancer of Split 1 gene (HESl) 
HESl, which belongs to the hairy and enhancer of split gene family, encodes 
basic helix-loop-helix transcriptional repressors that function in the Notch signaling 
pathway (Artavanis-Tsakonas et al., 1999) and repress neuronal differentiation in 
mammalian central nervous system (Ishibashi et a l , 1994). The HES gene family 
members, HESl to HES6, also encode basic helix-loop-helix transcriptional 
repressors that regulate myogenesis and neurogenesis (Ishibashi et al., 1994). The 
HES family members form a complex with TLE, the mammalian homologue of 
Groucho, and this interaction is mediated by the carboxyl terminal of the HES 
proteins. The HES/TLE complex functions by directly bind to DNA, instead of 
interfering with activator proteins. HESl is expressed in a variety of embryonic and 
adult tissues, such as lung, kidney, intestine and T-cell precursors (Sasai et al., 1992; 
Tomita et al., 1996). 
» 
• Besides differentiation regulation in the nervous system, HESl also plays an 
important role in controlling cell proliferation. HESl was shown to inhibit cell 
proliferation not only in neuronal cells (Castella et al., 2000), but also in colon and 
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mammary cancer cell lines (Strom et al., 2000). It was also shown that HESl was 
down-regulated by the E2 in breast carcinoma cell lines through the ERa regulation. 
Therefore, the E2-mediated down-regulation of HESl would increase cell 
proliferation. In addition, exogenous expression of HESl would suppress 
proliferation of cancer cells T47D and PC 12 under E2 treatment (Strom et al., 2000). 
Another study showed that HESl was a new target gene for aryl hydrocarbon 
receptor (AhR), which was known to antagonize estrogen action (Thornsen et al., 
2003). AhR was activated by xenobiotic compounds such as 2,3,7,8-
tetrachlorodibenzo-/?-dioxin (TCDD) (Puga et al., 2002), which regulated the 
expression of a variety of estrogen-inducible genes and counteracted the mitogenic 
effects of estrogen in T47D human mammary carcinoma cell line (Fernandez and 
Safe, 1992). As opposite to estrogen, HESl was up-regulated by TCDD. It was found 
that HESl was up-regulated by the TCDD-induced AhR complex, which together 
suppressed estrogen-induced proliferation of T47D cells (Fernandez and Safe, 1992). 
In our microarray data, the HESl gene showed a 2.14-fold under-expression in the 
prolapse cardinal ligament. Further studies are required to characterize its function in 
‘ transcription regulation and cell proliferation, as well as its relationship with the 
estrogen status in prolapse cardinal ligament. 
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AF4/FMR2 Family, Member 3 (AFF3) 
AFF3 encodes a tissue-restricted nuclear transcriptional activator that is 
preferentially expressed in lymphoid tissue. It is a member of a protein family 
including AF4, FMR2 and AF5q31, which show similarities in sizes of transcripts 
and proteins, as well as their nuclear localization of the proteins (Gecz et al., 1996; 
Ma and Staudt, 1996). AFF3 gene encodes a protein of 1,227 amino acids, with a 
putative nuclear localization signal in the carboxyl terminus. It contains at least 2 
domains with transactivation activity and can directly bind to DNA (Ma and Staudt, 
1996). This suggested that AFF3 might function as a transcriptional regulator. AFF3 
expression was found in various human tissues, such as adult heart, brain, and 
placenta, and the fetal brain, lung, liver, and kidney. In addition, AFF3 gene was 
reported to be expressed predominantly in pre-B cells, intermediately in mature B 
cells, and absent in plasma cells in human lymphoid cell lines, which suggested that 
AFF3 might play a regulatory role in early lymphoid development (Ma and Staudt, 
1996). Later studies also found that AFF3 gene was fused to MLL gene on l lq23 in 
patients with Acute Lymphoblastic Leukemia, which also suggested the role of AFF3 
‘ in early lymphoid development (Hiwatari et al., 2003; von Bergh et al., 2002). 
Another study showed that AFF3 was aberrantly expressed in human breast cancer 
cells and the level of AFF3 expression showed a significant association with the ER 
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status (To et al., 2005). Although AFF3 might acts as a transcriptional regulator and 
might play a role in early lymphoid development and oncogenesis, the precise 
physiological functions of AFF3 is not known. In our study, AFF3 gene showed a 
consistent significant under-expression in all the three prolapse stages when 
compared with controls. The 2.10-fold under-expression of this gene in prolapse 
cardinal ligament would imply a change in the transcription regulation. Thus, further 
studies are needed to characterize its function in transcription regulation and its role 
in the pathogenesis of uterine prolapse. 
A Disintegrin-like and Metalloprotease (Reprolysin Type) with Thrombospondin 
Type 1 Motif，9 (ADAMTS9) 
ADAMTS9 was first cloned and characterized by Clark et al., as a novel 
member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin 
motifs) protein family (Clark et al., 2000). Members of the family share several 
distinct protein modules, including a propeptide region, a metalloproteinase domain, 
a disintegrin-like domain, and a thrombospondin (TSP) type 1 motif, a spacer region, 
> 
‘ and a variable number of TSP-like submotifs at the C-terminal end of the protein 
(Tang and Hong, 1999). Individual members of this family differ in the number of 
C-terminal TSP motifs, and some have unique C-terminal domains (Tang and Hong, 
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1999). ADAMTS9 protein has a metalloprotease domain, a disintegrin-like domain, 
one internal TSPl motif, and three carboxyl-terminal TSPl-like submotifs. Like 
other ADAMTS family members, ADAMTS9 contains an amino-terminal signal 
peptide sequence and lacks a transmembrane domain (Clark et al., 2000). Members 
of the ADAMTS family have been implicated in the cleavage of proteoglycans, the 
control of organ shape during development, and the inhibition of angiogenesis 
(Blelloch and Kimble, 1999; Porter et al., 2005). ADAMTS9 was found in all fetal 
tissues examined and some adult tissues, such as ovary, pancreas, heart, kidney, lung, 
placenta, spinal cord and brain (Clark et al., 2000). The global expression of 
ADAMTS9 in all fetal tissues suggested its important role in development. In addition, 
one possible role for ADAMTS9 in the adult tissues was the suppression of 
angiogenesis through the TSPl motifs. TSPl repeats are found in thrombospondin-1 
and thrombospondin-2, which are multi-functional ECM proteins that can inhibit 
angiogenesis (Volpert et al., 1995). Thrombospondin 1 is a protein associates with 
extracellular matrix and showed anti-angiogenic activity in vivo (Good et al., 1990; 
Tolsma et al., 1993). Peptides derived from the TSPl repeat of thrombospondin-1 
I 
‘ specifically induced apoptosis in endothelial cells, suggesting the mechanism by 
which these proteins inhibit angiogenesis (Guo et al., 1997). The under-expression of 
ADAMTS9 (1.90-fold) in prolapse cardinal ligament would imply an increased 
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angiogenesis in the tissue. 
A Disintegrin-like and Metalloproteinase (Reprolysin Type) with Thromhospondin 
Type 1 Motif, 1 (ADAMTSl) 
ADAMTSl was an inflammation-associated gene and was first cloned from 
colon carcinoma cell line as a member of the ADAMTS (a disintegrin and 
metalloproteinase with thromhospondin motifs) protein family (Kuno et a l , 1997). 
ADAMTSl protein contains two disintegrin loops and three C-terminal TSP motifs 
(Vazquez et al., 1999). The expression of this gene is associated with various 
inflammatory processes, growth, female fertility, and angiogenesis (Kuno et al., 1997; 
Mittaz et al., 2004; Russell et al., 2003; Vazquez et al., 1999). 
Repairing wounded tissues is a complex process that requires temporal and 
spatial coordination of different events, including inflammation, formation of new 
tissues, angiogenesis, and matrix remodelling. These processes are regulated by 
growth factors, cytokines, as well as cell-cell and cell-matrix interactions (Martin, 
‘ 1997; Werner and Grose, 2003). Besides proteinases like plasmin, leukocyte elastase 
and matrix metalloproteinase, which are involved in cell migration, wound 
contraction, and scar remodelling in wound healing process, ADAMTS is another 
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proteinase family involved in wound healing (Lund et al., 1999; Parks, 1999; Zhu et 
al., 2002). ADAMTSl was identified as a novel player in wound-healing process. 
ADAMTSl expression was shown to increase in wounds of normal and particularly 
of healing-impaired genetically diabetic mice (Krampert et al., 2005). Recently, 
ADAMTSl mRNA levels were found to increase after surgical nerve injury in rats 
and in kainite-induced lesions in rat lesions in rat brain (Sasaki et a l , 2001). 
Inflammatory cells, macrophages were identified as the first producer of ADAMTS1 
in early wounds, whereas keratinocytes and fibroblasts produced this protein at the 
later stages of wound healing (Krampert el al., 2005). In addition, low concentration 
of ADAMTS 1 protein would stimulate both fibroblasts and endothelial cells 
migration via its proteolytic activity, while high concentrations of it would inhibit the 
migration as it would bind to fibroblast growth factor-2 and subsequent inhibition of 
its promotoenic activity (Krampert et al., 2005). These findings showed that 
ADAMTSl might play an important role in various repair processes by regulating the 
keratinocyte differentiation and migration of fibroblasts and endothelial cells in 
healing of wounds (Krampert et al., 2005). . 
» 
ADAMTSl has also been shown to inhibit angiogenesis by reducing the 
proliferative response induced by fibroblast growth factor 2 (FGF-2) and vascular 
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endothelial growth factor (VEGF) in endothelial cells (Vazquez et a l , 1999). 
ADAMTS1 would bind to VEGF, and resulting in inhibition of VEGF binding to 
transmembrane receptor (Luque et a l , 2003; Vazquez et al., 1999). Besides, 
ADAMTS 1 knock-out mice are characterized by changes in kidney structure, growth 
retardation and impaired female fertility. This demonstrates that ADAMTS 1 plays 
important roles in organogenesis (Mittaz et al., 2004). In our study, the 
under-expression of ADAMTS 1 (1.88-fold) in prolapse cardinal ligament, just like 
that in ADAMTS9, would also imply an increased angiogenesis in the tissue. 
FOS-like antigen 2 (F0SL2) 
F0SL2 belongs to the FOS gene family, which consists of four members: 
c-FOS, FOSB, FOSLl, and F0SL2. These genes encode leucine zipper proteins that 
can form a heterodimeric complex with proteins of the JUN family, such as c-JUN, 
JUNB and JUND. The complexes then bind to specific DNA sequences known as 
AP-1 binding sites (TGAC/GTCA) to function as a transcriptional regulators named 
transcription factor complex AP-1 (Angel and Karin, 1991). Fos/Jun family 
» 
‘ proteins (Ryder et al., 1988; Zerial et al., 1989), EGR family proteins (Chavrier et al., 
1988; Christy et al., 1988) and steroid or thyroid hormone receptor family proteins 
(Chavrier et al., 1988; Christy et al., 1988) are transcriptional regulators whose genes 
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are expressed independently of protein synthesis. These genes are called "immediate 
early genes" as they are induced as the initial cellular response to external stimuli 
(Lau and Nathans, 1987). Thus, it was implicated that the FOS proteins might play a 
role in the regulation of cell proliferation, differentiation, and transformation (Angel 
and Karin, 1991). 
F 0 S L 2 was originally recognized by a c-FOS antiserum in chicken embryo 
fibroblasts (Nishina et al., 1990). Structural genomics study showed that the four 
exons were conserved between c-FOS and F0SL2, but the introns and untranslated 
parts of the F0SL2 mRNA are larger than those of other Fos family members 
(Foletta et a l , 1994; Nishina et a., 1990; Yoshida et al., 1993). Like c-FOS, F0SL2 
was inducible by phorbol ester, camp and calcium ionophore, as well as serum. A 
study showed that the rat F0SL2 gene was strongly regulated in a myeloid leukaemia 
cell line undergoing cAMP-induced apoptosis (Lanotte et al., 1991). This suggested 
that F0SL2 might be involved in the death process of white blood cells. 
> 
“ Besides the classic steroid receptor-mediated pathways, estrogen acts through 
transactivation of fos/jun (API) mechanisms. A recent publication by Petz et al., 
2004 showed that estrogen-induced transcription of the human progesterone receptor 
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(PR) gene was inhibited by FOS and JUN in MCF-7 human breast cancer cells. In 
addition, it also showed that E2 would affect the expression of FOS and JUN. 
Another finding showed that PR expression in prolapse cardinal ligament of 
post-menopausal women with HRT was increased (Ewies et al., 2004). Therefore, the 
under-expression (1.76-fold) of F0SL2 in prolapse cardinal ligament would imply a 
change in transcriptional regulation of gene expression and estrogen may also play a 
role in the pathogenesis of uterine prolapse by regulating genes involved in the 
fos/juii (API) mechanisms. 
Early Growth Response 2 gene (EGR2; Krox-20) 
The EGR2 gene was originally identified as a serum-response 
immediate-early gene encoding a zinc-finger transcription factor with three tandem 
Cys2-His2-type zinc fingers (Chavrier et al., 1988). EGR2 belongs to the EGR protein 
family, which consists of four members (EGRl to 4). Common structure feature of 
the EGR proteins is a DNA-binding domain consisting of three zinc-fmger motifs 
(0 'Donovan et al., 1999). This domain binds the GCGGGGGCG sequence and the 
» 
• presence of it is known to facilitate transactivation of target genes (Rengarajan et al., 
2000). It was shown that transactivation of target genes by EGR2 is regulated by 
co-repressors such as members of the NGFI-A binding family and Ddx20 (Gillian 
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and Svaren, 2004; Svaren et al., 1998). In human, defect of the EGR2 gene is 
responsible for several hereditary neuronal diseases and type I Charcot-Marie-Tooth 
disease (Warner et al., 1998). EGR2 is also associated with the onset of myelination 
in the peripheral nervous system (Zorick et al., 1996). 
EGR2 is most widely studied in the nervous system, and studies has shown 
that £G7?2-knock-out mice would result in early lethality concurrent to defects in 
hindbrain patterning, peripheral nerve myelination, and bone formation (Gillian and 
Svaren, 2004). On the other hand, EGR2 also functions as a tumour suppressor based 
on the finding that endogenous EGR2 expression was significantly low in primary 
ovarian cancers (Unoki and Nakamura, 2001) and various cancer cell lines (Unoki 
and Nakamura, 2003a). It was also found that CpG islands in intron 1 of EGR2 were 
highly methylated in cells that expressed high levels of EGR2, but hypomethylated in 
cells showing decreased expression (Unoki and Nakamura, 2003b). In addition, by 
detecting transcriptional activity of unmethylated or methylated fragments of the 
intron 1 sequence, the methylated 1.2 kb fragment showed highest enhancer-like 
> 
• activity (Unoki and Nakamura, 2003b). Furthermore, EGR2, together with EGR3 are 
found to be negative regulators of T cell activation (Safford et al., 2005). The 
over-expression of EGR2 and EGR3 was associated with an increase in the E3 
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ubiquitin ligase Cbl-b and inhibition of T cell activation (Safford et a l , 2005). The 
E3 ligases such as Cbl-b, which are negative regulators of T ells, is involved in 
promoting anergy induction and negatively regulate T cell receptor (TCR)-induced 
activation (Heissmeyer et al., 2004). The iinder-expression of EGR2 (1.72-fold) in 
prolapse cardinal ligament would imply a change in transcription activation of its 
corresponding genes and regulation of T cell activation. 
Kruppel-like factor 10 (KLFIO) / TGFfi Inducible Early Growth Response (TIEG) 
TIEG gene was discovered and characterized as a three-zinc finger 
Kruppel-like transcription factor (Blok et al., 1995). TIEG was identified as a 
primary response gene for transforming growth factor-beta (TGFp) in human 
osteoblasts (Subramaniam et al., 1995). It encodes a protein of 480 amino acids 
(72kDa) (Blok et al., 1995). It is expressed in the nucleus, and serves as a regulator 
in the TGF|3 signal transduction pathway (Subramaniam et al., 1995). TGFp plays 
important roles in cellular differentiation, proliferation, migration and apoptosis 
(Hahn et al., 1996). TGFp exerts its effects by binding to specific type I and type II 
» 
• serine/threonine kinase receptors, which in turn initiate intracellular signaling via 
Smad proteins. Smad proteins then translocate to the nucleus and modulate target 
gene transcription (Miyazono, 2000; ten Dijke et al., 2000). 
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Over-expression of TIEG was showed to mimic the actions of TGF(3 in many 
cell types, such as human osteosarcoma and pancreatic carcinoma. For example, 
TIEG was shown to regulate markers of differentiation, control gene expression, 
regulate cell proliferation, and induced apoptosis (Hahn et al., 1996; Hefferan et al., 
2000; Ribeiro et al., 1999). In addition, TIEG over-expression in MG-63 
osteosarcoma cells increases alkaline phosphatase activity, decreases osteocalcin 
mRNA and protein, and decreases cell proliferation in a manner reminiscent of the 
effects of TGFP treatment (Hefferan et al., 2000). Furthermore, TIEG 
over-expression induces apoptosis in a manner similar to TGFp treatment in 
pancreatic, hepatic and lung epithelial cells (Chalaux et al., 1999; Ribeiro et a l , 1999; 
Tachibana et al., 1997). Finally, TIEG is expressed in a stage-specific manner in a set 
of breast cancer biopsies. Whereas normal breast tissue displays high levels of TIEG 
protein, in situ carcinomas display less than one-half the normal TIEG protein levels 
and invasive carcinomas show no detectable TIEG protein (Subramaniam et al., 
1998). In addition, TGFp and members of the TGFp/Smad signaling pathways 
showed anti-proliferative properties and are reported to be tumor suppressors in 
» 
• breast cancer cells (Knabbe et al., 1987; Valverius et al., 1989). 
It was shown that over-expression of TIEG would enhance TGFp induction of 
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Smad binding element (SBE) reporter activity. In addition, TIEG over-expression 
also enhance TGFp induction of the endogenous TGFp regulated genes p21 and 
PAI-1 (Johnsen et al., 2002). The ability of TIEG to enhance TGFp actions is Smad 
dependent since TIEG showed no effect on the SBE transcription in the absence of 
Smad4 expression or when an inhibitory Smad protein, Smad7, is over-expressed. 
Furthermore, TIEG over-expression increase TGFp induced Smad2 phosphorylation 
(Johnsen et al., 2002). The under-expression of TIEG (1.69-fold) in prolapse cardinal 
ligament would also imply a change in TGFp regulation, which might affect cell 
proliferation and apoptosis of the cells, and leads to the pathogenesis of uterine 
prolapse. 
Collagen, Type XVI, alpha 1 (C0L16A1) 
C0L16A1 gene encodes the alpha chain of type XVI collagen, which is a 
member of the fibril-associated collagens with interrupted helices (FACIT)-family of 
collagens (Pan et al., 1992). Collagen XVI contains ten collagenous domains 
interspersed with 11 non-collagenous regions. It is a homotrimeric molecule of about 
» 
‘ 210kDa for each native a l chain (Yamaguchi et al., 1992). Collagens can be divided 
into two major classes. The fibril-forming collagens, such as type I, II’ III, V, and XI, 
with a long central triple-helical domain and without Gly-Xaa-Xaa interruptions, 
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could form highly organized fibrils in a quarter-staggered fashion. Another class is 
the non-fibril-forming collagens with Gly-Xaa-Xaa repeating interruptions. The 
non-fibril-forming collagens, such as collagens IX，XII, XIV and XVI forms a 
subgroup called the FACIT family (Shaw and Olsen, 1991). Members of the FACIT 
collagen family are found to be localized on the surface of major collagen fibrils, 
such as collagen I and II，and they might serve as molecular bridges that could 
maintain the structural integrity of the extracellular matrix (Keene et al., 1991; 
Sugme et al., 1989; Vaughan et al., 1988). 
Collagen XVI is found to be a component of small heterotypic D-banded 
fibrils, mainly occurring in the territorial matrix of chondrocytes in cartilage 
(Kassner et al., 2003). These fibrils are molecular alloys with collagen II as the major 
collagenous component and collagen XI as a minor component (Hagg et al., 1998; 
Mendler et al., 1989). Besides in cartilage, collagen XVI is also a component of the 
extracellular fibrillar networks in skin (Kassner et al., 2003). Collagen XVI is 
integrated into particular fibrillin-rich microfibrils lacking an amorphous elastin core 
» 
‘ in skin (Kassner et al., 2003). In addition, it serves to maintain the integrity of the 
extracellular matrix. Recombinant collagen XVI interacts with fibrillin-1 and with 
fibronectin. This indicates multiple molecular interactions in which this ubiquitously 
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expressed and versatile FACIT-collagen can participate. It was showed that 
fibronectin bind to collagen XVI and this binding appeared to be much stronger than 
the interactions between collagen XVI and fibrillins (Kassner et al., 2004). It was 
also found that the fibronectin-collagen XVI interaction is mediated by one of the 
alternatively spliced regions, EIIIA, EIIIB and V, which as characteristic for specific 
stages of embryonic development and organogenesis (Gutman and Kornblihtt, 1987) 
and not by the collagen binding domain, and thus they may play a role in certain 
developmental or diseased stages. More detailed studies characterizing the 
fibronectin- collagen XVI interaction are necessary to clarify this issue. The 
under-expression of C0L16A1 (1,57-fold) in prolapse cardinal ligament would also 
imply a loss of maintenance of structural integrity of the ECM in the prolapse 
ligament. 
4.5 Implications of This Study 
Childbirth and hypoestrogenic state have long been considered as the major 
risk factors for uterine prolapse. Tissue trauma due to childbirth might initiate 
> 
‘ inflammatory responses, which involve the activation and over-expression of 
immune response genes and wound healing genes like IGKV, F2RL2, IGKC, ITGB2, 
III8, CCR and TYROBP. Thus, we could hypothesize that during the inflammation 
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processes, F2RL2 might play a role in coagulation and inflammation by thrombin 
activation, ITGB2 might mediate the migration and cell attachment of leukocytes, 
thus it allows the leukocytes leave the circulation to the inflammation site. ITGB2 
might also mediate the transcription of other inflammatory genes. In addition, IL18 
and CCRl might play a role in inflammatory response and angiogenesis, and CCRl 
might also be involved in the mobilization and activation of cells of the immune 
system, which allows a timely recruitment of specific leukocyte subpopulations to 
sites of cardinal ligament with tissue damage. Furthermore, TYRO BP might also 
couple with receptors on immune cells and function in signal transduction and 
inflammation. The over-expression of these seven immune response genes would 
imply an inflammatory process in the prolapse cardinal ligament after tissue injury. 
In addition, DNA-binding transcriptional regulators, such as SNFILK, 
PHLDAl, ELL2, EGR3, MYC, HESI, AFF3, EGR2 and KLFIO were found to be 
under-expressed in the prolapse cardinal ligament. Some of these genes (e.g. 
SNFILK, PHLDAl, MYC, HESI and KLFIO) are involved in cell proliferation or cell 
» 
‘ cycle. In which SNFILK, PHLDAl, HESI and KLFIO would decrease cell 
proliferation and the under-expression of these genes would imply there might be an 
increased cell proliferation of cells in the cardinal ligament, which are stretched and 
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lengthened during prolapse progression. In addition, genes like PHLDAl, MYC and 
KLFIO would increase apoptosis and the under-expression of these genes would 
imply a slower apoptotic rate of the cells in the prolapse ligament. Furthermore, 
genes like MYC, ADAMTSl and ADAMTS9 would decrease angiogenesis and the 
under-expression of these genes would imply there might be a higher angiogenesis 
activity in the prolapse cardinal ligament, which is consistent with the 
over-expression of angiogenesis-induced genes like IL18 and CCRl in the prolapse 
ligament. Moreover, genes like EGR3 and EGR2 are negative regulators of T cell 
activation, while PHLDAl would induce the apoptosis of T cells. Thus the 
under-expression of these genes would imply an increased T cell activation and 
immune response, and a slower apoptotic rate of T cells in the prolapse cardinal 
ligament. Genes like EGR3, HESl and F0SL2 are also affected by the estrogen 
action. Furthermore, the pathogenesis of uterine prolapse might also involve 
differential gene expression like C0L16A1 in ECM integrity. The under-expression 
of C0L16A1 would imply a loss of maintenance of structural integrity of the ECM in 
the prolapse cardinal ligament. 
» 
Therefore, the pathogenesis of uterine prolapse might involve an increased 
inflammation and immune response due to the tissue trauma in the ligament. In 
1 5 9 
addition, it might also involve increased cell proliferation, decreased apoptosis, 
higher angiogenesis activity, increased T-cell activation, and regulation of genes 
under estrogen action and loss of structural integrity of ECM in the prolapse cardinal 
ligament. 
4.6 Limitations of This Study 
In this study, 58 genes were found to satisfy the filtering criteria of lower 
bound fold change greater than 1.5, with only 14 genes showed a lower bound fold 
change greater than 2. One possible reason is that the sample size is not large enough. 
Another possible reason for the small number of differentially expressed genes found 
is the choice of tissue biopsy. Cardinal ligament is a condensation of subserous fascia 
extending from the uterus to the lateral pelvic wall (Lang et al., 2003). About 70-80% 
of the dry weight of ligaments was collagens and other ECM proteins like elastin, 
fibronectin, proteoglycans, etc. (Falconer et al., 1998). With fibroblasts were 
suggested to be the majority of cells in the ligaments and contribute only about 10% 
of the dry weight of ligaments (Hart et a l , 1995), therefore, total RNA extracted 
» 
‘ from cardinal ligaments, were mostly come from fibroblasts in the ligaments. Unlike 
the pubococcygeus muscle which is rich in actins and myosins, as well as other ECM 
proteins, molecular profiling differences in the cardinal ligament of patients with 
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uterine prolapse and controls might not be as great as that found in the 
pubococcygeus muscle (Visco and Yuan, 2003). In contrast, the differential 
expression of immune response genes and genes of transcription factors give us an 
insight of the relationships between uterine prolapse and immune response, 
transcription regulation, cell proliferation, apoptosis, T-cell activation, angiogenesis 
and estrogen response, extracellular matrix integrity, as well as their potential roles in 
the pathogenesis of uterine prolapse. 
In addition, this study only focus on the gene expression profile of prolapse 
cardinal ligament, and therefore is dependent on the cellular components of the 
ligament. However, about 70-80% of the dry weight of ligaments was collagens and 
ECM proteins (Falconer et al., 1998), and previous studies have showed that there 
were changes in ECM protein composition, such as elastin, collagen III and tenascin, 
in prolapse ligament (Ewies et al., 2003). In addition, genes related to inflammatory 
and immune responses were found to be differentially regulated in prolapse ligament 
in our microarray study, and these genes were mainly found in immune cells or cells 
» 
‘ related to immune response. Therefore, histological assessments should be made to 
investigate whether the ligaments differ in proportion of ECM components or in 
cellular components, such as chronic inflammatory infiltrates. 
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CHAPTER 5 CONCLUSIONS 
In this study, we found that there were 29 over-expressed and 29 
under-expressed genes in the cardinal ligament in patients with uterine prolapse. Of 
the 29 genes, 7 over-expressed genes {IGKV, F2RL2, IGKC, ITGB2, IL18, CCRl and 
TYROBP) and 13 under-expressed genes (SNFILK, PHLDAl, ELL2, EGR3, MYC, 
HESl, AFF3, ADAMTS9, ADAMTSl, F0SL2, EGR2, KLFIO and C0L16A1) were 
further validated and confirmed by quantitative real-time PCR. Based on the gene 
ontology analysis and literature studies of these 20 candidate genes, it was found that 
the pathogenesis of uterine prolapse might be related to a number of biological 
processes. 
The over-expression of immune response genes like IGKV, F2RL2, IGKC, 
ITGB2, III8, CCR and TYROBP implied an increased inflammation response, which 
might relate to tissue trauma in the prolapse cardinal ligament. Some of these genes 
would also regulate angiogenesis (e.g. Ill8 and CCRl) and transcription of 
» 
• inflammatory genes (e.g. ITGB2). Further characterization of these immune response 
or wound-healing genes could give us more understanding of the inflammation 
process and immune response in the pathogenesis of uterine prolapse and enable us 
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to identify molecular markers. In addition, DNA-binding transcriptional regulators, 
such as SNFILK, PHLDAl, ELL2, EGR3, MYC, HESl, AFF3, EGR2 and KLFIO 
were found to be under-expressed in the prolapse cardinal ligament. Some of these 
genes were involved in cell proliferation or cell cycle (e.g. SNFILK, PHLDAl, MYC, 
HESl and KLFIO), apoptosis (e.g. PHLDAl, MYC and KLFIO), regulators ofT-cell 
function and activation (e.g. PHLDAl, EGR3 and EGR2), angiogenesis (MYC, 
ADAMTS 1 and ADAMTS9) and estrogen response (e.g. EGR3, HESl and F0SL2). 
Furthermore, the pathogenesis of uterine prolapse might also involve differential 
gene expression in ECM integrity (e.g. C0L16A1). 
These data suggest that the molecular profiling differences in cardinal 
ligament between patients with uterine prolapse and controls may be related to 
differential gene expression of proteins related to proteins in immune response, 
transcription regulation, cell proliferation, apoptosis, T-cell activation, angiogenesis, 
estrogen response, and ECM integrity. These differential gene expressions may be 
the risk factors or markers for the pathogenesis of uterine prolapse. 
> 
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CHAPTER 6 FUTURE PROSPECT 
In order to further investigate the candidate genes, studies on genes in protein 
level should be carried out. In situ immunohistostaining can be performed to localize 
the protein expression of the genes in cardinal ligament tissue sections. Thus, the 
specific location of the protein products can be visualized and the protein expression 
level can be semi-quantified by image analysis of the stained area of the target 
protein. In addition, small interference RNA (siRNA) assay can be carried out in 
order to study the involved pathway of the candidate genes. Functional assays can 
also be carried out to study the candidate genes, especially the genes involved in cell 
proliferation and cell cycle. 
» 
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